Page last updated: 2024-10-28

haloperidol and Delirium

haloperidol has been researched along with Delirium in 328 studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Delirium: A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2)

Research Excerpts

ExcerptRelevanceReference
"The AID-ICU trial was a randomised, blinded, placebo-controlled trial investigating effects of haloperidol versus placebo in acutely admitted, adult patients admitted in intensive care unit (ICU) with delirium."9.69Haloperidol vs. placebo for the treatment of delirium in ICU patients: a pre-planned, secondary Bayesian analysis of the AID-ICU trial. ( Andersen-Ranberg, NC; Andreasen, AS; Bestle, M; Citerio, G; Collet, MO; Damgaard, K; Dey, N; Granholm, A; Hästbacka, J; Jensen, TB; Mathiesen, O; Morgan, M; Nielsen, LG; Pedersen, HS; Perner, A; Poulsen, LM; Sommer, T; Uslu, B; Weber, SO, 2023)
"This is an open-label, parallel-group, randomized controlled trial to compare the efficacy and safety of dexmedetomidine and haloperidol for nocturnal hyperactive delirium in non-intubated patients at two HDUs of a tertiary hospital."9.69Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial). ( Harada, H; Ikeda, K; Kamei, J; Kato, T; Kitajima, N; Kuriyama, A; Maeda, J; Matsuyama, A; Minami, T; Mizota, T; Ohtsuru, S; Sakai, Y; Sato, Y; Takatani, Y; Ueno, K; Watanabe, H; Yamaji, K; Yamashita, Y, 2023)
"The role of haloperidol as treatment for ICU delirium and related symptoms remains controversial despite two recent large controlled trials evaluating its efficacy and safety."9.69Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial. ( Boer, DP; Brouwers, AJBW; Devlin, JW; Gommers, DAMPJ; Hunfeld, NGM; Lens, JA; Osse, RJ; Ponssen, HH; Rietdijk, WJR; Schoonderbeek, JF; Simons, KS; Slooter, AJC; Smit, L; Trogrlic, Z; van den Boogaard, M; van der Jagt, M, 2023)
"Haloperidol is frequently used to treat delirium in patients in the intensive care unit (ICU), but evidence of its effect is limited."9.51Haloperidol for the Treatment of Delirium in ICU Patients. ( Aagaard, SR; Andersen-Ranberg, NC; Andreasen, AS; Bestle, MH; Brand, B; Brix, H; Caballero, J; Citerio, G; de Haas, I; Ebdrup, BH; Engstrøm, J; Eriksen, AS; Estrup, S; Fjeldsøe-Nielsen, H; Gramstrup Nielsen, L; Hästbacka, J; Haurum, C; Hildebrandt, T; Hyttel-Sørensen, S; Jensen, JV; Kingo Vesterlund, G; Kjær, MN; Kuivalainen, AM; La Cour, K; Laigaard, J; Lange, T; Mathiesen, O; Mikkelsen, VS; Morgan, M; Mortensen, CB; Nebrich, L; Nielsen, LO; Olesen, MW; Olsen, MH; Overgaard-Steensen, C; Oxenbøll Collet, M; Perner, A; Poulsen, LM; Rasmussen, BS; Scharling Pedersen, H; Schønemann-Lund, M; Thornberg Kyhnauv, P; Toft Boesen, HC; Uslu, B; Weber, SO; Westergaard, B; Wetterslev, J, 2022)
"To examine the association between the anticholinergic burden (ACB) and the duration and severity of delirium in older hip-surgery patients with or without haloperidol prophylaxis."9.41The effect of the anticholinergic burden on duration and severity of delirium in older hip-surgery patients with and without haloperidol prophylaxis: A post hoc analysis. ( Butterhoff-Terlingen, MH; Egberts, TCG; Kalisvaart, KJ; Stuffken, R; Tillemans, MPH; Vreeswijk, R, 2021)
"None of the three study arms - haloperidol, ketamine, or both drugs combined - was significantly superior to placebo for prevention of postoperative brain dysfunction and delirium (P = 0."9.41Ketamine vs. haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial. ( Brügger, J; Gysi, B; Hollinger, A; Huber, J; Rentsch, K; Riegger, H; Rüst, CA; Schmid, HR; Siegemund, M; Steiner, L; Surbeck, M; Toft, K; Tran, F, 2021)
"Treatment of delirium often includes haloperidol."9.34Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020)
"A preplanned secondary analysis of long-term outcomes of the pRophylactic haloperidol usE for DeliriUm in iCu patients at high risk for dElirium (REDUCE) study was conducted."9.30Prophylactic Haloperidol Effects on Long-term Quality of Life in Critically Ill Patients at High Risk for Delirium: Results of the REDUCE Study. ( Beishuizen, A; Pickkers, P; Rood, PJT; Simons, KS; Slooter, AJC; Spronk, PE; van den Boogaard, M; van der Hoeven, JG; van der Voort, PHJ; van der Woude, MCE; Zegers, M, 2019)
"AID-ICU is an investigator-initiated, pragmatic, international, randomised, blinded, parallel-group, trial allocating adult ICU patients with manifest delirium 1:1 to haloperidol or placebo."9.30Agents intervening against delirium in the intensive care unit (AID-ICU) - Protocol for a randomised placebo-controlled trial of haloperidol in patients with delirium in the ICU. ( Andersen-Ranberg, NC; Andreasen, AS; Bestle, M; Caballero, J; Citerio, G; Dey, N; Ebdrup, BH; Estrup, S; Hästbacka, J; Hildebrandt, T; Jensen, TB; Lange, T; Mathiesen, O; Morgan, MPG; Nielsen, LG; Oxenbøll-Collet, M; Pedersen, HBS; Perner, A; Poulsen, LM; Thee, C; Weber, SO; Wetterslev, J; Zafrani, L, 2019)
"because the few randomised placebo-controlled trials investigating the potential role for prophylactic haloperidol in delirium prevention have focused on specific surgical populations, we investigated its efficacy and safety in acutely hospitalised older patients."9.27Haloperidol versus placebo for delirium prevention in acutely hospitalised older at risk patients: a multi-centre double-blind randomised controlled clinical trial. ( Anten, S; Bet, PM; Bloemers, FW; Boelaarts, L; de Vries, OJ; Diepeveen, SHA; Kamper, AM; Kramer, MHH; Lagaay, AM; Nanayakkara, PWB; Schrijver, EJM; van de Ven, PM; van Marum, RJ; van Strien, AM, 2018)
"Results of studies on use of prophylactic haloperidol in critically ill adults are inconclusive, especially in patients at high risk of delirium."9.27Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. ( Beishuizen, A; Besselink, A; Brüggemann, RJM; de Koning, J; Dennesen, PJW; Donker, DW; Fuchs, M; Hannink, G; Hofstra, LS; Houterman, S; Karakus, A; Koeman, M; Pickkers, P; Pretorius, D; Schoonhoven, L; Simons, KS; Slooter, AJC; Spronk, PE; van den Bergh, W; van den Boogaard, M; van der Hoeven, JG; Van der Voort, PHJ; van Duijnhoven, M; Vermeijden, JW, 2018)
"The Baden PRIDe Trial is an investigator-initiated, phase IV, two-centre, randomised, placebo-controlled, double-blind clinical trial for the prevention of delirium with haloperidol, ketamine, and the combination of both vs."9.27Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial (PRIDe): a phase IV multicenter, randomized, placebo-controlled, double-blind clinical trial of ketamine versus haloperidol for prevention of postoperative delirium. ( Blum, A; Hollinger, A; Riegger, H; Seifert, B; Siegemund, M; Toft, K; Zehnder, T, 2018)
"In a randomized, double-blind, placebo-controlled trial, we assigned patients with acute respiratory failure or shock and hypoactive or hyperactive delirium to receive intravenous boluses of haloperidol (maximum dose, 20 mg daily), ziprasidone (maximum dose, 40 mg daily), or placebo."9.27Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. ( Bernard, GR; Boehm, LM; Bowton, DL; Brummel, NE; Carson, SS; Chandrasekhar, R; Dittus, RS; Douglas, IS; Ely, EW; Exline, MC; Feinstein, DJ; Girard, TD; Gong, MN; Hite, RD; Hough, CL; Hughes, CG; Hyzy, RC; Jackson, JC; Khan, B; Malhotra, A; Masica, AL; Owens, RL; Pandharipande, PP; Patel, MB; Pisani, MA; Pun, BT; Rock, P; Schmidt, GA; Schweickert, WD; Stollings, JL; Strength, C; Thompson, JL, 2018)
"To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of advanced cancer."9.24Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. ( Amin, S; Breitbart, W; Bruera, E; De La Cruz, M; Delgado-Guay, M; Dibaj, SS; Epner, D; Frisbee-Hume, S; Hall, S; Hess, K; Hui, D; Liu, D; Nguyen, T; Reddy, A; Tanco, K; Vidal, M; Walker, P; Williams, J; Wilson, A; Zhukovsky, DS, 2017)
"The aim of this study was to evaluate the safety and efficacy of the early administration haloperidol in preventing the aggravation of postoperative delirium in elderly patients."9.24Haloperidol prophylaxis for preventing aggravation of postoperative delirium in elderly patients: a randomized, open-label prospective trial. ( Akiyama, H; Ando, M; Fujishiro, K; Fukata, S; Hattori, H; Kawabata, Y; Kitagawa, Y; Kuroiwa, K; Takemura, M, 2017)
"To determine efficacy of risperidone or haloperidol relative to placebo in relieving target symptoms of delirium associated with distress among patients receiving palliative care."9.24Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial. ( Agar, MR; Caplan, GA; Currow, DC; Devilee, L; Draper, B; Eckermann, S; Fazekas, B; Hardy, J; Hill, M; Lawlor, PG; Le, B; McCaffrey, N; Quinn, S; Rowett, D; Sanderson, C, 2017)
"To compare the efficacy and safety of scheduled low-dose haloperidol versus placebo for the prevention of delirium (Intensive Care Delirium Screening Checklist ≥ 4) administered to critically ill adults with subsyndromal delirium (Intensive Care Delirium Screening Checklist = 1-3)."9.22Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. ( Al-Qadheeb, NS; Devlin, JW; Pacheco, MN; Roberts, RJ; Ruthazer, RR; Schumaker, G; Skrobik, Y, 2016)
"To evaluate the clinical effectiveness, safety, and cost of dexmedetomidine for the treatment of agitated delirium refractory to haloperidol in nonintubated critically ill patients."9.22Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial. ( Baeza, N; Cabré, L; Calizaya, M; Carrasco, G; Gimeno, G; Manzanedo, D; Portillo, E, 2016)
" One hundred and seventeen adult patients undergoing cardiac surgery were included before introduction of a screening and treatment protocol with haloperidol for delirium, and 123 patients were included after."9.19Effects of a screening and treatment protocol with haloperidol on post-cardiotomy delirium: a prospective cohort study. ( Balslev Jørgensen, M; Kirkegaard, T; Lind Jørgensen, V; Schrøder Pedersen, S, 2014)
"The preventive administration of low-dose haloperidol did not induce any adverse events, but also did not significantly decrease the incidence or severity of postoperative delirium or shorten its persistence."9.19Haloperidol prophylaxis does not prevent postoperative delirium in elderly patients: a randomized, open-label prospective trial. ( Akiyama, H; Ando, M; Fujisiro, K; Fukata, S; Hattori, H; Katagawa, Y; Kawabata, Y; Kawamura, T; Kuroiwa, K; Terabe, Y, 2014)
"The HARPOON study will provide relevant information on the efficacy and safety of prophylactic haloperidol treatment for in-hospital delirium and its effects on relevant clinical outcomes in elderly at-risk medical and surgical patients."9.19Efficacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk patients acutely admitted to hospital through the emergency department: study protocol of a multicenter, randomised, double-blind, placebo-control ( Anten, S; Bet, PM; Boelaarts, L; de Graaf, K; de Vries, OJ; Diepeveen, SH; Kamper, AM; Kramer, MH; Kuipéri, E; Lagaay, AM; Nanayakkara, PW; Pons, D; Schrijver, EJ; Siegel, A; van de Ven, PM; van Marum, RJ; van Strien, AM; Verburg, A, 2014)
"Patients were randomized into 2 groups; in group 1, patients received 5mg of haloperidol intramuscularly and in group 2, patients received 5mg of morphine sulfate intramuscularly to control delirium symptoms."9.17Morphine is a reasonable alternative to haloperidol in the treatment of postoperative hyperactive-type delirium after cardiac surgery. ( Akgün, S; Atalan, N; Başaran, C; Efe Sevim, M; Fazlıoğulları, O, 2013)
"Low-dose quetiapine and haloperidol may be equally effective and safe for controlling delirium symptoms."9.17Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial. ( Chittawatanarat, K; Maneeton, B; Maneeton, N; Srisurapanont, M, 2013)
"This will be the first large-scale multicenter randomized controlled prevention study with haloperidol in ICU patients with a high risk of delirium, adequately powered to demonstrate an effect on 28-day survival."9.17Prevention of ICU delirium and delirium-related outcome with haloperidol: a study protocol for a multicenter randomized controlled trial. ( Beishuizen, A; Brüggemann, RJ; Hoogendoorn, ME; Houterman, S; Kuiper, MA; Pickkers, P; Schoonhoven, L; Schouten, JA; Slooter, AJ; Spronk, PE; van den Boogaard, M; van der Hoeven, JG; van der Voort, PH, 2013)
"These results do not support the hypothesis that haloperidol modifies duration of delirium in critically ill patients."9.17Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. ( Alce, T; Ely, EW; Gates, S; Jackson, J; McAuley, DF; Page, VJ; Perkins, GD; Shintani, A; Zhao, XB, 2013)
"This study was a before/after evaluation of a delirium prevention project using prophylactic treatment with haloperidol."9.17Haloperidol prophylaxis in critically ill patients with a high risk for delirium. ( Pickkers, P; Schoonhoven, L; van Achterberg, T; van den Boogaard, M; van der Hoeven, JG, 2013)
"To evaluate the efficacy and safety of short-term low-dose intravenous haloperidol for delirium prevention in critically ill elderly patients after noncardiac surgery."9.16Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: a randomized controlled trial*. ( Chen, KS; Gu, XE; Li, HL; Li, SL; Wang, DX; Wang, W; Yao, GQ; Zhu, SN; Zhu, X, 2012)
"To investigate the controlling efficacy of ondasetron and haloperidol in regard to the postcardiotomy delirium."9.16Ondasetron versus haloperidol for the treatment of postcardiotomy delirium: a prospective, randomized, double-blinded study. ( Daskalopoulos, ME; Gogaki, E; Papaliagkas, V; Parisis, C; Sataitidis, I; Tagarakis, GI; Tsagalas, I; Tsilimingas, NB; Tsolaki, F; Tsolaki, M; Voucharas, C, 2012)
" haloperidol in patients of delirium admitted to medical and surgical wards."9.15Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. ( Chakrabarti, S; Grover, S; Kumar, V, 2011)
"Although a sample size of 440 patients was planned, after inclusion of 104 patients with delirium who were eligible for the intention-to-treat analysis (n=54 on rivastigmine, n=50 on placebo), the DSMB recommended that the trial be halted because mortality in the rivastigmine group (n=12, 22%) was higher than in the placebo group (n=4, 8%; p=0·07)."9.14Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. ( Honing, ML; Karakus, A; Kesecioglu, J; Kuiper, MA; Roes, KC; Slooter, AJ; Spronk, PE; van der Jagt, M; van der Mast, RC; van Eijk, MM; van Gool, WA, 2010)
" The prophylactic use of haloperidol did not reduce the delirium incidence (RR: 0."9.12Haloperidol for preventing delirium in ICU patients: a systematic review and meta-analysis. ( Buonanno, P; Iacovazzo, C; Kotfis, K; Marra, A; Servillo, G; Vargas, M, 2021)
"To compare the safety and estimate the response profile of olanzapine, a second-generation antipsychotic, to haloperidol in the treatment of delirium in the critical care setting."9.11Olanzapine vs haloperidol: treating delirium in a critical care setting. ( Bergeron, N; Dumont, M; Gottfried, SB; Skrobik, YK, 2004)
"To study the effectiveness of haloperidol prophylaxis on incidence, severity, and duration of postoperative delirium in elderly hip-surgery patients at risk for delirium."9.11Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. ( Bogaards, MJ; Burger, BJ; de Jonghe, JF; Egberts, TC; Eikelenboom, P; Kalisvaart, KJ; van Gool, WA; Vreeswijk, R, 2005)
"The purpose of this study was to examine the efficacy and side effects of haloperidol, chlorpromazine, and lorazepam for the treatment of the symptoms of delirium in adult AIDS patients in a randomized, double-blind, comparison trial."9.08A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. ( Breitbart, W; Corbera, K; Derevenco, M; Grau, C; Jacobson, P; Lund, S; Marotta, R; Platt, MM; Raymond, S; Weisman, H, 1996)
"Although haloperidol is mainly used for the medical treatment of delirium in cancer patients, there are no universally accepted guidelines for its usage."9.08Usage of haloperidol for delirium in cancer patients. ( Akechi, T; Fukue, M; Kagaya, A; Nishida, A; Okamura, H; Oomori, N; Uchitomi, Y; Yamawaki, S, 1996)
"Sixty-six patients (47 men, 19 women, mean age 65 years) with delirium were treated with mianserin (10-60 mg/day) or haloperidol (2-6 mg/day) at Kurume University Hospital."9.08Does plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on delirium. ( Nakamura, J; Nakazawa, Y; Uchimura, N; Yamada, S, 1997)
"Mianserin (10-60 mg), haloperidol (2-6 mg) and oxypertine (20-60 mg) were administered once before bedtime in patients with delirium in Kurume University Hospital."9.07[Effects of mianserin hydrochloride on delirium: comparison with the effects of oxypertine and haloperidol]. ( Nakamura, J; Nakazawa, Y; Uchimura, N; Yamada, S, 1994)
"Haloperidol is the most frequently used drug to treat delirium in the critically ill patients."9.05Haloperidol for the treatment of delirium in critically ill patients: A systematic review with meta-analysis and Trial Sequential Analysis. ( Andersen-Ranberg, NC; Barbateskovic, M; Collet, MO; Jakobsen, JC; Krauss, SR; Mathiesen, O; Perner, A; Wetterslev, J, 2020)
"To identify the efficacy and safety of haloperidol prophylaxis in adult patients with a high risk for delirium."9.05Efficacy and safety of haloperidol for delirium prevention in adult patients: An updated meta-analysis with trial sequential analysis of randomized controlled trials. ( Chen, R; Chen, Z; Deng, Y; Guo, H; Hou, Y; Liu, G; Su, Y; Wei, X; Wen, S; Ye, Z; Zheng, D; Zuo, L, 2020)
"Our study is a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing haloperidol versus placebo for treatment and/or prophylaxis of ICU-related delirium."9.01Haloperidol for the management of delirium in adult intensive care unit patients: A systematic review and meta-analysis of randomized controlled trials. ( Aburahma, A; Bachuwa, G; Banifadel, M; Barbarawi, M; Chahine, A; Haykal, T; Kheiri, B; Rashdan, L; Seedahmed, E; Zayed, Y, 2019)
"Our ambition with this systematic review is to provide reliable and powered evidence to better inform decision makers on the use of or future trials with haloperidol for the management of delirium in critically ill patients."8.98Haloperidol for delirium in critically ill patients - protocol for a systematic review. ( Barbateskovic, M; Collet, MO; Jakobsen, JC; Kraus, SR; Mathiesen, O; Perner, A; Wetterslev, J, 2018)
"The aim of this systematic review and meta-analysis was to investigate whether or not the use of haloperidol could reduce the incidence of delirium in adult patients."8.98Effects of Haloperidol on Delirium in Adult Patients: A Systematic Review and Meta-Analysis. ( Ji, FH; Meng, XW; Peng, K; Shen, YZ; Zhang, J, 2018)
"To identify the effectiveness of haloperidol prophylaxis in critically ill patients with a high risk for delirium."8.95Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk of delirium: a systematic review. ( Apóstolo, J; Cardoso, D; Cunha, M; Neves, H; Rodrigues, M; Santos, E, 2017)
"Haloperidol is generally considered the drug of choice for in-hospital delirium management."8.93Efficacy and safety of haloperidol for in-hospital delirium prevention and treatment: A systematic review of current evidence. ( de Graaf, K; de Vries, OJ; Maier, AB; Nanayakkara, PW; Schrijver, EJ, 2016)
"Adjunctive low-dose haloperidol prophylaxis reduces delirium severity, duration, and subsequent hospitalization length in elderly at-risk patients."8.84Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients. ( Caselli, RJ; Demaerschalk, BM; Schrader, SL; Wellik, KE; Wingerchuk, DM; Woodruff, BK, 2008)
"Intravenous haloperidol is the agent of choice for controlling severe agitated delirium in seriously ill cardiac patients in many institutions."8.79Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. ( Di Salvo, TG; O'Gara, PT, 1995)
"Delirium is a common distressing symptom observed in patients with terminal respiratory diseases and is treated with antipsychotic medications such as haloperidol."8.31Efficacy of blonanserin transdermal patch on terminal delirium in patients with respiratory diseases. ( Ando, K; Suzuki, A; Yoshida, H, 2023)
"Haloperidol is frequently used as first-line treatment for delirium."8.31[Haloperidol is not the first choice for every case of delirium]. ( Aebischer, O; Charlier, C; Jaren, L, 2023)
"For the treatment of delirium, antipsychotics such as haloperidol are used as standard treatments."8.12A retrospective comparison of haloperidol and hydroxyzine combination therapy with haloperidol alone in the treatment of overactive delirium. ( Sato, J; Tanaka, R, 2022)
"Haloperidol and clonidine are commonly used to treat agitation in delirious intensive care unit (ICU) patients, but it is unclear whether these agents may shorten the duration of delirium."8.02Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study. ( Dijkstra-Kersten, SMA; Slooter, AJC; Smit, L; van der Jagt, M; Zaal, IJ, 2021)
"The aim of this study was to evaluate outcomes of pediatric intensive care unit (PICU) patients with delirium treated with haloperidol or quetiapine compared with propensity-matched, untreated patients."8.02Haloperidol and Quetiapine for the Treatment of ICU-Associated Delirium in a Tertiary Pediatric ICU: A Propensity Score-Matched Cohort Study. ( Cronin, MT; Dervan, LA; Di Gennaro, JL; Watson, RS, 2021)
"Haloperidol is commonly administered in the ICU to reduce the burden of delirium and its related symptoms despite no clear evidence showing haloperidol helps to resolve delirium or improve survival."8.02Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults. ( Briesacher, BA; Devlin, JW; Duprey, MS; Griffith, JL; Pickkers, P; Saczynski, JS; van den Boogaard, M; van der Hoeven, JG, 2021)
"To characterize the pharmacogenomic response of low-dose haloperidol for delirium treatment in critically ill adults."7.96Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium. ( Devlin, JW; Hunfeld, NGM; Koch, BCP; Nieboer, D; Osse, RJ; Trogrlić, Z; van der Jagt, M; van Schaik, RHN, 2020)
"As delirium in critically ill children is increasingly recognized, more children are treated with the antipsychotic drug haloperidol, while current dosing guidelines are lacking solid evidence and appear to be associated with a high risk of adverse events."7.88Monitoring Haloperidol Plasma Concentration and Associated Adverse Events in Critically Ill Children With Delirium: First Results of a Clinical Protocol Aimed to Monitor Efficacy and Safety. ( de Wildt, SN; Ista, E; Jessurun, N; Slooff, VD; Tibboel, D; van Beusekom, BS; van den Dungen, DK, 2018)
"We assessed the prevalence and variables associated with haloperidol use for delirium in ICU patients and explored any associations of haloperidol use with 90-day mortality."7.88Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study. ( Barbateskovic, M; Bozza, FA; Caballero, J; Citerio, G; Collet, MO; Colpaert, K; Egerod, I; Haenggi, M; Hästbacka, J; Jensen, A; Krog, MB; Lange, T; Nibro, HL; Nydahl, P; Perner, A; Rose, L; Schandl, A; Sonneville, R; van den Boogaard, M; Wetterslev, J; Wøien, H, 2018)
"In this retrospective, descriptive cohort study of 192 patients, pipamperone as monotherapy and as an adjunct to haloperidol, haloperidol alone, or atypical antipsychotics were compared with respect to their effectiveness in the management of delirium and its subtypes over the course of 20 days."7.85Pipamperone and delirium: a preliminary evaluation of its effectiveness in the management of delirium and its subtypes. ( Boettger, S; Garcia Nuñez, D; Jenewein, J; Klaghofer, R; Knöpfel, S; Plichta, MM; Schubert, M, 2017)
" Dexmedetomidine significantly decreased the ICU LOS and ICU LOS after the occurrence of delirium compared to haloperidol (13."7.83Use of Dexmedetomidine in Liver Transplant Recipients With Postoperative Agitated Delirium. ( Choi, JY; Gwak, MS; Joh, JW; Kim, GS; Kim, JM; Kim, SJ; Ko, JS; Kwon, CH; Lee, S; Lee, SK; Park, JB, 2016)
"The aim of this study was to compare the efficacy and side-effect profile of the typical antipsychotic haloperidol with that of the atypical antipsychotics risperidone, olanzapine, and aripiprazole in the management of delirium."7.81Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. ( Boettger, S; Breitbart, W; Jenewein, J, 2015)
"To evaluate the association between cumulative dose of haloperidol and next-day diagnosis of delirium in a cohort of older medical ICU patients, with adjustment for its time-dependent confounding with fentanyl and intubation."7.81Association of cumulative dose of haloperidol with next-day delirium in older medical ICU patients. ( Araujo, KL; Murphy, TE; Pisani, MA, 2015)
"Practice guidelines recommend the use of low dose haloperidol when medication is needed to treat delirium with acute agitation in hospitalized older people."7.79Haloperidol overdosing in the treatment of agitated hospitalized older people with delirium: a retrospective chart review from a community teaching hospital. ( Dorokhine, I; Knapp, CM; Musuku, M; Patel, N; Zirker, W, 2013)
"This study was a 6-day, prospective, comparative clinical observational study of haloperidol versus atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in patients with delirium at a tertiary level hospital."7.79Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. ( Choi, SH; Choi, WJ; Kim, JJ; Park, JY; Park, KM; Seok, JH; Yoon, HJ, 2013)
" Haloperidol, a butyrophenone derivative and dopamine antagonist, is commonly prescribed for nausea, vomiting, and delirium in hospice/palliative care."7.79Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium. ( Agar M, M; Crawford, GB; Currow, DC; Doogue, M; Litster, C; Michael, N; Phillips, J; Quinn, SJ; Rowett, D, 2013)
"To compare the efficacy and tolerability of aripiprazole and haloperidol in the amelioration of distressing symptoms of delirium and its motoric subtypes."7.77Aripiprazole and haloperidol in the treatment of delirium. ( Boettger, S; Breitbart, W; Friedlander, M; Passik, S, 2011)
" We measured CAM-ICU compliance, interrater reliability, and delirium knowledge, and compared the haloperidol use, as a proxy for delirium incidence, before and after the implementation of the CAM-ICU."7.75Implementation of a delirium assessment tool in the ICU can influence haloperidol use. ( Pickkers, P; Roodbol, G; Schoonhoven, L; van Achterberg, T; van den Boogaard, M; van der Hoeven, H, 2009)
"The aim of this study was to determine the risk of adverse events for risperidone and haloperidol in delirium patients."7.74Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients. ( Hoshino, S; Miyaji, S; Miyaoka, H; Sakai, Y; Yamamoto, H; Yamamoto, K, 2007)
"The phenomenon of restlessness, agitation, or cognitive disturbances experienced by dying patients is well-known in palliative care; more than half of these patients will experience delirium symptoms at end-of-life."7.11An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home. ( Chong, PH; Kan, AD; Koh, YH; Lin, K; Lyu, XJ; Yeo, ZZ, 2022)
"Haloperidol is a preferred agent for the treatment of delirium in this population because of its rapid onset of action and lack of hemodynamic effects."6.48Haloperidol dosing strategies in the treatment of delirium in the critically ill. ( Ensom, MH; Loh, GW; Mabasa, VH; Wang, EH, 2012)
"Delirium is common in acutely ill patients and can result in substantial morbidity if left untreated."6.44Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. ( Battistone, S; Devlin, JW; Fong, JJ; Rea, RS, 2007)
"The AID-ICU trial was a randomised, blinded, placebo-controlled trial investigating effects of haloperidol versus placebo in acutely admitted, adult patients admitted in intensive care unit (ICU) with delirium."5.69Haloperidol vs. placebo for the treatment of delirium in ICU patients: a pre-planned, secondary Bayesian analysis of the AID-ICU trial. ( Andersen-Ranberg, NC; Andreasen, AS; Bestle, M; Citerio, G; Collet, MO; Damgaard, K; Dey, N; Granholm, A; Hästbacka, J; Jensen, TB; Mathiesen, O; Morgan, M; Nielsen, LG; Pedersen, HS; Perner, A; Poulsen, LM; Sommer, T; Uslu, B; Weber, SO, 2023)
"This is an open-label, parallel-group, randomized controlled trial to compare the efficacy and safety of dexmedetomidine and haloperidol for nocturnal hyperactive delirium in non-intubated patients at two HDUs of a tertiary hospital."5.69Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial). ( Harada, H; Ikeda, K; Kamei, J; Kato, T; Kitajima, N; Kuriyama, A; Maeda, J; Matsuyama, A; Minami, T; Mizota, T; Ohtsuru, S; Sakai, Y; Sato, Y; Takatani, Y; Ueno, K; Watanabe, H; Yamaji, K; Yamashita, Y, 2023)
"The role of haloperidol as treatment for ICU delirium and related symptoms remains controversial despite two recent large controlled trials evaluating its efficacy and safety."5.69Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial. ( Boer, DP; Brouwers, AJBW; Devlin, JW; Gommers, DAMPJ; Hunfeld, NGM; Lens, JA; Osse, RJ; Ponssen, HH; Rietdijk, WJR; Schoonderbeek, JF; Simons, KS; Slooter, AJC; Smit, L; Trogrlic, Z; van den Boogaard, M; van der Jagt, M, 2023)
"Haloperidol is frequently used to treat delirium in patients in the intensive care unit (ICU), but evidence of its effect is limited."5.51Haloperidol for the Treatment of Delirium in ICU Patients. ( Aagaard, SR; Andersen-Ranberg, NC; Andreasen, AS; Bestle, MH; Brand, B; Brix, H; Caballero, J; Citerio, G; de Haas, I; Ebdrup, BH; Engstrøm, J; Eriksen, AS; Estrup, S; Fjeldsøe-Nielsen, H; Gramstrup Nielsen, L; Hästbacka, J; Haurum, C; Hildebrandt, T; Hyttel-Sørensen, S; Jensen, JV; Kingo Vesterlund, G; Kjær, MN; Kuivalainen, AM; La Cour, K; Laigaard, J; Lange, T; Mathiesen, O; Mikkelsen, VS; Morgan, M; Mortensen, CB; Nebrich, L; Nielsen, LO; Olesen, MW; Olsen, MH; Overgaard-Steensen, C; Oxenbøll Collet, M; Perner, A; Poulsen, LM; Rasmussen, BS; Scharling Pedersen, H; Schønemann-Lund, M; Thornberg Kyhnauv, P; Toft Boesen, HC; Uslu, B; Weber, SO; Westergaard, B; Wetterslev, J, 2022)
"To examine the association between the anticholinergic burden (ACB) and the duration and severity of delirium in older hip-surgery patients with or without haloperidol prophylaxis."5.41The effect of the anticholinergic burden on duration and severity of delirium in older hip-surgery patients with and without haloperidol prophylaxis: A post hoc analysis. ( Butterhoff-Terlingen, MH; Egberts, TCG; Kalisvaart, KJ; Stuffken, R; Tillemans, MPH; Vreeswijk, R, 2021)
" Meta-analyses and GRADE level of evidence ratings show no increased delirium risk for Haloperidol (OR: 0."5.41Delirium-associated medication in people at risk: A systematic update review, meta-analyses, and GRADE-profiles. ( Biasi, J; Fellendorf, FT; Reininghaus, EZ; Reisinger, M; Schoberer, D, 2023)
"None of the three study arms - haloperidol, ketamine, or both drugs combined - was significantly superior to placebo for prevention of postoperative brain dysfunction and delirium (P = 0."5.41Ketamine vs. haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial. ( Brügger, J; Gysi, B; Hollinger, A; Huber, J; Rentsch, K; Riegger, H; Rüst, CA; Schmid, HR; Siegemund, M; Steiner, L; Surbeck, M; Toft, K; Tran, F, 2021)
"This was a pre-planned secondary analysis of a double-blind, randomized clinical trial comparing the use of a single dose of lorazepam plus haloperidol versus placebo plus haloperidol in patients with agitated delirium."5.41Association among rescue neuroleptic use, agitation, and perceived comfort: secondary analysis of a randomized clinical trial on agitated delirium. ( Bruera, E; Chen, M; Hui, D; Tang, M, 2021)
"This was a preplanned secondary analysis of a double-blind randomized clinical trial examining the sedative effect of chlorpromazine and/or haloperidol in patients with agitated delirium."5.41Personalized sedation goal for agitated delirium in patients with cancer: Balancing comfort and communication. ( Bruera, E; De La Rosa, A; Hui, D; Nguyen, T; Urbauer, DL, 2021)
"Haloperidol was initiated at 5 mg intravenous every 6 h and titrated up to a dose of 60 mg /day over 5 days."5.39Neuroleptic malignant syndrome associated with haloperidol use in critical care setting: should haloperidol still be considered the drug of choice for the management of delirium in the critical care setting? ( Adelman, M; Dixit, D; Shrestha, P, 2013)
"Treatment of delirium often includes haloperidol."5.34Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020)
"The AID-ICU trial aims to assess the benefits and harms of haloperidol for the treatment of delirium in acutely admitted, adult intensive care unit (ICU) patients."5.34The Agents Intervening against Delirium in the Intensive Care Unit Trial (AID-ICU trial): A detailed statistical analysis plan. ( Andersen-Ranberg, N; Bestle, MH; Caballero, J; Citerio, G; Dey, N; Ebdrup, BH; Estrup, S; Hästbacka, J; Jensen, TB; Lange, T; Mathiesen, O; Morgan, MPG; Mortensen, CB; Nielsen, LG; Oxenbøll-Collet, M; Pedersen, HBS; Perner, A; Poulsen, LM; Sofie Andreasen, A; Thee, C; Uslu, B; Weber, SO; Wetterslev, J, 2020)
"Therefore treatment of delirium with a cholinesterase-inhibitor seems logical."5.32[Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine]. ( Boelaarts, L; de Jonghe, JF; Hovinga, IM; Kalisvaart, CJ; Kat, MG, 2004)
"A new delirium was induced when, after discharge from the hospital, betahistine was restarted because of dizziness."5.32[Delirium in a 73-year-old man after many years of unwise use of betahistine]. ( Hoenders, HJ; Wilterdink, J, 2004)
"A preplanned secondary analysis of long-term outcomes of the pRophylactic haloperidol usE for DeliriUm in iCu patients at high risk for dElirium (REDUCE) study was conducted."5.30Prophylactic Haloperidol Effects on Long-term Quality of Life in Critically Ill Patients at High Risk for Delirium: Results of the REDUCE Study. ( Beishuizen, A; Pickkers, P; Rood, PJT; Simons, KS; Slooter, AJC; Spronk, PE; van den Boogaard, M; van der Hoeven, JG; van der Voort, PHJ; van der Woude, MCE; Zegers, M, 2019)
"AID-ICU is an investigator-initiated, pragmatic, international, randomised, blinded, parallel-group, trial allocating adult ICU patients with manifest delirium 1:1 to haloperidol or placebo."5.30Agents intervening against delirium in the intensive care unit (AID-ICU) - Protocol for a randomised placebo-controlled trial of haloperidol in patients with delirium in the ICU. ( Andersen-Ranberg, NC; Andreasen, AS; Bestle, M; Caballero, J; Citerio, G; Dey, N; Ebdrup, BH; Estrup, S; Hästbacka, J; Hildebrandt, T; Jensen, TB; Lange, T; Mathiesen, O; Morgan, MPG; Nielsen, LG; Oxenbøll-Collet, M; Pedersen, HBS; Perner, A; Poulsen, LM; Thee, C; Weber, SO; Wetterslev, J; Zafrani, L, 2019)
"because the few randomised placebo-controlled trials investigating the potential role for prophylactic haloperidol in delirium prevention have focused on specific surgical populations, we investigated its efficacy and safety in acutely hospitalised older patients."5.27Haloperidol versus placebo for delirium prevention in acutely hospitalised older at risk patients: a multi-centre double-blind randomised controlled clinical trial. ( Anten, S; Bet, PM; Bloemers, FW; Boelaarts, L; de Vries, OJ; Diepeveen, SHA; Kamper, AM; Kramer, MHH; Lagaay, AM; Nanayakkara, PWB; Schrijver, EJM; van de Ven, PM; van Marum, RJ; van Strien, AM, 2018)
"Results of studies on use of prophylactic haloperidol in critically ill adults are inconclusive, especially in patients at high risk of delirium."5.27Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. ( Beishuizen, A; Besselink, A; Brüggemann, RJM; de Koning, J; Dennesen, PJW; Donker, DW; Fuchs, M; Hannink, G; Hofstra, LS; Houterman, S; Karakus, A; Koeman, M; Pickkers, P; Pretorius, D; Schoonhoven, L; Simons, KS; Slooter, AJC; Spronk, PE; van den Bergh, W; van den Boogaard, M; van der Hoeven, JG; Van der Voort, PHJ; van Duijnhoven, M; Vermeijden, JW, 2018)
"The current study was a secondary analysis of a randomized controlled trial to compare the effect of lorazepam versus placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium."5.27The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. ( Arthur, J; Bruera, E; Dalal, S; Dev, R; Dibaj, SS; Hess, K; Hui, D; Reddy, S, 2018)
"The Baden PRIDe Trial is an investigator-initiated, phase IV, two-centre, randomised, placebo-controlled, double-blind clinical trial for the prevention of delirium with haloperidol, ketamine, and the combination of both vs."5.27Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial (PRIDe): a phase IV multicenter, randomized, placebo-controlled, double-blind clinical trial of ketamine versus haloperidol for prevention of postoperative delirium. ( Blum, A; Hollinger, A; Riegger, H; Seifert, B; Siegemund, M; Toft, K; Zehnder, T, 2018)
"In a randomized, double-blind, placebo-controlled trial, we assigned patients with acute respiratory failure or shock and hypoactive or hyperactive delirium to receive intravenous boluses of haloperidol (maximum dose, 20 mg daily), ziprasidone (maximum dose, 40 mg daily), or placebo."5.27Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. ( Bernard, GR; Boehm, LM; Bowton, DL; Brummel, NE; Carson, SS; Chandrasekhar, R; Dittus, RS; Douglas, IS; Ely, EW; Exline, MC; Feinstein, DJ; Girard, TD; Gong, MN; Hite, RD; Hough, CL; Hughes, CG; Hyzy, RC; Jackson, JC; Khan, B; Malhotra, A; Masica, AL; Owens, RL; Pandharipande, PP; Patel, MB; Pisani, MA; Pun, BT; Rock, P; Schmidt, GA; Schweickert, WD; Stollings, JL; Strength, C; Thompson, JL, 2018)
"To assess the efficacy of haloperidol in reducing postoperative delirium in individuals undergoing thoracic surgery."5.27Preventing Postoperative Delirium After Major Noncardiac Thoracic Surgery-A Randomized Clinical Trial. ( Boustani, MA; Campbell, NL; Fuchita, M; Gao, S; Kesler, K; Khan, BA; Khan, SH; Perkins, AJ; Wang, S; Weber, DJ; Zarzaur, BL, 2018)
"To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of advanced cancer."5.24Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. ( Amin, S; Breitbart, W; Bruera, E; De La Cruz, M; Delgado-Guay, M; Dibaj, SS; Epner, D; Frisbee-Hume, S; Hall, S; Hess, K; Hui, D; Liu, D; Nguyen, T; Reddy, A; Tanco, K; Vidal, M; Walker, P; Williams, J; Wilson, A; Zhukovsky, DS, 2017)
"The aim of this study was to evaluate the safety and efficacy of the early administration haloperidol in preventing the aggravation of postoperative delirium in elderly patients."5.24Haloperidol prophylaxis for preventing aggravation of postoperative delirium in elderly patients: a randomized, open-label prospective trial. ( Akiyama, H; Ando, M; Fujishiro, K; Fukata, S; Hattori, H; Kawabata, Y; Kitagawa, Y; Kuroiwa, K; Takemura, M, 2017)
"To determine efficacy of risperidone or haloperidol relative to placebo in relieving target symptoms of delirium associated with distress among patients receiving palliative care."5.24Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial. ( Agar, MR; Caplan, GA; Currow, DC; Devilee, L; Draper, B; Eckermann, S; Fazekas, B; Hardy, J; Hill, M; Lawlor, PG; Le, B; McCaffrey, N; Quinn, S; Rowett, D; Sanderson, C, 2017)
"To compare the efficacy and safety of scheduled low-dose haloperidol versus placebo for the prevention of delirium (Intensive Care Delirium Screening Checklist ≥ 4) administered to critically ill adults with subsyndromal delirium (Intensive Care Delirium Screening Checklist = 1-3)."5.22Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. ( Al-Qadheeb, NS; Devlin, JW; Pacheco, MN; Roberts, RJ; Ruthazer, RR; Schumaker, G; Skrobik, Y, 2016)
"To evaluate the clinical effectiveness, safety, and cost of dexmedetomidine for the treatment of agitated delirium refractory to haloperidol in nonintubated critically ill patients."5.22Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial. ( Baeza, N; Cabré, L; Calizaya, M; Carrasco, G; Gimeno, G; Manzanedo, D; Portillo, E, 2016)
"Patients enrolled in a randomized controlled clinical trial of melatonin versus placebo on occurrence of delirium in hip-fracture patients."5.20In-Hospital Haloperidol Use and Perioperative Changes in QTc-Duration. ( Blom, MT; de Boer, A; de Jonghe, A; de Rooij, SE; Jansen, S; Tan, HL; van der Velde, N; van Munster, BC, 2015)
" One hundred and seventeen adult patients undergoing cardiac surgery were included before introduction of a screening and treatment protocol with haloperidol for delirium, and 123 patients were included after."5.19Effects of a screening and treatment protocol with haloperidol on post-cardiotomy delirium: a prospective cohort study. ( Balslev Jørgensen, M; Kirkegaard, T; Lind Jørgensen, V; Schrøder Pedersen, S, 2014)
"The preventive administration of low-dose haloperidol did not induce any adverse events, but also did not significantly decrease the incidence or severity of postoperative delirium or shorten its persistence."5.19Haloperidol prophylaxis does not prevent postoperative delirium in elderly patients: a randomized, open-label prospective trial. ( Akiyama, H; Ando, M; Fujisiro, K; Fukata, S; Hattori, H; Katagawa, Y; Kawabata, Y; Kawamura, T; Kuroiwa, K; Terabe, Y, 2014)
"The HARPOON study will provide relevant information on the efficacy and safety of prophylactic haloperidol treatment for in-hospital delirium and its effects on relevant clinical outcomes in elderly at-risk medical and surgical patients."5.19Efficacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk patients acutely admitted to hospital through the emergency department: study protocol of a multicenter, randomised, double-blind, placebo-control ( Anten, S; Bet, PM; Boelaarts, L; de Graaf, K; de Vries, OJ; Diepeveen, SH; Kamper, AM; Kramer, MH; Kuipéri, E; Lagaay, AM; Nanayakkara, PW; Pons, D; Schrijver, EJ; Siegel, A; van de Ven, PM; van Marum, RJ; van Strien, AM; Verburg, A, 2014)
"Patients were randomized into 2 groups; in group 1, patients received 5mg of haloperidol intramuscularly and in group 2, patients received 5mg of morphine sulfate intramuscularly to control delirium symptoms."5.17Morphine is a reasonable alternative to haloperidol in the treatment of postoperative hyperactive-type delirium after cardiac surgery. ( Akgün, S; Atalan, N; Başaran, C; Efe Sevim, M; Fazlıoğulları, O, 2013)
"Low-dose quetiapine and haloperidol may be equally effective and safe for controlling delirium symptoms."5.17Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial. ( Chittawatanarat, K; Maneeton, B; Maneeton, N; Srisurapanont, M, 2013)
"This will be the first large-scale multicenter randomized controlled prevention study with haloperidol in ICU patients with a high risk of delirium, adequately powered to demonstrate an effect on 28-day survival."5.17Prevention of ICU delirium and delirium-related outcome with haloperidol: a study protocol for a multicenter randomized controlled trial. ( Beishuizen, A; Brüggemann, RJ; Hoogendoorn, ME; Houterman, S; Kuiper, MA; Pickkers, P; Schoonhoven, L; Schouten, JA; Slooter, AJ; Spronk, PE; van den Boogaard, M; van der Hoeven, JG; van der Voort, PH, 2013)
"These results do not support the hypothesis that haloperidol modifies duration of delirium in critically ill patients."5.17Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. ( Alce, T; Ely, EW; Gates, S; Jackson, J; McAuley, DF; Page, VJ; Perkins, GD; Shintani, A; Zhao, XB, 2013)
"This study was a before/after evaluation of a delirium prevention project using prophylactic treatment with haloperidol."5.17Haloperidol prophylaxis in critically ill patients with a high risk for delirium. ( Pickkers, P; Schoonhoven, L; van Achterberg, T; van den Boogaard, M; van der Hoeven, JG, 2013)
"To evaluate the efficacy and safety of short-term low-dose intravenous haloperidol for delirium prevention in critically ill elderly patients after noncardiac surgery."5.16Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: a randomized controlled trial*. ( Chen, KS; Gu, XE; Li, HL; Li, SL; Wang, DX; Wang, W; Yao, GQ; Zhu, SN; Zhu, X, 2012)
"To investigate the controlling efficacy of ondasetron and haloperidol in regard to the postcardiotomy delirium."5.16Ondasetron versus haloperidol for the treatment of postcardiotomy delirium: a prospective, randomized, double-blinded study. ( Daskalopoulos, ME; Gogaki, E; Papaliagkas, V; Parisis, C; Sataitidis, I; Tagarakis, GI; Tsagalas, I; Tsilimingas, NB; Tsolaki, F; Tsolaki, M; Voucharas, C, 2012)
" haloperidol in patients of delirium admitted to medical and surgical wards."5.15Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. ( Chakrabarti, S; Grover, S; Kumar, V, 2011)
"Agitated delirium is common in patients undergoing mechanical ventilation, and is often treated with haloperidol despite concerns about safety and efficacy."5.14Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. ( Ainslie, WR; Bates, S; Bellomo, R; Goldsmith, D; O'Sullivan, K; Reade, MC, 2009)
"To compare the efficacy and safety of scheduled quetiapine to placebo for the treatment of delirium in critically ill patients requiring as-needed haloperidol."5.14Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. ( Devlin, JW; Fong, JJ; Garpestad, E; Hill, NS; Riker, RR; Robbins, T; Roberts, RJ; Skrobik, Y, 2010)
"Although a sample size of 440 patients was planned, after inclusion of 104 patients with delirium who were eligible for the intention-to-treat analysis (n=54 on rivastigmine, n=50 on placebo), the DSMB recommended that the trial be halted because mortality in the rivastigmine group (n=12, 22%) was higher than in the placebo group (n=4, 8%; p=0·07)."5.14Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. ( Honing, ML; Karakus, A; Kesecioglu, J; Kuiper, MA; Roes, KC; Slooter, AJ; Spronk, PE; van der Jagt, M; van der Mast, RC; van Eijk, MM; van Gool, WA, 2010)
" Hip surgery patients (n = 112) aged 70 years and older, who participated in a controlled clinical trial of haloperidol prophylaxis for delirium, were followed for an average of 30 months after discharge."5.13Long-term cognitive outcome of delirium in elderly hip surgery patients. A prospective matched controlled study over two and a half years. ( de Jonghe, JF; Eikelenboom, P; Kalisvaart, KJ; Kat, MG; van der Ploeg, T; van Gool, WA; Vreeswijk, R, 2008)
" The prophylactic use of haloperidol did not reduce the delirium incidence (RR: 0."5.12Haloperidol for preventing delirium in ICU patients: a systematic review and meta-analysis. ( Buonanno, P; Iacovazzo, C; Kotfis, K; Marra, A; Servillo, G; Vargas, M, 2021)
"To compare the safety and estimate the response profile of olanzapine, a second-generation antipsychotic, to haloperidol in the treatment of delirium in the critical care setting."5.11Olanzapine vs haloperidol: treating delirium in a critical care setting. ( Bergeron, N; Dumont, M; Gottfried, SB; Skrobik, YK, 2004)
"To study the effectiveness of haloperidol prophylaxis on incidence, severity, and duration of postoperative delirium in elderly hip-surgery patients at risk for delirium."5.11Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. ( Bogaards, MJ; Burger, BJ; de Jonghe, JF; Egberts, TC; Eikelenboom, P; Kalisvaart, KJ; van Gool, WA; Vreeswijk, R, 2005)
"The purpose of this study was to examine the efficacy and side effects of haloperidol, chlorpromazine, and lorazepam for the treatment of the symptoms of delirium in adult AIDS patients in a randomized, double-blind, comparison trial."5.08A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. ( Breitbart, W; Corbera, K; Derevenco, M; Grau, C; Jacobson, P; Lund, S; Marotta, R; Platt, MM; Raymond, S; Weisman, H, 1996)
"Although haloperidol is mainly used for the medical treatment of delirium in cancer patients, there are no universally accepted guidelines for its usage."5.08Usage of haloperidol for delirium in cancer patients. ( Akechi, T; Fukue, M; Kagaya, A; Nishida, A; Okamura, H; Oomori, N; Uchitomi, Y; Yamawaki, S, 1996)
"Sixty-six patients (47 men, 19 women, mean age 65 years) with delirium were treated with mianserin (10-60 mg/day) or haloperidol (2-6 mg/day) at Kurume University Hospital."5.08Does plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on delirium. ( Nakamura, J; Nakazawa, Y; Uchimura, N; Yamada, S, 1997)
"Mianserin (10-60 mg), haloperidol (2-6 mg) and oxypertine (20-60 mg) were administered once before bedtime in patients with delirium in Kurume University Hospital."5.07[Effects of mianserin hydrochloride on delirium: comparison with the effects of oxypertine and haloperidol]. ( Nakamura, J; Nakazawa, Y; Uchimura, N; Yamada, S, 1994)
"Haloperidol is the most frequently used drug to treat delirium in the critically ill patients."5.05Haloperidol for the treatment of delirium in critically ill patients: A systematic review with meta-analysis and Trial Sequential Analysis. ( Andersen-Ranberg, NC; Barbateskovic, M; Collet, MO; Jakobsen, JC; Krauss, SR; Mathiesen, O; Perner, A; Wetterslev, J, 2020)
"To identify the efficacy and safety of haloperidol prophylaxis in adult patients with a high risk for delirium."5.05Efficacy and safety of haloperidol for delirium prevention in adult patients: An updated meta-analysis with trial sequential analysis of randomized controlled trials. ( Chen, R; Chen, Z; Deng, Y; Guo, H; Hou, Y; Liu, G; Su, Y; Wei, X; Wen, S; Ye, Z; Zheng, D; Zuo, L, 2020)
" All of the participants had delirium, were treated with haloperidol, and were randomised to receive either lorazepam or placebo in combination with it."5.05Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an intensive care unit. ( Chen, J; Jin, Y; Li, N; Li, Y; Ma, J; Mu, W; Shang, HC; Si, JH; Wang, J; Zheng, R, 2020)
"Across 16 RCTs and 10 observational studies of hospitalized adults, there was no difference in sedation status (low and moderate SOE), delirium duration, hospital length of stay (moderate SOE), or mortality between haloperidol and second-generation antipsychotics versus placebo."5.01Antipsychotics for Treating Delirium in Hospitalized Adults: A Systematic Review. ( Needham, DM; Neufeld, KJ; Nikooie, R; Oh, ES; Robinson, KA; Wilson, LM; Zhang, A, 2019)
" There were no differences in delirium incidence or duration, hospital length of stay (high strength of evidence [SOE]), and mortality between haloperidol and placebo used for delirium prevention."5.01Antipsychotics for Preventing Delirium in Hospitalized Adults: A Systematic Review. ( Needham, DM; Neufeld, KJ; Nikooie, R; Oh, ES; Robinson, KA; Wilson, LM; Zhang, A, 2019)
"Our study is a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing haloperidol versus placebo for treatment and/or prophylaxis of ICU-related delirium."5.01Haloperidol for the management of delirium in adult intensive care unit patients: A systematic review and meta-analysis of randomized controlled trials. ( Aburahma, A; Bachuwa, G; Banifadel, M; Barbarawi, M; Chahine, A; Haykal, T; Kheiri, B; Rashdan, L; Seedahmed, E; Zayed, Y, 2019)
"This network meta-analysis demonstrated that haloperidol plus lorazepam might be the best treatment and ramelteon the best preventive medicine for delirium."5.01Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis. ( Carvalho, AF; Chen, TY; Chen, YW; Chu, CS; Hsu, CY; Liang, CS; Lin, PY; Matsuoka, YJ; Stubbs, B; Su, KP; Tseng, PT; Tu, YK; Wada, S; Wu, YC; Yeh, TC, 2019)
"Our ambition with this systematic review is to provide reliable and powered evidence to better inform decision makers on the use of or future trials with haloperidol for the management of delirium in critically ill patients."4.98Haloperidol for delirium in critically ill patients - protocol for a systematic review. ( Barbateskovic, M; Collet, MO; Jakobsen, JC; Kraus, SR; Mathiesen, O; Perner, A; Wetterslev, J, 2018)
"The aim of this systematic review and meta-analysis was to investigate whether or not the use of haloperidol could reduce the incidence of delirium in adult patients."4.98Effects of Haloperidol on Delirium in Adult Patients: A Systematic Review and Meta-Analysis. ( Ji, FH; Meng, XW; Peng, K; Shen, YZ; Zhang, J, 2018)
"There is probably little or no difference between haloperidol and placebo for preventing ICU delirium but further studies are needed to increase our confidence in the findings."4.98Interventions for preventing intensive care unit delirium in adults. ( Bekker Mortensen, C; Egerod, I; Greve, IE; Herling, SF; Møller, AM; Svenningsen, H; Thomsen, T; Vasilevskis, EE, 2018)
"To identify the effectiveness of haloperidol prophylaxis in critically ill patients with a high risk for delirium."4.95Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk of delirium: a systematic review. ( Apóstolo, J; Cardoso, D; Cunha, M; Neves, H; Rodrigues, M; Santos, E, 2017)
"Haloperidol is generally considered the drug of choice for in-hospital delirium management."4.93Efficacy and safety of haloperidol for in-hospital delirium prevention and treatment: A systematic review of current evidence. ( de Graaf, K; de Vries, OJ; Maier, AB; Nanayakkara, PW; Schrijver, EJ, 2016)
"The use of antipsychotics for surgical ICU patients and dexmedetomidine for mechanically ventilated patients as a preventive strategy may reduce the prevalence of delirium in the ICU."4.91Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review. ( Bozza, FA; do Brasil, PE; Ely, EW; Salluh, JI; Serafim, RB; Soares, M; Tura, BR, 2015)
"Haloperidol (HP) is used for the symptomatic treatment of psychosis, manic phases, hyperactivity, aggressiveness, and acute delirium."4.89Haloperidol cytotoxicity and its relation to oxidative stress. ( Adam, V; Babula, P; Gumulec, J; Kizek, R; Masarik, M; Novakova, M; Polanska, H; Raudenska, M; Stracina, T; Sztalmachova, M, 2013)
"The existing limited data indicates no superiority for second-generation antipsychotics over haloperidol in managing delirium."4.85Pharmacological management of delirium in hospitalized adults--a systematic evidence review. ( Ademuyiwa, A; Ayub, A; Boustani, MA; Campbell, N; Farber, M; Fox, GC; Guzman, O; Munger, SL; Ott, C; Singh, R, 2009)
"To compare the efficacy and incidence of adverse effects of haloperidol with risperidone, olanzapine, and quetiapine in the treatment of delirium."4.84Antipsychotics for delirium. ( Britton, AM; Lonergan, E; Luxenberg, J; Wyller, T, 2007)
"A review of current literature supports the conclusion that atypical antipsychotic medications demonstrate similar rates of efficacy as haloperidol for the treatment of delirium in the elderly patient, with a lower rate of extrapyramidal side effects."4.84Atypical antipsychotics for the treatment of delirious elders. ( Kaiser, RM; Ozbolt, LB; Paniagua, MA, 2008)
"Adjunctive low-dose haloperidol prophylaxis reduces delirium severity, duration, and subsequent hospitalization length in elderly at-risk patients."4.84Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients. ( Caselli, RJ; Demaerschalk, BM; Schrader, SL; Wellik, KE; Wingerchuk, DM; Woodruff, BK, 2008)
"The data from one study of 30 patients would perhaps suggest that haloperidol is the most suitable drug therapy for the treatment of patients with delirium near the end of life."4.82Drug therapy for delirium in terminally ill patients. ( Jackson, KC; Lipman, AG, 2004)
"Intravenous haloperidol is the agent of choice for controlling severe agitated delirium in seriously ill cardiac patients in many institutions."4.79Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. ( Di Salvo, TG; O'Gara, PT, 1995)
"Intravenous haloperidol is recommended as the drug of choice to treat delirium in ICU patients."4.79Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients. ( Fraser, GL; Richen, P; Riker, RR, 1997)
"Delirium is a common distressing symptom observed in patients with terminal respiratory diseases and is treated with antipsychotic medications such as haloperidol."4.31Efficacy of blonanserin transdermal patch on terminal delirium in patients with respiratory diseases. ( Ando, K; Suzuki, A; Yoshida, H, 2023)
"The findings of this cohort study suggest that the discontinuation rate of newly initiated APMs for delirium following infection-related hospitalization was lower in atypical APM users than in haloperidol users, with prolonged hospitalization and dementia as major associated variables."4.31Antipsychotic Medication Use Among Older Adults Following Infection-Related Hospitalization. ( Bessette, LG; Lin, KJ; Wilkins, JM; Wong, V; York, C; Zhang, Y, 2023)
"Haloperidol is frequently used as first-line treatment for delirium."4.31[Haloperidol is not the first choice for every case of delirium]. ( Aebischer, O; Charlier, C; Jaren, L, 2023)
"For the treatment of delirium, antipsychotics such as haloperidol are used as standard treatments."4.12A retrospective comparison of haloperidol and hydroxyzine combination therapy with haloperidol alone in the treatment of overactive delirium. ( Sato, J; Tanaka, R, 2022)
" Inquiries were made regarding: (i) choice of drug class in the first-line treatment, (ii) administration methods of the first-line antipsychotic treatment, (iii) starting dose of antipsychotics in the first line treatment and maximum dose of antipsychotics in refractory delirium, and (iv) choice of treatment when the first-line haloperidol treatment failed."4.12Current practice of pharmacological treatment for hyperactive delirium in terminally ill cancer patients: results of a nationwide survey of Japanese palliative care physicians and liaison psychiatrists. ( Kashiwagi, H; Matsuda, Y; Morita, T; Naito, AS; Otani, H; Oya, K; Tagami, K, 2022)
"Haloperidol and clonidine are commonly used to treat agitation in delirious intensive care unit (ICU) patients, but it is unclear whether these agents may shorten the duration of delirium."4.02Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study. ( Dijkstra-Kersten, SMA; Slooter, AJC; Smit, L; van der Jagt, M; Zaal, IJ, 2021)
"The aim of this study was to evaluate outcomes of pediatric intensive care unit (PICU) patients with delirium treated with haloperidol or quetiapine compared with propensity-matched, untreated patients."4.02Haloperidol and Quetiapine for the Treatment of ICU-Associated Delirium in a Tertiary Pediatric ICU: A Propensity Score-Matched Cohort Study. ( Cronin, MT; Dervan, LA; Di Gennaro, JL; Watson, RS, 2021)
"Haloperidol is commonly administered in the ICU to reduce the burden of delirium and its related symptoms despite no clear evidence showing haloperidol helps to resolve delirium or improve survival."4.02Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults. ( Briesacher, BA; Devlin, JW; Duprey, MS; Griffith, JL; Pickkers, P; Saczynski, JS; van den Boogaard, M; van der Hoeven, JG, 2021)
"Although extrapyramidal adverse effects are less common with olanzapine than with typical antipsychotics, they sometimes occur and can mimic manifestations of delirium."4.02Extrapyramidal Symptoms Induced by Treatment for Delirium: A Case Report. ( Rose, MQ; Santos, CD, 2021)
"To characterize the pharmacogenomic response of low-dose haloperidol for delirium treatment in critically ill adults."3.96Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium. ( Devlin, JW; Hunfeld, NGM; Koch, BCP; Nieboer, D; Osse, RJ; Trogrlić, Z; van der Jagt, M; van Schaik, RHN, 2020)
" Patients who showed positive Confusion Assessment Method or received haloperidol within 4 days postoperatively were enrolled as those with postoperative delirium (+)."3.88Hydroxyethyl starch is associated with early postoperative delirium in patients undergoing esophagectomy. ( Ahn, HJ; Jung, DM; Kim, DK; Kim, JA; Lee, SM; Park, JH; Yang, M, 2018)
"As delirium in critically ill children is increasingly recognized, more children are treated with the antipsychotic drug haloperidol, while current dosing guidelines are lacking solid evidence and appear to be associated with a high risk of adverse events."3.88Monitoring Haloperidol Plasma Concentration and Associated Adverse Events in Critically Ill Children With Delirium: First Results of a Clinical Protocol Aimed to Monitor Efficacy and Safety. ( de Wildt, SN; Ista, E; Jessurun, N; Slooff, VD; Tibboel, D; van Beusekom, BS; van den Dungen, DK, 2018)
"We assessed the prevalence and variables associated with haloperidol use for delirium in ICU patients and explored any associations of haloperidol use with 90-day mortality."3.88Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study. ( Barbateskovic, M; Bozza, FA; Caballero, J; Citerio, G; Collet, MO; Colpaert, K; Egerod, I; Haenggi, M; Hästbacka, J; Jensen, A; Krog, MB; Lange, T; Nibro, HL; Nydahl, P; Perner, A; Rose, L; Schandl, A; Sonneville, R; van den Boogaard, M; Wetterslev, J; Wøien, H, 2018)
" Fentanyl, midazolam, and dexmedetomidine were the first choices of agents for analgesic, sedation, and delirium treatment."3.85A National Multicenter Survey on Management of Pain, Agitation, and Delirium in Intensive Care Units in China. ( Hu, B; Li, JG; Peng, ZY; Rao, X; Wang, J; Zhou, WH, 2017)
"In this retrospective, descriptive cohort study of 192 patients, pipamperone as monotherapy and as an adjunct to haloperidol, haloperidol alone, or atypical antipsychotics were compared with respect to their effectiveness in the management of delirium and its subtypes over the course of 20 days."3.85Pipamperone and delirium: a preliminary evaluation of its effectiveness in the management of delirium and its subtypes. ( Boettger, S; Garcia Nuñez, D; Jenewein, J; Klaghofer, R; Knöpfel, S; Plichta, MM; Schubert, M, 2017)
"A patient with bipolar I disorder has been treated with lithium and haloperidol for the last 20 years and received an ACE inhibitor for his hypertension since 9 years ago."3.85Hypertensive bipolar: chronic lithium toxicity in patients taking ACE inhibitor. ( Abdul Aziz, MF; Masiran, R, 2017)
"To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS)."3.83Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study. ( Goya, S; Kai, T; Kanemura, S; Kashiwagi, Y; Maeda, I; Matsuda, Y; Nakajima, S; Okamoto, Y; Taira, T; Takei, K; Tanimukai, H; Tokoro, A; Tokuyama, M; Tsujimoto, H; Tsujio, I; Watanabe, M, 2016)
" The outcome of interest was death within 14 days from commencement of haloperidol treatment for delirium."3.83Predictors of Mortality for Delirium in Palliative Care. ( Agar, MR; Collier, A; Crawford, GB; Currow, DC; Phillips, JL; Quinn, SJ; Ritchie, CS, 2016)
" Dexmedetomidine significantly decreased the ICU LOS and ICU LOS after the occurrence of delirium compared to haloperidol (13."3.83Use of Dexmedetomidine in Liver Transplant Recipients With Postoperative Agitated Delirium. ( Choi, JY; Gwak, MS; Joh, JW; Kim, GS; Kim, JM; Kim, SJ; Ko, JS; Kwon, CH; Lee, S; Lee, SK; Park, JB, 2016)
"The World Health Organization recommends that anxiety, depression, agitation and delirium at end of life should be treated with drugs such as lorazepam, diazepam, midazolam and haloperidol."3.83Look again at psychedelic drugs. ( Cameron, R, 2016)
"The aim of this study was to compare the efficacy and side-effect profile of the typical antipsychotic haloperidol with that of the atypical antipsychotics risperidone, olanzapine, and aripiprazole in the management of delirium."3.81Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. ( Boettger, S; Breitbart, W; Jenewein, J, 2015)
"To evaluate the association between cumulative dose of haloperidol and next-day diagnosis of delirium in a cohort of older medical ICU patients, with adjustment for its time-dependent confounding with fentanyl and intubation."3.81Association of cumulative dose of haloperidol with next-day delirium in older medical ICU patients. ( Araujo, KL; Murphy, TE; Pisani, MA, 2015)
"Completion of a survey containing 10 hypothetical ICU cases in which patients had agitated delirium for which a psychiatrist recommended intravenous haloperidol 5 mg every 6 hours."3.79Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation. ( Al-Qadheeb, NS; Devlin, JW; Estes, NA; Fongemie, JM; Roberts, RJ; Ruthazer, R; Temtanakitpaisan, Y, 2013)
"Practice guidelines recommend the use of low dose haloperidol when medication is needed to treat delirium with acute agitation in hospitalized older people."3.79Haloperidol overdosing in the treatment of agitated hospitalized older people with delirium: a retrospective chart review from a community teaching hospital. ( Dorokhine, I; Knapp, CM; Musuku, M; Patel, N; Zirker, W, 2013)
"This study was a 6-day, prospective, comparative clinical observational study of haloperidol versus atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in patients with delirium at a tertiary level hospital."3.79Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. ( Choi, SH; Choi, WJ; Kim, JJ; Park, JY; Park, KM; Seok, JH; Yoon, HJ, 2013)
" Haloperidol, a butyrophenone derivative and dopamine antagonist, is commonly prescribed for nausea, vomiting, and delirium in hospice/palliative care."3.79Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium. ( Agar M, M; Crawford, GB; Currow, DC; Doogue, M; Litster, C; Michael, N; Phillips, J; Quinn, SJ; Rowett, D, 2013)
"Two female Caucasian acute promyelocytic leukemia patients aged 46 and 56 years developed delirium during their induction treatment with all-trans retinoic acid and idarubicin."3.79Delirium in acute promyelocytic leukemia patients: two case reports. ( Ambrosio, M; Cavallari, M; Cibien, F; Cuneo, A; Daghia, G; Formigaro, L; Lista, E; Martinelli, S; Pizzolato, M; Rigolin, GM; Sofritti, O, 2013)
"this is a secondary analysis based on data from a controlled clinical trial evaluating efficacy of haloperidol prophylaxis for delirium conducted in a large medical school-affiliated general hospital in Alkmaar, The Netherlands."3.77Mortality associated with delirium after hip-surgery: a 2-year follow-up study. ( de Jonghe, JF; Eikelenboom, P; Kalisvaart, KJ; Kat, MG; van der Ploeg, T; van Gool, WA; Vreeswijk, R, 2011)
"To compare the efficacy and tolerability of aripiprazole and haloperidol in the amelioration of distressing symptoms of delirium and its motoric subtypes."3.77Aripiprazole and haloperidol in the treatment of delirium. ( Boettger, S; Breitbart, W; Friedlander, M; Passik, S, 2011)
"Secondary analysis of haloperidol prophylaxis for delirium clinical trial data."3.77Anesthesia and postoperative delirium in older adults undergoing hip surgery. ( de Jonghe, JF; Eikelenboom, P; Groot, E; Kalisvaart, KJ; Ploeg, TV; Schmand, B; Slor, CJ; Snoeck, M; van Gool, WA; Vreeswijk, R, 2011)
"Age, use of opioids, and haloperidol were associated with persistent delirium."3.76Factors associated with persistent delirium after intensive care unit admission in an older medical patient population. ( Araujo, KL; Murphy, TE; Pisani, MA; Van Ness, PH, 2010)
" We measured CAM-ICU compliance, interrater reliability, and delirium knowledge, and compared the haloperidol use, as a proxy for delirium incidence, before and after the implementation of the CAM-ICU."3.75Implementation of a delirium assessment tool in the ICU can influence haloperidol use. ( Pickkers, P; Roodbol, G; Schoonhoven, L; van Achterberg, T; van den Boogaard, M; van der Hoeven, H, 2009)
"The aim of this study was to determine the risk of adverse events for risperidone and haloperidol in delirium patients."3.74Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients. ( Hoshino, S; Miyaji, S; Miyaoka, H; Sakai, Y; Yamamoto, H; Yamamoto, K, 2007)
"We explored the possibility that the administration of intravenous dopamine increases the risk for delirium as manifested by need for haloperidol."3.71Is dopamine administration possibly a risk factor for delirium? ( Kraemer, HC; Sommer, BR; Wise, LC, 2002)
" Administration of large intravenous doses of haloperidol was necessary for control of psychomotor agitation due to delirium."3.70Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. ( Bélisle, S; Carrier, M; Cartier, R; Denault, AY; Perrault, LP, 2000)
"A 52-year-old woman with bipolar disorder, rapid-cycling type, developed delirium while taking therapeutic doses of carbamazepine and neuroleptics."3.67Case report of a possible interaction between neuroleptics and carbamazepine. ( Ciccone, JR; Kanter, GL; Yerevanian, BI, 1984)
"More than 2,000 medically ill patients with delirium have been treated by intravenous administration of a combination of haloperidol and lorazepam."3.67Emergency intravenous sedation of the delirious, medically ill patient. ( Adams, F, 1988)
"A case of agitated delirium secondary to bilateral occipital cerebral infarctions in a cancer patient was refractory to trials of large doses of intravenous psychotropic agents, but continuous intravenous infusion of haloperidol controlled agitation rapidly and safely."3.67Treatment of severe, refractory agitation with a haloperidol drip. ( Adams, F; Fernandez, F; Holmes, VF; Kavanaugh, JJ, 1988)
"A report is made on two cases of a pharmacogenic delirium as a result of combined lithium-haloperidol therapy, and on one case of lithium-induced diabetes insipidus renales with second-degree high pressure."3.65[Dangerous side effects of lithium therapy]. ( Ehle, G; Uebelhack, R, 1977)
"The phenomenon of restlessness, agitation, or cognitive disturbances experienced by dying patients is well-known in palliative care; more than half of these patients will experience delirium symptoms at end-of-life."3.11An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home. ( Chong, PH; Kan, AD; Koh, YH; Lin, K; Lyu, XJ; Yeo, ZZ, 2022)
"Delirium is a common disorder among hospitalized older patients and results in increased morbidity and mortality."3.01Efficacy of quetiapine for delirium prevention in hospitalized older medical patients: a randomized double-blind controlled trial. ( Assavapokee, T; Chansirikarnjana, S; Charernwat, P; Ittasakul, P; Ngamkala, T; Ruangritchankul, S; Saranburut, K; Sriwannopas, O; Sukumalin, L; Thanapluetiwong, S, 2021)
" Treatment with antipsychotics in this limited pilot trial did not improve the number of days alive without delirium or coma, nor did it increase adverse outcomes."2.75Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. ( Bernard, GR; Canonico, AE; Carson, SS; Dittus, RS; Ely, EW; Girard, TD; Meltzer, HY; Pandharipande, PP; Pun, BT; Schmidt, GA; Shintani, AK; Thompson, JL; Wright, PE, 2010)
"Delirium is a syndrome characterised by an acute disturbance of attention and awareness which develops over a short time period and fluctuates in severity over the course of the day."2.66Drug therapy for delirium in terminally ill adults. ( Candy, B; Finucane, AM; Jones, L; Leurent, B; Sampson, EL; Stone, P; Tookman, A, 2020)
" Dosing recommendations however are often based on strategies used in patients with normal body habitus."2.66Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium. ( Barletta, JF; Erstad, BL, 2020)
"Since pharmacological treatment of delirium is not highly effective, focus of research has shifted towards developing preventive strategies."2.66Antipsychotic Drugs in Prevention of Postoperative Delirium-What Is Known in 2020? ( Czempik, PF; Dziech, M; Krzych, ŁJ; Pluta, MP; Szczepańska, AJ, 2020)
"Patients with delirium are frequently treated with antipsychotic medications that are well known to induce akathisia as a side effect."2.53Antipsychotic-induced akathisia in delirium: A systematic review. ( Alici, Y; Forcen, FE; Matsoukas, K, 2016)
"The therapy of delirium is mostly determined by non-pharmacological measures aiming at early identification, reorientation and mobilization of the patient, improving cerebral activity and establishing adequate wake-sleep cycles."2.53[Delirium and delirium management in critically ill patients]. ( Kersten, A; Reith, S, 2016)
"Delirium is the most common and distressing neuropsychiatric syndrome in cancer patients."2.53Neuroleptics in the management of delirium in patients with advanced cancer. ( Bruera, E; Dev, R; Hui, D, 2016)
"Delirium is a complex but common disorder in palliative care with a prevalence between 13 and 88 % but a particular frequency at the end of life (terminal delirium)."2.52Management of delirium in palliative care: a review. ( Berardi, MA; Caraceni, A; Caruso, R; Grassi, L; Mitchell, AJ; Nanni, MG; Riba, M, 2015)
" Dosing schedules are derived from expert opinion and various clinical practice guidelines as evidence-based data from palliative care settings are limited."2.50Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development. ( Breitbart, W; Bruera, E; Bush, SH; Currow, DC; Davis, DHJ; Gagnon, B; Gagnon, PR; Hartwick, M; Kanji, S; Lawlor, PG; Meagher, D; Pereira, JL; Rabheru, K; Regnier, L; Wright, D, 2014)
"Treatment with lorazepam only should be avoided."2.49[Pharmacological treatment of delirium in palliative care patients. A systematic literature review]. ( Golla, H; Perrar, KM; Voltz, R, 2013)
"Haloperidol is a butyrophenone neuroleptic agent characterized as a high-affinity dopamine antagonist, originally used for the treatment of schizophrenia."2.48Role of haloperidol in palliative medicine: an update. ( Prommer, E, 2012)
"Haloperidol is a preferred agent for the treatment of delirium in this population because of its rapid onset of action and lack of hemodynamic effects."2.48Haloperidol dosing strategies in the treatment of delirium in the critically ill. ( Ensom, MH; Loh, GW; Mabasa, VH; Wang, EH, 2012)
"Delirium is frequently encountered in the ICU and is associated with significant adverse outcomes."2.48ICU delirium: an update. ( Jones, SF; Pisani, MA, 2012)
"Delirium is one of the most serious and common complications that up to one third of older patients admitted to hospital develop."2.48Confusion, agitation and delirium. ( Martin, JJ, 2012)
"The prognosis of CCI patients with coma or delirium has not yet been thoroughly studied, but preliminary studies suggest this population is at high risk for detrimental outcomes associated with acute brain dysfunction."2.48Brain dysfunction in patients with chronic critical illness. ( Girard, TD, 2012)
"Delirium is a syndrome characterised by a disturbance of consciousness (often fluctuating), cognition and perception."2.48Drug therapy for delirium in terminally ill adult patients. ( Candy, B; Jackson, KC; Jones, L; King, M; Leurent, B; Tookman, A, 2012)
"The primary goal in the detection and treatment of ICU delirium is to ensure the safety of the patient and caregiver(s)."2.46Intensive care unit delirium. ( Bruno, JJ; Warren, ML, 2010)
"Delirium is common in the last weeks of life, occurring in 26% to 44% of people with advanced cancer in hospital, and in up to 88% of people with terminal illness in the last days of life."2.45Delirium at the end of life. ( Keeley, PW, 2009)
"Delirium is a common problem in older patients admitted to the hospital."2.44[Delirium--management in the hospital: diagnosis and treatment]. ( Rahn, A, 2008)
"Delirium is common in acutely ill patients and can result in substantial morbidity if left untreated."2.44Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. ( Battistone, S; Devlin, JW; Fong, JJ; Rea, RS, 2007)
"Oral haloperidol was associated with more frequent extrapyramidal side effects, but overall, all agents were well tolerated."2.43Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. ( Lacasse, H; Perreault, MM; Williamson, DR, 2006)
"Delirium affects 10 to 30 percent of hospitalized patients with medical illness; more than 50 percent of persons in certain high-risk populations are affected."2.42Delirium. ( Gleason, OC, 2003)
"Delirium is highly prevalent in terminally ill patients, especially in the last weeks of life, when some cognitive impairment develops in as many as 85% of patients."2.41Delirium in the terminally ill. ( Breitbart, W; Strout, D, 2000)
"Delirium is frequently underdiagnosed in clinical practice."2.41Diagnosing and managing delirium in the elderly. ( Conn, DK; Lieff, S, 2001)
" Cramping abdominal pain associated with mechanical bowel obstruction often can be managed with morphine (titrating the dosage for pain) and octreotide."2.41Management of common symptoms in terminally ill patients: Part II. Constipation, delirium and dyspnea. ( Alexander, CS; Ross, DD, 2001)
"Delirium is a common psychiatric complication in somatically ill in-patients and is associated with increased morbidity and mortality, longer lengths of stay and higher cost of treatment."2.41[Diagnosis and treatment of delirium]. ( Hepp, U, 2002)
"The occurrence of confusion in the elderly patient should alert the physician to the need of investigation to detect underlying severe disease without delay."2.39[Confusional states in the elderly--an underdiagnosed syndrome with a poor prognosis]. ( Pitkälä, K, 1996)
"Pharmacologic treatments of delirium in adults and children are outlined, with particular emphasis on intravenous use of butyrophenone neuroleptics."2.39Delirium. Advances in diagnosis, pathophysiology, and treatment. ( Trzepacz, PT, 1996)
"Delirium is the second most common psychiatric diagnosis among hospitalized elderly cancer patients."2.38Delirium in cancer patients. ( Holland, J; Stiefel, F, 1991)
"Two patients who developed choreoathetosis in the course of lithium treatment are described, and other cases of choreoathetosis in lithium-treated patients are reviewed."2.38Choreoathetosis: a sign of lithium toxicity. ( Reed, SM; Timmerman, I; Wise, MG, 1989)
"Delirium is the most common neuropsychiatric complication of hospitalized AIDS patients."2.38Management of delirium in terminally ill AIDS patients. ( Fernandez, F; Levy, JK; Mansell, PW, 1989)
"Delirium is an acute disturbance in attention, cognition, and awareness that fluctuates over time."1.91Delirium in Older Persons: Prevention, Evaluation, and Management. ( Chin, E; Jaqua, EE; Nguyen, VTN, 2023)
"Delirium is highly prevalent in the intensive care unit (ICU) and is associated with high morbidity and mortality."1.72Agents intervening against delirium in the intensive care unit trial-Protocol for a secondary Bayesian analysis. ( Andersen-Ranberg, N; Andreasen, AS; Bestle, MH; Citerio, G; Damgaard, K; Dey, N; Granholm, A; Hästbacka, J; Jensen, TB; Mathiesen, O; Morgan, MPG; Nielsen, LG; Oxenbøll-Collet, M; Pedersen, HBS; Perner, A; Poulsen, LM; Sommer, T; Uslu, B; Weber, SO, 2022)
"The most prescribed treatment for delirium was injectable haloperidol (n=82 490; 56."1.72Demographic and clinical characteristics of patients with delirium: analysis of a nationwide Japanese medical database. ( Igarashi, M; Ogawa, A; Okuda, S; Okumura, Y; Okuyama, K; P Qureshi, Z; Sano, H; Takahashi, K; Tokita, S; Ueda, N, 2022)
"Risperidone has weight-based dosing and a liquid dosage form available, making it a good option for use in the NICU."1.62Delirium in the NICU: Risk or Reality? ( Liviskie, C; McPherson, C, 2021)
"As its name suggests, delirious mania presents as a mixture of hyperactive delirium and mania; additional features may include psychosis, autonomic activation, and catatonia."1.62Pseudodelirium: Psychiatric Conditions to Consider on the Differential for Delirium. ( Ainsworth, A; Andrews, P; Ely, EW; Oldham, MA; Roy, K; Wilson, JE, 2021)
"Postoperative delirium is the most common neurological complication of cardiac surgery."1.48The influence of oxygen delivery during cardiopulmonary bypass on the incidence of delirium in CABG patients; a retrospective study. ( Golab, H; Leenders, J; Overdevest, E; van Straten, B, 2018)
" We therefore designed a population pharmacokinetic study to gain more insight into the pharmacokinetics of haloperidol in terminally ill patients and to find clinically relevant covariates that may be used in developing an individualised dosing regimen."1.46Population pharmacokinetics of haloperidol in terminally ill adult patients. ( Baar, FPM; de Winter, BCM; Franken, LG; Koch, BCP; Masman, AD; Mathot, RAA; Tibboel, D; van Gelder, T, 2017)
"Strategies to prevent and treat delirium during hospitalization for hip fracture have been less studied."1.40[Delirium prevention and treatment in elderly hip fracture]. ( Formiga, F; Robles, MJ; Vidán, MT, 2014)
"Agitated delirium is a palliative care emergency."1.40High-dose neuroleptics and neuroleptic rotation for agitated delirium near the end of life. ( Bascom, PB; Bordley, JL; Lawton, AJ, 2014)
"Haloperidol was initiated at 5 mg intravenous every 6 h and titrated up to a dose of 60 mg /day over 5 days."1.39Neuroleptic malignant syndrome associated with haloperidol use in critical care setting: should haloperidol still be considered the drug of choice for the management of delirium in the critical care setting? ( Adelman, M; Dixit, D; Shrestha, P, 2013)
"To determine the dosing patterns and total doses of fentanyl, lorazepam, and haloperidol according to nursing shift in a cohort of older patients in a medical intensive care unit."1.39Patterns of opiate, benzodiazepine, and antipsychotic drug dosing in older patients in a medical intensive care unit. ( Akgün, KM; Araujo, KL; Bramley, K; Murphy, TE; Pisani, MA; Vest, MT, 2013)
"However, interictal delirium is uncommon in absence of risk factors."1.38Delayed onset and prolonged interictal delirium following electroconvulsive therapy. ( Praharaj, SK; Selvaraj, AG, 2012)
"Haloperidol was perceived by many (42%) to have 1 or more randomized trials supporting its use for delirium and Food and Drug Administration approval for this indication (34%)."1.37Current perceptions and practices surrounding the recognition and treatment of delirium in the intensive care unit: a survey of 250 critical care pharmacists from eight states. ( Bhat, S; Devlin, JW; Roberts, RJ; Skrobik, Y, 2011)
"Delirium is an acute organ dysfunction common amongst patients treated in intensive care units."1.36A national survey of the management of delirium in UK intensive care units. ( Barber, V; Ely, EW; Mac Sweeney, R; McAuley, DF; Page, V; Perkins, GD; Young, JD, 2010)
" Limited information is available regarding the dosage requirements and efficacy of neuroleptics in the palliative care setting."1.36Neuroleptic dose in the management of delirium in patients with advanced cancer. ( Bruera, E; Bush, SH; Gallo, LE; Hui, D; Palmer, JL; Yennurajalingam, S, 2010)
"Delirium is a common, underdiagnosed and serious problem in intensive care unit patients."1.35Tackling agitated delirium--the tip of the iceberg. ( Page, VJ, 2009)
"Drug-induced delirium is a common matter in the elderly and anticholinergics, together with a number of different drugs, may significantly contribute to the delirium onset, especially in demented people."1.34Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient. ( Cotroneo, A; De Fazio, P; De Fazio, S; De Sarro, G; Gallelli, L; Gareri, P; Lacava, R, 2007)
"Haloperidol was associated with significantly lower hospital mortality."1.33Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. ( Angus, DC; Clermont, G; Fink, MP; Kersten, A; Kong, L; Milbrandt, EB; Weissfeld, LA, 2005)
"Delirium is a syndrome, not a disease, and has many causes, all of which result in a similar pattern of signs and symptoms relating to a patient's level of consciousness and cognitive impairment."1.33Case report: delirium associated with ovarian hyperstimulation syndrome. ( Karamustafalioglu, O; Mercan, R; Mercan, S, 2005)
"The authors use a clinical case of a paranoiac patient to highlight the role played by writing, drawing, and painting in the psychoanalytical treatment of psychosis."1.33Reading and writing: psychoanalytical treatment in a case of paranoia. ( Assadi, TC; Bueno, DS; Colucci, VL; de Cerqueira Leite, AC; Freire, JM; Pereira, ME; Portella, LB; Ribes, SI, 2005)
"Therefore treatment of delirium with a cholinesterase-inhibitor seems logical."1.32[Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine]. ( Boelaarts, L; de Jonghe, JF; Hovinga, IM; Kalisvaart, CJ; Kat, MG, 2004)
"A new delirium was induced when, after discharge from the hospital, betahistine was restarted because of dizziness."1.32[Delirium in a 73-year-old man after many years of unwise use of betahistine]. ( Hoenders, HJ; Wilterdink, J, 2004)
"Depression in cancer patients is common and occurs throughout the course of cancer illness."1.31[Management of psychiatric symptoms in cancer patients]. ( Uchitomi, Y, 2002)
"Haloperidol was used in 67% cases for the treatment of delirium."1.31A survey on the drug therapy for delirium. ( Endo, T; Hara, T; Someya, T; Suzuki, J; Yagi, G, 2001)
"The delirium was reversible when all drugs were stopped; however, dyskinesia was found to be persistent after a period of 6 months."1.30Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction. ( Berger, M; Brandt, C; Normann, C; Walden, J, 1998)
"Delirium in the cancer patient is particularly problematic given the coexisting medical problems these patients experience."1.29A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. ( Baile, WF; Meyers, CA; Olofsson, SM; Valentine, AD; Weitzner, MA, 1996)

Research

Studies (328)

TimeframeStudies, this research(%)All Research%
pre-199029 (8.84)18.7374
1990's30 (9.15)18.2507
2000's63 (19.21)29.6817
2010's153 (46.65)24.3611
2020's53 (16.16)2.80

Authors

AuthorsStudies
Tillemans, MPH1
Butterhoff-Terlingen, MH1
Stuffken, R1
Vreeswijk, R6
Egberts, TCG1
Kalisvaart, KJ6
Liu, J1
Yu, D1
Li, J1
Sato, J1
Tanaka, R1
Yoshihiro, S1
Taito, S1
Lyu, XJ1
Kan, AD1
Chong, PH1
Lin, K1
Koh, YH1
Yeo, ZZ1
Andersen-Ranberg, N2
Poulsen, LM5
Perner, A8
Hästbacka, J6
Morgan, MPG3
Citerio, G6
Oxenbøll-Collet, M3
Weber, SO5
Andreasen, AS4
Bestle, MH3
Uslu, B4
Pedersen, HBS3
Nielsen, LG4
Damgaard, K2
Jensen, TB4
Sommer, T2
Dey, N4
Mathiesen, O7
Granholm, A2
Matsuda, Y2
Morita, T1
Oya, K1
Tagami, K1
Naito, AS1
Kashiwagi, H1
Otani, H1
Ueda, N1
Igarashi, M1
Okuyama, K1
Sano, H1
Takahashi, K1
P Qureshi, Z1
Tokita, S1
Ogawa, A1
Okumura, Y1
Okuda, S1
Reisinger, M1
Reininghaus, EZ1
Biasi, J1
Fellendorf, FT1
Schoberer, D1
Jaworska, N1
Moss, SJ1
Krewulak, KD1
Stelfox, Z1
Niven, DJ1
Ismail, Z1
Burry, LD1
Fiest, KM1
Andersen-Ranberg, NC4
Wetterslev, J6
Estrup, S3
Morgan, M2
Caballero, J4
Lange, T4
Kjær, MN1
Ebdrup, BH3
Engstrøm, J1
Olsen, MH1
Oxenbøll Collet, M1
Mortensen, CB2
Scharling Pedersen, H1
Gramstrup Nielsen, L1
Toft Boesen, HC1
Jensen, JV1
Nebrich, L1
La Cour, K1
Laigaard, J1
Haurum, C1
Olesen, MW1
Overgaard-Steensen, C1
Westergaard, B1
Brand, B1
Kingo Vesterlund, G1
Thornberg Kyhnauv, P1
Mikkelsen, VS1
Hyttel-Sørensen, S1
de Haas, I1
Aagaard, SR1
Nielsen, LO1
Eriksen, AS1
Rasmussen, BS1
Brix, H1
Hildebrandt, T2
Schønemann-Lund, M1
Fjeldsøe-Nielsen, H1
Kuivalainen, AM1
Marcantonio, ER2
Hayase, T1
Saiga, H1
Yamaguchi, T1
Ando, K1
Suzuki, A1
Yoshida, H1
Zhang, Y1
Wilkins, JM1
Bessette, LG1
York, C1
Wong, V1
Lin, KJ1
Tanner, M1
Collet, MO4
Bestle, M2
Pedersen, HS1
Charlier, C1
Jaren, L1
Aebischer, O1
Minami, T1
Watanabe, H1
Kato, T1
Ikeda, K1
Ueno, K1
Matsuyama, A1
Maeda, J1
Sakai, Y2
Harada, H1
Kuriyama, A1
Yamaji, K1
Kitajima, N1
Kamei, J1
Takatani, Y1
Sato, Y1
Yamashita, Y1
Mizota, T1
Ohtsuru, S1
Huang, YQ1
Weiss, S1
Gros, P1
Wong, E1
Piché, PP1
Vyas, MV1
Tam, AKH1
Watt, JA1
Jaqua, EE1
Nguyen, VTN1
Chin, E1
Smit, L3
Slooter, AJC6
Devlin, JW11
Trogrlic, Z3
Hunfeld, NGM3
Osse, RJ3
Ponssen, HH2
Brouwers, AJBW1
Schoonderbeek, JF1
Simons, KS3
van den Boogaard, M11
Lens, JA1
Boer, DP1
Gommers, DAMPJ1
Rietdijk, WJR2
van der Jagt, M5
Dietrich, M1
Reuß, CJ1
Beynon, C1
Hecker, A1
Jungk, C1
Michalski, D1
Nusshag, C1
Schmidt, K1
Weigand, MA1
Bernhard, M1
Brenner, T1
Nikooie, R2
Neufeld, KJ3
Oh, ES2
Wilson, LM2
Zhang, A2
Robinson, KA2
Needham, DM2
Lewis, KA1
Spence, J1
Dionne, JC1
Rochwerg, B1
Barbateskovic, M3
Krauss, SR1
Jakobsen, JC2
Chen, Z1
Chen, R1
Zheng, D1
Su, Y1
Wen, S1
Guo, H1
Ye, Z1
Deng, Y1
Liu, G1
Zuo, L1
Wei, X1
Hou, Y1
Finucane, AM1
Jones, L2
Leurent, B2
Sampson, EL1
Stone, P1
Tookman, A2
Candy, B2
Li, Y1
Ma, J1
Jin, Y1
Li, N1
Zheng, R1
Mu, W1
Wang, J2
Si, JH1
Chen, J1
Shang, HC1
van der Vorst, MJDL1
Neefjes, ECW1
Boddaert, MSA1
Verdegaal, BATT1
Beeker, A1
Teunissen, SCC1
Beekman, ATF1
Wilschut, JA1
Berkhof, J1
Zuurmond, WWA1
Verheul, HMW1
Nieboer, D1
Koch, BCP2
van Schaik, RHN1
Kim, MS1
Rhim, HC1
Park, A1
Kim, H1
Han, KM1
Patkar, AA2
Pae, CU1
Han, C2
Hui, D9
De La Rosa, A2
Wilson, A2
Nguyen, T3
Wu, J1
Delgado-Guay, M2
Azhar, A1
Arthur, J2
Epner, D2
Haider, A1
De La Cruz, M2
Heung, Y1
Tanco, K2
Dalal, S2
Reddy, A3
Williams, J2
Amin, S2
Armstrong, TS1
Breitbart, W7
Bruera, E10
Erstad, BL1
Barletta, JF1
Sofie Andreasen, A1
Thee, C2
Remelli, F1
Bugada, M1
Matteucci, G1
Brunori, M1
Gianotti, G1
Zurlo, A1
Volpato, S1
Pluta, MP1
Dziech, M1
Czempik, PF1
Szczepańska, AJ1
Krzych, ŁJ1
Khoodoruth, MAS1
Khan, AA1
Gommers, D1
Hollinger, A2
Rüst, CA1
Riegger, H2
Gysi, B1
Tran, F1
Brügger, J1
Huber, J1
Toft, K2
Surbeck, M1
Schmid, HR1
Rentsch, K1
Steiner, L1
Siegemund, M2
Lodewijckx, E1
Debain, A1
Lieten, S1
Bravenboer, B1
Mets, T1
Dijkstra-Kersten, SMA1
Zaal, IJ1
Marra, A1
Vargas, M1
Buonanno, P1
Iacovazzo, C1
Kotfis, K1
Servillo, G1
Cronin, MT1
Di Gennaro, JL1
Watson, RS1
Dervan, LA1
Liviskie, C1
McPherson, C1
Thanapluetiwong, S1
Ruangritchankul, S1
Sriwannopas, O1
Chansirikarnjana, S1
Ittasakul, P1
Ngamkala, T1
Sukumalin, L1
Charernwat, P1
Saranburut, K1
Assavapokee, T1
Duprey, MS2
van der Hoeven, JG5
Pickkers, P9
Briesacher, BA1
Saczynski, JS1
Griffith, JL1
Santos, CD1
Rose, MQ1
Park, SK1
Lim, T1
Cho, H1
Yoon, HK1
Lee, HJ2
Lee, JH1
Yoo, S1
Kim, JT1
Kim, WH1
Pinkhasov, AM1
Collantes, CMC1
Chen, M2
Fazzari, MJ1
Coriolan, S1
Lam, S1
Tang, M1
Prendergast, NT1
Girard, TD5
Wilson, JE1
Andrews, P1
Ainsworth, A1
Roy, K1
Ely, EW7
Oldham, MA2
Urbauer, DL1
Lee, J1
Holbrook, A1
Hirst, JM1
Vaughan, CL1
Irwin, SA1
Peng, ZY1
Zhou, WH1
Hu, B1
Rao, X1
Li, JG1
Santos, E2
Cardoso, D2
Neves, H2
Cunha, M2
Rodrigues, M2
Apóstolo, J2
Valentine, A1
Bogman, ACCF1
Schieveld, JNM2
Elsayem, AF1
Fisch, MJ1
Morgan, AA1
Sinclair, CT1
Agar, MR3
Draper, B2
Caplan, GA2
Franken, LG1
Mathot, RAA1
Masman, AD1
Baar, FPM1
Tibboel, D3
van Gelder, T1
de Winter, BCM1
Regan, DW1
Kashiwagi, D1
Dougan, B1
Sundsted, K1
Mauck, K1
Boettger, S3
Knöpfel, S1
Schubert, M1
Garcia Nuñez, D1
Plichta, MM1
Klaghofer, R1
Jenewein, J2
Thom, RP1
Mock, CK1
Teslyar, P1
Masiran, R1
Abdul Aziz, MF1
Frisbee-Hume, S1
Dibaj, SS2
Walker, P1
Zhukovsky, DS1
Vidal, M1
Hall, S1
Liu, D1
Hess, K2
Schrijver, EJM2
de Vries, OJ3
van de Ven, PM2
Bet, PM2
Kamper, AM2
Diepeveen, SHA1
van Marum, RJ4
van Strien, AM4
Anten, S2
Lagaay, AM2
Boelaarts, L3
Bloemers, FW1
Kramer, MHH1
Nanayakkara, PWB2
Kathirvel, N1
Ghosh, AK1
Teale, EA1
van Keulen, K1
Knol, W1
Jung, DM1
Ahn, HJ1
Yang, M1
Kim, JA1
Kim, DK1
Lee, SM1
Park, JH1
Slooff, VD2
van den Dungen, DK1
van Beusekom, BS2
Jessurun, N2
Ista, E1
de Wildt, SN2
Kraus, SR1
Brüggemann, RJM1
Schoonhoven, L4
Beishuizen, A3
Vermeijden, JW1
Pretorius, D1
de Koning, J1
Dennesen, PJW1
Van der Voort, PHJ3
Houterman, S2
Besselink, A1
Hofstra, LS1
Spronk, PE4
van den Bergh, W1
Donker, DW1
Fuchs, M1
Karakus, A2
Koeman, M1
van Duijnhoven, M1
Hannink, G1
Dev, R2
Reddy, S1
Seifert, B1
Blum, A1
Zehnder, T1
Shen, YZ1
Peng, K1
Zhang, J1
Meng, XW1
Ji, FH1
Schildmann, E1
Pörnbacher, S1
Kalies, H1
Bausewein, C1
Shrikant Kulkarni, N1
Sonneville, R1
Bozza, FA2
Nydahl, P1
Schandl, A1
Wøien, H1
Haenggi, M1
Colpaert, K1
Rose, L2
Jensen, A1
Krog, MB1
Egerod, I2
Nibro, HL1
Burry, L1
Mehta, S1
Perreault, MM2
Luxenberg, JS1
Siddiqi, N1
Hutton, B1
Fergusson, DA1
Bell, C1
Latronico, N1
Leenders, J1
Overdevest, E1
van Straten, B1
Golab, H1
Strik, JJMH1
Torbic, H1
Duggal, A1
van Schijndel, AW1
Franssen, EJF1
Rijkenberg, S1
Garetto, F1
Cancelli, F1
Rossi, R1
Maltoni, M1
Bleck, TP1
Exline, MC1
Carson, SS2
Hough, CL1
Rock, P1
Gong, MN1
Douglas, IS1
Malhotra, A1
Owens, RL1
Feinstein, DJ1
Khan, B1
Pisani, MA6
Hyzy, RC1
Schmidt, GA2
Schweickert, WD1
Hite, RD1
Bowton, DL1
Masica, AL1
Thompson, JL2
Chandrasekhar, R1
Pun, BT2
Strength, C1
Boehm, LM1
Jackson, JC1
Pandharipande, PP2
Brummel, NE1
Hughes, CG1
Patel, MB1
Stollings, JL1
Bernard, GR2
Dittus, RS2
Siuciuno, T1
Shimakawa, N1
Shibuya, H1
Suzuki, H1
Ozawa, A1
Moriwaki, K1
Hirao, M1
Khan, BA3
Perkins, AJ3
Campbell, NL3
Gao, S2
Khan, SH2
Wang, S2
Fuchita, M1
Weber, DJ1
Zarzaur, BL2
Boustani, MA4
Kesler, K1
Herling, SF1
Greve, IE1
Vasilevskis, EE1
Bekker Mortensen, C1
Møller, AM1
Svenningsen, H1
Thomsen, T1
Zayed, Y1
Barbarawi, M1
Kheiri, B1
Banifadel, M1
Haykal, T1
Chahine, A1
Rashdan, L1
Aburahma, A1
Bachuwa, G1
Seedahmed, E1
Farber, MO1
Ingravallo, F1
de Nooijer, K1
Pucci, V1
Casini, C1
Miccinesi, G1
Rietjens, JAC1
Morino, P1
Wu, YC1
Tseng, PT1
Tu, YK1
Hsu, CY1
Liang, CS1
Yeh, TC1
Chen, TY1
Chu, CS1
Matsuoka, YJ1
Stubbs, B1
Carvalho, AF1
Wada, S1
Lin, PY1
Chen, YW1
Su, KP1
Tenser, RB1
Lee, HB1
Ishiki, H1
Satomi, E1
Shimizu, K1
Nishigaki, A1
Kawano, T1
Iwata, H1
Aoyama, B1
Yamanaka, D1
Tateiwa, H1
Shigematsu-Locatelli, M1
Eguchi, S1
Locatelli, FM1
Yokoyama, M1
Matsuoka, H1
Agar, M1
Vandersman, Z1
Good, P1
Fazekas, B2
Brown, L1
Hardy, J2
Weil, J1
Currow, DC5
O'Regan, NA1
Mohamad, MM1
Meagher, DJ2
Rood, PJT1
Zegers, M1
van der Woude, MCE1
Zafrani, L1
Perrar, KM1
Golla, H1
Voltz, R1
Fongemie, JM1
Al-Qadheeb, NS2
Estes, NA1
Roberts, RJ5
Temtanakitpaisan, Y1
Ruthazer, R2
McLoughlin, L1
Leonard, M1
Hannon, N1
Dunne, C1
O'Regan, N1
Zirker, W1
Dorokhine, I1
Knapp, CM1
Patel, N1
Musuku, M1
Robles, MJ1
Formiga, F1
Vidán, MT1
Atalan, N1
Efe Sevim, M1
Akgün, S1
Fazlıoğulları, O1
Başaran, C1
Dixit, D1
Shrestha, P1
Adelman, M1
Jones, C1
Maneeton, B1
Maneeton, N1
Srisurapanont, M1
Chittawatanarat, K1
Bramley, K1
Vest, MT1
Akgün, KM1
Araujo, KL4
Murphy, TE4
Yoon, HJ1
Park, KM1
Choi, WJ1
Choi, SH1
Park, JY1
Kim, JJ1
Seok, JH1
Bascom, PB1
Bordley, JL1
Lawton, AJ1
Crawford, GB2
Agar M, M1
Quinn, SJ2
Phillips, J1
Litster, C1
Michael, N1
Doogue, M1
Rowett, D2
Raudenska, M1
Gumulec, J1
Babula, P1
Stracina, T1
Sztalmachova, M1
Polanska, H1
Adam, V1
Kizek, R1
Novakova, M1
Masarik, M1
Rigolin, GM1
Martinelli, S1
Formigaro, L1
Cibien, F1
Lista, E1
Cavallari, M1
Ambrosio, M1
Pizzolato, M1
Daghia, G1
Sofritti, O1
Cuneo, A1
Slooter, AJ2
Brüggemann, RJ1
Kuiper, MA2
van der Voort, PH1
Hoogendoorn, ME1
Schouten, JA1
Schrøder Pedersen, S1
Kirkegaard, T1
Balslev Jørgensen, M1
Lind Jørgensen, V1
Skrobik, Y7
Page, VJ3
Gates, S1
Zhao, XB1
Alce, T1
Shintani, A1
Jackson, J1
Perkins, GD2
McAuley, DF2
Viana, MV1
Moraes, RB1
Tonietto, TA1
Boniatti, MM1
Bush, SH2
Kanji, S1
Pereira, JL1
Davis, DHJ1
Meagher, D1
Rabheru, K1
Wright, D1
Hartwick, M1
Gagnon, PR2
Gagnon, B1
Regnier, L1
Lawlor, PG2
Fukata, S2
Kawabata, Y2
Fujisiro, K1
Katagawa, Y1
Kuroiwa, K2
Akiyama, H2
Terabe, Y1
Ando, M2
Kawamura, T1
Hattori, H2
Mattison, ML1
Catic, A1
Davis, RB1
Olveczky, D1
Moran, J1
Yang, J1
Aronson, M1
Zeidel, M1
Lipsitz, L1
Vermeulen Windsant-van den Tweel, A1
Leliveld-van den Heuvel, M1
di Biase, M1
van den Brule, AJ1
Schrijver, EJ2
Verburg, A1
de Graaf, K2
Diepeveen, SH1
Siegel, A1
Kuipéri, E1
Pons, D1
Kramer, MH1
Nanayakkara, PW2
Spaans, E1
van Puijenbroek, E1
de Hoog, M1
Tanimukai, H1
Tsujimoto, H1
Tokoro, A1
Kanemura, S1
Watanabe, M1
Tsujio, I1
Maeda, I1
Takei, K1
Nakajima, S1
Taira, T1
Tokuyama, M1
Kai, T1
Okamoto, Y1
Goya, S1
Kashiwagi, Y1
Grassi, L1
Caraceni, A1
Mitchell, AJ1
Nanni, MG1
Berardi, MA1
Caruso, R1
Riba, M1
Yara, M1
Tomino, M1
Miyata, K1
Ishida, Y1
Saiki, I1
Seta, N1
Hara, N1
Uchino, H1
Kiberd, M1
Hall, R1
Blom, MT1
Jansen, S1
de Jonghe, A1
van Munster, BC1
de Boer, A1
de Rooij, SE1
Tan, HL1
van der Velde, N1
Serafim, RB1
Soares, M1
do Brasil, PE1
Tura, BR1
Salluh, JI1
Forcen, FE1
Matsoukas, K1
Alici, Y1
Schumaker, G2
Pacheco, MN1
Ruthazer, RR1
Maier, AB1
Górska, A1
Marszałł, M1
Sloderbach, A1
Hermus, IP1
Willems, SJ1
Bogman, AC1
Brabers, L1
Schieveld, JN3
Tampi, RR1
Tampi, DJ1
Ghori, AK1
Kersten, A2
Reith, S1
Corona, A2
Colombo, R2
Catena, E1
Carrasco, G1
Baeza, N1
Cabré, L1
Portillo, E1
Gimeno, G1
Manzanedo, D1
Calizaya, M1
Teegarden, BM1
Prough, DS1
Ritchie, CS1
Phillips, JL1
Collier, A1
Choi, JY1
Kim, JM1
Kwon, CH1
Joh, JW1
Lee, S1
Park, JB1
Ko, JS1
Gwak, MS1
Kim, GS1
Kim, SJ1
Lee, SK1
Park, JI1
Cameron, R1
Al-Qadheeb, N1
Roberts, R1
Fujishiro, K1
Kitagawa, Y1
Takemura, M1
Dotson, B1
Freter, S1
Koller, K1
Dunbar, M1
MacKnight, C1
Rockwood, K1
Carlton, EF1
Mahowald, MK1
Malas, N1
Quinn, S1
Sanderson, C1
Le, B1
Eckermann, S1
McCaffrey, N1
Devilee, L1
Hill, M1
Kat, MG4
de Jonghe, JF6
van der Ploeg, T3
van Gool, WA6
Eikelenboom, P5
Fricchione, GL1
Nejad, SH1
Esses, JA1
Cummings, TJ1
Querques, J1
Cassem, NH2
Murray, GB3
Caplan, JP2
Rahn, A1
Faaij, RA1
Ziere, G1
Zietse, R1
Van der Cammen, TJ1
Campbell, N1
Ayub, A1
Fox, GC1
Munger, SL1
Ott, C1
Guzman, O1
Farber, M2
Ademuyiwa, A1
Singh, R1
Reade, MC2
O'Sullivan, K1
Bates, S1
Goldsmith, D1
Ainslie, WR1
Bellomo, R1
van der Hoeven, H1
Roodbol, G1
van Achterberg, T2
Klich-Raczka, A1
Piotrowicz, K1
Grodzicki, T1
Grover, S2
Malhotra, S1
Bharadwaj, R1
Bn, S1
Kumar, S1
Fong, JJ3
Riker, RR3
Hill, NS2
Robbins, T1
Garpestad, E2
Joffe, AM1
Coursin, DB1
Coursin, DR1
Balas, MC1
Wright, PE1
Canonico, AE1
Shintani, AK1
Meltzer, HY1
Mac Sweeney, R1
Barber, V1
Page, V1
Young, JD1
Gallo, LE1
Palmer, JL1
Yennurajalingam, S1
Van Ness, PH1
Sheldon, T1
Bruno, JJ1
Warren, ML1
van Eijk, MM1
Roes, KC1
Honing, ML1
van der Mast, RC3
Kesecioglu, J1
Özdemir, B1
Çelik, C1
Çinar, A1
Özşahin, A1
Friedlander, M1
Passik, S1
Campbell, T1
Hui, SL1
Abernathy, G1
Buckley, J1
Sing, R1
Tricker, J1
Zawahiri, M1
Keeley, PW1
Slor, CJ1
Groot, E1
Ploeg, TV1
Snoeck, M1
Schmand, B1
Palla, S1
Vochteloo, AJ1
Moerman, S1
van der Burg, BL1
de Boo, M1
de Vries, MR1
Niesten, DD1
Tuinebreijer, WE1
Nelissen, RG1
Pilot, P1
Kashyap, GL1
Patel, AG1
Kumar, V1
Chakrabarti, S1
Hinderleider, E1
Bhat, S1
Prommer, E1
Wang, EH1
Mabasa, VH1
Loh, GW1
Ensom, MH1
Wang, W1
Li, HL1
Wang, DX1
Zhu, X1
Li, SL1
Yao, GQ1
Chen, KS1
Gu, XE1
Zhu, SN1
Tahir, TA1
Farewell, D1
Bisson, J1
Jones, SF1
Martin, JJ1
Tagarakis, GI1
Voucharas, C1
Tsolaki, F1
Daskalopoulos, ME1
Papaliagkas, V1
Parisis, C1
Gogaki, E1
Tsagalas, I1
Sataitidis, I1
Tsolaki, M1
Tsilimingas, NB1
Praga, F1
Minari, C1
Giannotti, C1
Castelli, A1
Raimondi, F1
Selvaraj, AG1
Praharaj, SK1
Jackson, KC2
King, M1
Cheung, D1
Wolfe, B1
Wald, H1
Cumbler, E1
Sommer, BR1
Wise, LC1
Kraemer, HC1
Uchitomi, Y2
Finucane, TE1
Gleason, OC1
VOLMAT, R1
BEAUDOUIN, JL1
COLLIN, J1
NICOLAS-CHARLES, PJ1
ALLERS, G1
Awata, S1
Skrobik, YK1
Bergeron, N1
Dumont, M1
Gottfried, SB1
Lipman, AG1
Liu, CY1
Juang, YY1
Liang, HY1
Lin, NC1
Yeh, EK1
de Rooij, S1
de Jonge, E1
Vella-Brincat, J1
Macleod, AD1
Frankenburg, FR1
Young, CC1
Lujan, E1
Kalisvaart, CJ1
Hovinga, IM1
Hoenders, HJ1
Wilterdink, J1
Milbrandt, EB1
Kong, L1
Weissfeld, LA1
Clermont, G1
Fink, MP1
Angus, DC1
Schweickert, W1
Hall, JB1
Leentjens, AF2
Nakasato, Y1
Servat, J1
Amador, F1
Teasdale, TA1
Kim, JY1
Jung, IK1
Cho, SH1
Kim, L1
Kim, SH1
Lee, BH1
Kim, YK1
Mercan, S1
Mercan, R1
Karamustafalioglu, O1
Meijer, K1
Slaets, JP1
Huyse, FJ1
Freire, JM1
de Cerqueira Leite, AC1
Bueno, DS1
Portella, LB1
Ribes, SI1
Assadi, TC1
Colucci, VL1
Pereira, ME1
Bogaards, MJ1
Egberts, TC1
Burger, BJ1
Legris, P1
Wang, MD1
Seitz, D1
Gill, SS1
Leroy, PL1
Lacasse, H1
Williamson, DR1
Dijkstra, M1
van Dis, H1
Gareri, P1
De Fazio, P1
Cotroneo, A1
Lacava, R1
Gallelli, L1
De Fazio, S1
De Sarro, G1
Ito, H1
Harada, D1
Hayashida, K1
Ishino, H1
Nakayama, K1
Rea, RS1
Battistone, S1
Short, MR1
Winstead, PS1
Lonergan, E1
Britton, AM1
Luxenberg, J1
Wyller, T1
Miyaji, S1
Yamamoto, K1
Hoshino, S1
Yamamoto, H1
Miyaoka, H1
Grover, M1
Edwards, F1
Hitchcock, K1
Stevens, MM1
Ozbolt, LB1
Paniagua, MA1
Kaiser, RM1
Füessl, HS1
Schrader, SL1
Wellik, KE1
Demaerschalk, BM1
Caselli, RJ1
Woodruff, BK1
Wingerchuk, DM1
Sari, A1
Akkaya, C1
Taskapilioglu, O1
Erer, S1
Bora, I1
Ramirez, AL1
Kanter, GL1
Yerevanian, BI2
Ciccone, JR1
Hales, RE1
Holtz, JL1
Cassem, EH1
Magni, G1
De Leo, D1
Kulik, AV1
Wilbur, R1
Di Salvo, TG1
O'Gara, PT1
Tamai, S1
Soares, JC1
Fráguas Júnior, R1
Nakamura, J2
Uchimura, N2
Yamada, S2
Nakazawa, Y2
Sanders, KM2
Stern, TA1
Metzger, E1
Friedman, R1
Dixon, D1
Craven, J1
Marotta, R1
Platt, MM1
Weisman, H1
Derevenco, M1
Grau, C1
Corbera, K1
Raymond, S1
Lund, S1
Jacobson, P1
Byerly, MJ1
Christensen, RC1
Evans, OL1
Pitkälä, K1
Trzepacz, PT1
Olofsson, SM1
Weitzner, MA1
Valentine, AD1
Baile, WF1
Meyers, CA1
Akechi, T1
Okamura, H1
Fukue, M1
Kagaya, A1
Nishida, A1
Oomori, N1
Yamawaki, S1
Galen, DM1
Beck, M1
Buchbinder, D1
Kunkel, EJ1
Matsushima, E1
Nakajima, K1
Moriya, H1
Matsuura, M1
Motomiya, T1
Kojima, T1
Fraser, GL1
Richen, P1
Blitzstein, SM1
Brandt, GT1
Paul, KL1
Bhatara, VS1
Spisla, C1
Bünter, M1
Manos, PJ1
Wu, R1
Still, J1
Friedman, B1
Law, E1
Deppe, S1
Epperly, N1
Orlet, H1
Normann, C1
Brandt, C1
Berger, M1
Walden, J1
O'Keeffe, ST1
Lavan, JN1
Hurford, WE1
Perrault, LP1
Denault, AY1
Carrier, M1
Cartier, R1
Bélisle, S1
Strout, D1
Tauscher, J1
Tauscher-Wisniewski, S1
Kasper, S1
Conn, DK1
Lieff, S1
Someya, T1
Endo, T1
Hara, T1
Yagi, G1
Suzuki, J1
Tabet, N1
Howard, R1
Ross, DD1
Alexander, CS1
Arrants, J1
Hepp, U1
Ehle, G1
Uebelhack, R1
Cutler, NR1
Heiser, JF1
Moore, DP1
Gelfand, SB1
Indelicato, J1
Benjamin, J1
Nisijima, K1
Hirayama, M1
Stiefel, F1
Holland, J1
van den Broek, WM1
Moleman, P2
Adams, F3
Reed, SM1
Wise, MG1
Timmerman, I1
Fernandez, F3
Levy, JK1
Mansell, PW1
Fuller, MA1
Sajatovic, M1
Moulaert, P1
Zisook, S1
Braff, DL1
Menza, MA1
Holmes, VF2
Rafuls, WA1
Jansen, PA1
Bekker, FM1
van Nieuwkerk, JF1
Nolen, WA1
Schols, D1
Kavanaugh, JJ1
Andersson, BS1
Hodgman, CH1
Petrova, ES1
Raft, DD1
Newmark, C1
Toomey, T1
Heiberg, A1
Castaigne, P1
Lapresle, J1
Chain, F1
de Barros-Ferreira, M1
Mattos, E1
Entin, GM1
Voelkel, A1

Clinical Trials (48)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Open-label Randomized Controlled Trial of Oral Transmucosal Haloperidol and Olanzapine in the Treatment of Terminal Delirium[NCT04750395]Phase 280 participants (Anticipated)Interventional2021-09-01Recruiting
Agents Intervening Against Delirium in Intensive Care Unit (AID-ICU) A Randomized, Blinded, Placebo-controlled Trial[NCT03392376]Phase 41,000 participants (Anticipated)Interventional2018-06-13Active, not recruiting
Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE) : A Multicenter Randomized Controlled Trial[NCT06029244]160 participants (Anticipated)Interventional2023-12-10Not yet recruiting
Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer[NCT01539733]101 participants (Actual)Interventional2010-03-31Completed
Haloperidol and/or Chlorpromazine for Refractory Agitated Delirium in the Palliative Care Unit[NCT03021486]Phase 2/Phase 370 participants (Actual)Interventional2017-06-05Active, not recruiting
Efficacy of Haloperidol to Decrease the Burden of Delirium in Adult Critically Ill Patients (EuRIDICE): a Prospective Randomised Multi-center Double-blind Placebo-controlled Clinical Trial[NCT03628391]Phase 3142 participants (Actual)Interventional2018-02-22Terminated (stopped due to The study was stopped because of futility of being able to reach a one-day difference between treatment groups in the primary outcome of DCFD in the intended sample size.)
Baden PRIDe Trial - Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial[NCT02433041]Phase 4200 participants (Actual)Interventional2013-07-31Completed
A Survey of Management of Analgesia, Sedation and Delirium in ICU Patients in China[NCT04217915]800 participants (Anticipated)Observational2021-07-12Recruiting
Virtual Reality Stimulation to Relax and Reduce the Incidence of Delirium[NCT04498585]920 participants (Anticipated)Interventional2021-04-14Suspended (stopped due to Decreased resources due to COVID-19)
A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit[NCT01949662]Phase 293 participants (Actual)Interventional2014-01-31Active, not recruiting
HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial[NCT04833023]Phase 372 participants (Anticipated)Interventional2022-05-18Recruiting
Prophylactic Haloperidol Use for Delirium in ICU Patients; a Randomized Placebo-controlled Double-blind Multicentre Trial[NCT01785290]Phase 41,800 participants (Actual)Interventional2013-06-30Completed
El DORADO STUDY (Evaluation of Delivery of Oxygen on Renal, Arrhythmia and Delirium Outcomes Study)[NCT04895384]600 participants (Anticipated)Observational2021-07-27Recruiting
Effect of Flumazenil on Hypoactive Delirium in the ICU: A Double-Blind, Placebo-Controlled Pilot Study[NCT02899156]Phase 422 participants (Actual)Interventional2016-03-31Terminated (stopped due to A planned interim analysis led to the trial being stopped early based on the observed size effect and power analysis.)
MIND-USA Study: Modifying the Impact of ICU-Associated Neurological Dysfunction[NCT01211522]Phase 3566 participants (Actual)Interventional2011-12-14Completed
Preventing Post-Operative Delirium in Pneumonectomy, Esophagectomy and Thoracotomy Patients[NCT02213900]Phase 4135 participants (Actual)Interventional2013-09-30Completed
Pharmacological Management of Delirium[NCT00842608]551 participants (Actual)Interventional2009-02-28Completed
Compare Efficacy and Safety Between Quetiapine and Haloperidol in Treatment Delirium[NCT00954603]Phase 352 participants (Actual)Interventional2009-06-30Terminated (stopped due to few delirious patients were enrolled.)
Structured Cognitive Therapy to Improve Neurocognitive Dysfunction in Older Intensive Care Unit Sepsis Survivors[NCT04081090]1 participants (Actual)Interventional2019-01-15Terminated (stopped due to Delay due to COVID. Lost funding.)
Delirium: Is Prophylactic Drug Therapy Useful in High Risk Patients as Defined by the Delirium Risk Prediction Model?[NCT03199950]Phase 41,366 participants (Anticipated)Interventional2017-06-23Recruiting
Early Pharmacological Intervention to Prevent Delirium: Haloperidol Prophylaxis in Older Emergency Department Patients[NCT01530308]Phase 4242 participants (Actual)Interventional2012-11-30Completed
Subsyndromal Delirium in Intensive Care Unit, a Multicenter Study[NCT03813459]400 participants (Actual)Observational2018-08-01Completed
Effect of Clonidine vs. Dexmedetomidine in Addition to Standard Treatment in Agitated Delirium in Intensive Care Patients: Pilot Study.[NCT04758936]Phase 450 participants (Anticipated)Interventional2021-02-01Recruiting
Effect of Regional Anaesthesia and General Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Hip Fracture Surgery: a Multicenter Randomized Controlled Trial.[NCT02213380]950 participants (Actual)Interventional2014-09-30Completed
Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)[NCT01700816]40 participants (Actual)Interventional2012-10-31Terminated (stopped due to Low incidence of delirium.)
Evaluating the Effects of Implementing an Scenario-based Education Initiative and OSCE for Recognition and Management of Delirium in Adult Intensive Care Unit: Randomised Controlled Trial[NCT03642249]72 participants (Actual)Interventional2019-11-05Completed
A Randomised Open Label Pilot Study of the Efficacy of Dexmedetomidine and Haloperidol in Ventilated Patients With ICU-associated Agitation and Delirium[NCT00505804]Phase 220 participants (Actual)Interventional2005-01-31Completed
Prospective, Double-Blind, Randomized Controlled Trial of Quetiapine as a Treatment for Delirium in Critically Ill Children[NCT03572257]Phase 2/Phase 30 participants (Actual)Interventional2019-04-15Withdrawn (stopped due to Closed due to inability to enroll)
Trazodone vs. Quetiapine for the Treatment of ICU Delirium: A Prospective Observational Pilot Study[NCT05307003]60 participants (Anticipated)Observational2023-04-01Recruiting
Dynamic Light Application to Prevent ICU Acquired Delirium[NCT01274819]1,000 participants (Actual)Interventional2011-07-31Completed
Comparison of Trazodone vs Quetiapine vs Placebo for the Treatment of ICU Delirium: A Randomized Controlled Trial (The TraQ Study)[NCT05085808]Phase 430 participants (Anticipated)Interventional2024-03-01Not yet recruiting
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone[NCT00096863]Phase 2102 participants (Actual)Interventional2004-12-31Completed
Rivastigmine for Delirium in Intensive Care Patients, a Double-blind, Randomized Placebo-controlled add-on Trial[NCT00704301]Phase 4104 participants (Actual)Interventional2008-11-30Terminated (stopped due to The study is prematurely terminated due to a safety issue)
Randomized Double-Blind Clinical Trial to Compare Haloperidol and Non-Pharmacologic Treatment Versus Non-Pharmacologic Treatment and Placebo, in Elderly Hospitalized Patients With Hypoactive Delirium[NCT02345902]Phase 360 participants (Anticipated)Interventional2016-01-31Recruiting
Southern Medical University Clinical Research Project Initiative:Efficacy and Safety of a Multicomponent Physical Therapy Program in Mechanically Ventilated Patient With Sepsis[NCT03406494]800 participants (Anticipated)Interventional2018-03-31Not yet recruiting
Evaluation Study of a Delirium Prevention Policy Using Prophylactic Haloperidol in Critically Ill Patients With a High Risk for Delirium[NCT01187667]650 participants (Actual)Observational2010-08-31Completed
Objective Assessment of Delirium in Hospitalized Patients[NCT02258386]200 participants (Anticipated)Observational2014-10-31Not yet recruiting
Haloperidol vs Olanzapine for the Management of ICU Delirium: A Randomized Clinical Trial[NCT00833300]200 participants (Anticipated)Interventional2008-06-30Terminated
A Randomized Prospective Pilot Study Of Haloperidol In Addition To Standard Sedation In Mechanically Ventilated Patients With Delirium[NCT00429676]Phase 220 participants (Anticipated)Interventional2005-12-31Completed
ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium[NCT00300391]Phase 340 participants (Actual)Interventional2006-03-31Terminated (stopped due to Insufficient recruitment to meet aims.)
Impact of Dexmedetomidine Combined With Ropivacaine for Postoperative Continuous Femoral Nerve Block on Postoperative Delirium and Long-term Oucomes in Elderly Patients After Single Knee Arthroplasty[NCT03629483]Phase 4736 participants (Anticipated)Interventional2018-12-10Suspended (stopped due to Trial stopped by the sponsor because of no funding.)
Impact of Dexmedetomidine Supplemented Intravenous Analgesia on Postoperative Delirium and Long-term Outcomes in Elderly After Orthopedic Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial[NCT03629262]Phase 4712 participants (Actual)Interventional2018-10-28Active, not recruiting
Impact of Dexmedetomidine Supplemented Analgesia on Delirium and Long-term Outcomes in Elderly After Hip Fracture Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial[NCT04955249]Phase 41,440 participants (Anticipated)Interventional2021-11-18Recruiting
Risk Assessment for Postoperative Delirium: Derivation of a Self-Administered Tablet Computer-based Clinical Screening Tool[NCT02377115]54 participants (Actual)Interventional2015-03-31Completed
Cukurova University Faculty of Medicine[NCT02360982]120 participants (Actual)Observational2012-03-31Completed
Namenda as Prevention for Post-Operative Delirium[NCT00303433]Phase 430 participants Interventional2006-03-31Terminated
The Effect of Steroid on Reducing Facial Swelling After Orthognathic Surgery[NCT01431014]Phase 456 participants (Actual)Interventional2011-08-31Completed
Prospective Evaluation of Perioperative Steroid Dosing on Postsurgical Edema in Orthognathic Surgery[NCT03190642]Phase 4180 participants (Actual)Interventional2018-01-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in RASS Score (0-30 Minutes)

RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The secondary outcome was mean change in RASS score between time 0 (immediately before initiation of masked treatment) and 30 minutes later. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid over sedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 30 minutes later.

Interventionscore on a scale (Mean)
Escalation Group-2.6
Rotation Group-2.4
Combination Group-2.1

Change in Richmond Agitation Sedation Score (RASS) (0-24h)

RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The primary outcome was mean change in RASS score between time 0 (immediately before initiation of masked treatment) and 24 h later. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid oversedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 24 hours after study medication administration

Interventionscore on a scale (Mean)
Escalation Group-3.6
Rotation Group-3.3
Combination Group-3.0

Memorial Delirium Assessment Scale (MDAS)

The Memorial Delirium Assessment Scale (MDAS) is a 10-item clinician-rated assessment scale validated for assessment of delirium in cancer patients. It examines the level of consciousness, disorientation, memory, recall, attention, disorganized thinking, perceptual disturbance, delusions, psychomotor activity and sleep, assigning a score between 0 to 3, for a total score between 0-30. A total score of 13 or higher indicates delirium. We measured the change in Memorial Delirium Rating scale between baseline and 24 hours. (NCT03021486)
Timeframe: Baseline and 24 hours

Interventionscore on a scale (Mean)
Escalation Group-2.7
Rotation Group1
Combination Group0.3

Number of Participants With RASS Score of >=1

RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The secondary outcome was the proportion of breakthrough restlessness participants with a RASS score of >=1 during the first 24 hours. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid oversedation in the Intensive Care Unit. (NCT03021486)
Timeframe: 0 or Baseline and 24 hours later

InterventionParticipants (Count of Participants)
Escalation Group12
Rotation Group7
Combination Group9

Percentage of Participants With RASS Score -2 to 0

RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The Secondary outcome was the percentage of participants with target RASS score of -2 to 0 within the first 24 hours. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid over sedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 24 hours later.

InterventionParticipants (Count of Participants)
Escalation Group2
Rotation Group3
Combination Group5

Change in Delirium Experience Questionnaire

This 14-item questionnaire examines both the recalled frequency of 7 delirium symptoms and associated distress in the rater: disorientation to time, disorientation to place, visual hallucinations, tactile hallucinations, auditory hallucinations, delusional thoughts and psychomotor agitation. The score for recalled frequency ranges between 0 and 4, where 0=not present, 1=a little of the time, 2=some of the time, 3=good part of the time, and 4=most or all of the time. The score for distress in the rater related to each delirium symptom also ranges from 0 to 4, where 0=no distress, 1=a little, 2=a fair amount, 3=very much and 4=extremely distressed. Due to an error in the data collection form, the last category was omitted as a choice and thus the score only ranged from 0 to 3. (NCT03021486)
Timeframe: Baseline and Day 3

,,
Interventionscore on a scale (Mean)
Nursing assessment, disorientation to time - frequencyNursing assessment, disorientation to place - frequencyNursing assessment, visual hallucination - frequencyNursing assessment, tactile hallucination - frequencyNursing assessment, auditory hallucination - frequencyNursing assessment, delusional thoughts - frequencyNursing assessment, psychomotor agitation- frequencyNursing assessment, disorientation to time - distressNursing assessment, disorientation to place - distressNursing assessment, visual hallucination - distressNursing assessment, tactile hallucination - distressNursing assessment, auditory hallucination - distressNursing assessment, delusional thoughts - distressNursing assessment, psychomotor agitation - distress
Combination Group0.20.3-0.7-0.9-0.40.2-0.4-0.5-0.4-0.4-0.5-0.2-0.1-0.8
Escalation Group-0.8-0.9-1-0.4-0.1-0.8-1.2-0.3-0.3-0.6-0.5-0.3-0.6-0.8
Rotation Group-0.8-0.800.10.10-0.8-0.3-0.30.1000-0.5

Edmonton Expression Assessment System, ESAS

Edmonton Symptom Assessment System (ESAS) has been validated and widely used in different clinical settings, including the acute palliative care unit. It assessed the average symptom intensity of 10 symptoms over the past 24 hours. Each symptom was assessed using an 11-point numeric rating scale, ranging from 0 (none) to 10 (worst). It was measured as change in ESAS as Perceived by Caregivers between baseline and day 1, mean. (NCT03021486)
Timeframe: Baseline and 24 hours

,,
Interventionscore on a scale (Mean)
PainFatigueNauseaDepressionAnxietyDrowsinessAppetiteFeeling of well being*Shortness of breathSleep
Combination Group-1.11-0.4-0.8-0.90.70.100-2.7
Escalation Group-1.3-0.50.1-1.4-1.5-0.2-0.30.20.8-2.7
Rotation Group-4.1-3-1.8-1.2-4.8-0.6-0.6-1.6-2.2-5.1

Pattern of Medication Use

Use of neuroleptics and benzodiazepines during the first 24 hours was retrieved from the Medication Administration Record. (NCT03021486)
Timeframe: Baseline and 24 hours

,,
InterventionParticipants (Count of Participants)
Need for study med dose escalation in first 24 hrsBenzodiazepine use in first 24 hrs (scheduled)Benzodiazepine use in first 24 hrs (as needed)
Combination Group704
Escalation Group410
Rotation Group100

Perceived Comfort Level as Assessed by Caregiver

"On day 1 (after initiation of blinded treatment), we asked the blinded caregivers to provide their overall impression of change in patient comfort level and the agitation level. The response ranged from strongly agree, agree, neutral, disagree, and strongly disagree. In this study, strongly agree and agree were combined for analysis. The participants who reported 'Agree' and 'Strongly Agree' responses to perceived comfort level have a high level of comfort (more comfortable). And similarly, the participants who reported 'Agree' and 'Strongly Agree' responses to perceived agitation level have a low level of agitation (less agitated)." (NCT03021486)
Timeframe: Baseline and 24 hour

,,
InterventionParticipants (Count of Participants)
Perceived To Have A High Level of Comfort (More Comfortable)Perceived To Have A Low Level of Agitation (Less Agitated)
Combination Group66
Escalation Group89
Rotation Group1010

Perceived Comfort Level as Assessed by Nurse

"On day 1 (after initiation of blinded treatment), we asked the blinded caregivers to provide their overall impression of change in patient comfort level and the agitation level. The response ranged from strongly agree, agree, neutral, disagree, and strongly disagree. In this study, strongly agree and agree were combined for analysis. The participants who reported 'Agree' and 'Strongly Agree' responses to perceived comfort level have a high level of comfort (more comfortable). And similarly, the participants who reported 'Agree' and 'Strongly Agree' responses to perceived agitation level have a low level of agitation (less agitated)." (NCT03021486)
Timeframe: Baseline and 24 hour

,,
InterventionParticipants (Count of Participants)
Perceived To Have A High Level of Comfort (More Comfortable)Perceived To Have A Low Level of Agitation (Less Agitated)
Combination Group77
Escalation Group98
Rotation Group98

Udvalg for Kliniske Undersogelser, UKU

We also documented the selected adverse effects associated with neuroleptics using the Udvalg for Kliniske Undersogelser (UKU) side effects rating scale. Specifically, we assessed 8 neurologic symptoms (dystonia, rigidity, hypokinesia/akinesia, hyperkinesia, tremor, akathisia, epileptic seizures, paraesthesias). We are reporting only the neurologic symptoms (tremor and akathisia) that had changes during the study. Each item was assigned a score by the research coordinator 0 (absent) to 3 (most severe) based on symptom severity of the last 3 days. (NCT03021486)
Timeframe: Baseline and 3 days

,,
InterventionParticipants (Count of Participants)
Tremor (decreased)Akathisia (decreased)
Combination Group11
Escalation Group00
Rotation Group00

Absolute Richmond Agitation-Sedation Scale Score at 8 Hour, Points

Absolute score of Richmond Agitation-Sedation Scale at 8 hr, points. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: 8 hours

Interventionscore on a scale (Mean)
Intervention Group (Lorazepam & Haloperidol)-2.5
Control Group (Placebo & Haloperidol)-0.7

Change in Richmond Agitation-Sedation Scale Score (Baseline to 8 hr), Points

The primary outcome was change in Richmond Agitation-Sedation Scale score from baseline to 8 hours after treatment administration. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 8 hours

Interventionscore on a scale (Mean)
Intervention Group (Lorazepam & Haloperidol)-4.1
Control Group (Placebo & Haloperidol)-2.3

Change in Richmond Agitation-Sedation Scale Score From Baseline to 30 Min

Change in Richmond Agitation-Sedation Scale score from baseline to 30 min. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 30 minutes

Interventionscore on a scale (Mean)
Intervention Group (Lorazepam & Haloperidol)-3.6
Control Group (Placebo & Haloperidol)-1.6

Number of Participants With Richmond Agitation-Sedation Scale Score >=1 Within 8 hr

Number of participants with Richmond Agitation-Sedation Scale score >=1 within 8 hr. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 8 hours

InterventionParticipants (Count of Participants)
Intervention Group (Lorazepam & Haloperidol)8
Control Group (Placebo & Haloperidol)22

Average Duration of Study Infusion

average duration of time patient was randomized to each infusion up to 72 hours (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion

Interventionhours (Mean)
Flumazenil Group54.8
Placebo Group58.2

Average Maximum Rate of Study Infusion

average maximum rate (ml/hr) during the 72 hours after study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion

Interventionmilliliters per hour (Mean)
Flumazenil Group5
Placebo Group5.2

Intensive Care Unit Length of Stay

length of time that the patient was admitted to an intensive care unit service during the hospital stay (NCT02899156)
Timeframe: duration of admission to the intensive care unit

Interventiondays (Mean)
Flumazenil Group7.8
Placebo Group7

Number of Delirium-free Days

Defined by the number of days in the 14-day period after randomization that the patient was alive and not delirious (i.e. CAM-ICU negative). Zero delirium-free days will be observed for patients that die within the 14-day period. (NCT02899156)
Timeframe: up to 14 days after randomization

Interventiondays (Median)
Flumazenil Group12.7
Placebo Group9.2

Number of Mechanical Ventilator Free Days

number of days within the first 28 days after enrollment that the patient was free from needing mechanical ventilation (NCT02899156)
Timeframe: up to 28 days after randomization

Interventiondays (Mean)
Flumazenil Group23.6
Placebo Group24.9

Number of Participants With Delirium Resolution

defined by the proportion of patients who were delirium free at 14 days after randomization (NCT02899156)
Timeframe: up to 14 days after randomization

InterventionParticipants (Count of Participants)
Flumazenil Group9
Placebo Group7

Occurrence of Agitation Requiring Use of Rescue Sedatives While on Study Infusion

number of times that a RASS score of + 2 to +4 occurred that did not resolve with decreasing study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion

InterventionParticipants (Count of Participants)
Flumazenil Group0
Placebo Group0

Delirium Duration

Duration of delirium during the intervention period (NCT01211522)
Timeframe: 14 days

Interventiondays (Median)
Haloperidol4
Ziprasidone4
Placebo4

Delirium/Coma-free Days (DCFDs)

Defined as the number of days during the 14-day intervention period (beginning on the day of randomization) that the patient was alive and experienced neither delirium nor coma. (NCT01211522)
Timeframe: 14 days

Interventiondays (Median)
Haloperidol8
Ziprasidone8
Placebo7

Number of Participants With Extrapyramidal Symptoms

(NCT01211522)
Timeframe: 14 days plus 4-day post-study drug period (if longer than 14 days)

InterventionParticipants (Count of Participants)
Haloperidol1
Ziprasidone1
Placebo1

Number of Participants With Neuroleptic Malignant Syndrome

(NCT01211522)
Timeframe: 14 days plus 4-day post-study drug period (if longer than 14 days)

InterventionParticipants (Count of Participants)
Haloperidol0
Ziprasidone0
Placebo0

Number of Participants With Torsades de Pointes

(NCT01211522)
Timeframe: 14 days plus 4-day post-study drug period (if longer than 14 days)

InterventionParticipants (Count of Participants)
Haloperidol2
Ziprasidone0
Placebo0

Time to Final ICU Discharge

"Days from randomization to final, successful ICU discharge, where successful indicates that discharge was followed by at least 48 hours alive. ICU discharge is represented by readiness for ICU discharge indicated by a physician order for transfer to a lower level of care even if a bed availability problems prevent actual discharge from the ICU." (NCT01211522)
Timeframe: 90 days

Interventiondays (Median)
Haloperidol5
Ziprasidone6
Placebo5

Time to Hospital Discharge

"Days from randomization to successful hospital discharge, where successful indicates that discharge was followed by at least 48 hours alive." (NCT01211522)
Timeframe: 90 days

Interventiondays (Median)
Haloperidol13
Ziprasidone12
Placebo13

Time to ICU Readmission

Days from first ICU discharge to next ICU readmission. (NCT01211522)
Timeframe: 90 days after first ICU discharge

Interventiondays (Median)
Haloperidol5
Ziprasidone5
Placebo4

Time to Liberation From Mechanical Ventilation

"Days from randomization to successful liberation from mechanical ventilation, where successful indicates that liberation was followed by at least 48 hours alive and without reinitiation of invasive or noninvasive ventilation." (NCT01211522)
Timeframe: 30 days

Interventiondays (Median)
Haloperidol2
Ziprasidone3
Placebo3

Mortality

Deaths within the specified timeframe (NCT01211522)
Timeframe: 30-day and 90-day

,,
InterventionParticipants (Count of Participants)
30-day mortality90-day mortality
Haloperidol5073
Placebo5063
Ziprasidone5365

Efficacy of Low-dose Haloperidol in Reducing Days With Delirium

Test the efficacy of low dose haloperidol in reducing the number of days with delirium among patients who are status post esophagectomy, pneumonectomy or thoracotomy compared to placebo. (NCT02213900)
Timeframe: Up to 30 days

InterventionDays with Delirium (Mean)
Haloperidol0.3
Placebo0.5

Efficacy of Low-dose Haloperidol in Reducing Delirium Incidence

Test the efficacy of low dose haloperidol in reducing delirium incidence among patients who are status post esophagectomy, pneumonectomy or thoracotomy compared to placebo. (NCT02213900)
Timeframe: Up to 30 days

InterventionParticipants (Count of Participants)
Haloperidol15
Placebo19

Efficacy of Low-dose Haloperidol in Reducing Cognitive Impairment at Post-operative Follow-up

Test the efficacy of low dose haloperidol in reducing cognitive impairment at post-operative follow-up among patients who are status post esophagectomy, pneumonectomy or thoracotomy compared to placebo. Cognitive status is assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The RBANS measures attention, language, visuospatial/constructional abilities, and memory. It is made up of 12 subtests. The subtests produce 5 index scores and a total scale score. All the subtest scores are summed to calculate a Total Index score. The Total Index score is presented. The Total Index score scale is from 0-100 with higher scores indicating less cognitive impairment. (NCT02213900)
Timeframe: Up to 3 months after hospital discharge on average.

,
InterventionUnits on a scale (Mean)
Baseline RBANS Total Score3 Month RBANS Total Score
Haloperidol31.731.8
Placebo30.122.7

Efficacy of Low-dose Haloperidol in Reducing ICU and Hospital Length of Stay

Test the efficacy of low dose haloperidol in reducing ICU and hospital length of stay among patients who are status post esophagectomy or pneumonectomy compared to placebo. (NCT02213900)
Timeframe: Date of hospital admission through date of hospital discharge, up to 3 weeks on average.

,
InterventionDays (Mean)
ICU Length of StayOverall Length of Stay
Haloperidol2.59.3
Placebo2.810.2

Days Free of Delirium and Coma

(NCT00842608)
Timeframe: Admission through day 8 of stay

Interventiondays (Median)
Haloperidol Eligible Intervention4
Haloperidol Eligible Usual Care5
Haldol-Ineligible Arm4
Haldol Ineligible Usual Care5

Hospital Length of Stay Post Randomization

(NCT00842608)
Timeframe: Participants were followed for the duration of hospital stay, an average of 11 days

Interventiondays (Mean)
Haloperidol Eligible Intervention20.2
Haloperidol Eligible Usual Care18.6
Haldol-Ineligible Arm18.8
Haldol Ineligible Usual Care14.9

Mortality

(NCT00842608)
Timeframe: ICU, in-hospital, 30-days post hospitalization

InterventionParticipants (Count of Participants)
Haloperidol Eligible Intervention20
Haloperidol Eligible Usual Care32
Haldol-Ineligible Arm11
Haldol Ineligible Usual Care8

30 Day Mortality

Mortality within 30 days post operation (NCT02213380)
Timeframe: 30 days after surgery

InterventionParticipants (Count of Participants)
Group RA8
Group GA4

Acute Pain Score Using Visual Analogue Scale (VAS)

The worst pain score within 7 days post-operation in both groups. The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between no pain(0 point) to worst pain (100 points). (NCT02213380)
Timeframe: In 7days post operation

Interventionscore on a scale (Median)
Group RA0
Group GA0

Costs of Anesthetic Procedure

Costs of anesthetic procedure only (NCT02213380)
Timeframe: 1 day after operation

Interventiondollars (Median)
Group RA159
Group GA268

Length of Hospital Stay

Length of hospital stay are measured from the anesthesia starting day to the discharge day (NCT02213380)
Timeframe: till the day of discharge from hospital, an average of 7 days

Interventiondays (Median)
Group RA7
Group GA7

Number of Participants With Post-operative Delirium in 7 Days Post Operation

Post-operative delirium diagnosed with Confusion Assessment Method (NCT02213380)
Timeframe: in 7 days post operation

InterventionParticipants (Count of Participants)
Group RA29
Group GA24

Severity of Delirium

The worst severity scores of delirium was diagnosed with the DRS-R-98 within 7 days (NCT02213380)
Timeframe: within first 7days post operation

Interventionscore on a scale (Mean)
Group RA23.48
Group GA24.22

Total In-hospital Costs

Entire expenditure in-hospital (NCT02213380)
Timeframe: till the day of discharge

Interventiondollars (Median)
Group RA5582
Group GA5908

Hematocrit (HCT)

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

Interventionvolume percentage (vol%) of red blood ce (Median)
Bright Light Therapy28.20
Sham Light26.70

Hemoglobin (HGB)

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

Interventiong/dl (Median)
Bright Light Therapy9.70
Sham Light9.55

Hospital Length of Stay

(NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

Interventiondays (Median)
Bright Light Therapy18
Sham Light18.5

Number of Participants Who Developed Delirium Based on Meeting Criteria on the Delirium Rating Scale and/or Memorial Delirium Assessment Scale

Monday, Wednesday, and Friday assessments will begin after beginning light therapy and include the Delirium Rating Scale-Revised-98 (DRS-98)and Memorial Delirium Assessment Scale (MDAS) (NCT01700816)
Timeframe: From hospital admission until the date of first documented delirium, assessed up to 28 days post-transplant

InterventionParticipants (Count of Participants)
Bright Light Therapy1
Sham Light0

Platelet Count

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

Interventionthousand cells/uL (Median)
Bright Light Therapy39
Sham Light33.5

Red Blood Cells (RBC)

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

InterventionM/uL (Median)
Bright Light Therapy3.21
Sham Light2.93

Severity of Delirium Episodes: Memorial Delirium Assessment Scale (MDAS)

"Monday, Wednesday, and Friday assessments of the Memorial Delirium Assessment Scale (MDAS); Patients will receive assessments after beginning light therapy until day 28 post-transplant or discharge, whichever comes first.~10 item scale Items are rated on a four-point scale from 0 (none) to 3 (severe) depending on the level of impairment, rendering a maximum possible score of 30.~A score of 13 has been recommended as a cut-off for establishing the diagnosis of delirium" (NCT01700816)
Timeframe: From first documented episode of delirium until discharge from the hospital, assessed up to 28 days post-transplant

Interventionunits on a scale (Number)
Bright Light Therapy18

White Blood Cells (WBC)

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

InterventionK/uL (Median)
Bright Light Therapy2.30
Sham Light4.75

Serum Creatinine and Blood Urea Nitrogen (BUN)

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

,
Interventionmg/dl (Median)
Serum CreatinineBlood Urea Nitrogen (BUN)
Bright Light Therapy0.669
Sham Light0.758.5

Sodium (Na), Potassium (K), Chloride (Cl), and Carbon Dioxide (CO2)

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT (Hematopoietic Stem Cell Transplantation). (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

,
Interventionmmol/L (Median)
Sodium (Na)Potassium (K)Chloride (Cl)Carbon Dioxide (CO2)
Bright Light Therapy1393.610524.9
Sham Light138.03.80103.025.10

28-day All-cause Mortality

(NCT00300391)
Timeframe: Daily

InterventionParticipants (Count of Participants)
Delirium4
Persistent Coma2
No Delirium1

90-day All-cause Mortality

(NCT00300391)
Timeframe: 90 Days from enrollment in study

InterventionParticipants (Count of Participants)
Delirium4
Persistent Coma2
No Delirium1

Duration of Mechanical Ventilation

(NCT00300391)
Timeframe: daily

Interventionday (Median)
Delirium4.5
Persistent Coma6
No Delirium4

ICU Length of Stay

(NCT00300391)
Timeframe: Daily

Interventionday (Median)
Delirium9
Persistent Coma6
No Delirium7

Effect of Perioperative Steroid for the Postoperative Swelling After Orthognathic Surgery

Measure of facial swelling will be performed using 3-dimensional photogrammetry. The 3d photo acquisition is non-invasive without radiation concern. The images will be taken before and after surgery to measure and compare the degree of facial swelling. Side effects from the steroid use are expected to be low under normal clinical dosage, but will also be monitored. Symptoms of wound infection, psychosis, and prolonged wound healing will be studied. There should be no long term complication, since the steroid use is one single dose. (NCT01431014)
Timeframe: 1 year

,
Interventionml (Mean)
36 hours postoperatively1week postoperatively1month postoperatively
"DexamethasoneHigh-dose"167.0661.3929.85
"DexamethasoneLow-dose"190.7357.6219.34

Reviews

72 reviews available for haloperidol and Delirium

ArticleYear
Delirium-associated medication in people at risk: A systematic update review, meta-analyses, and GRADE-profiles.
    Acta psychiatrica Scandinavica, 2023, Volume: 147, Issue:1

    Topics: Adult; Delirium; Haloperidol; Humans; Prospective Studies

2023
A scoping review of perceptions from healthcare professionals on antipsychotic prescribing practices in acute care settings.
    BMC health services research, 2022, Oct-21, Volume: 22, Issue:1

    Topics: Antipsychotic Agents; Critical Care; Delirium; Delivery of Health Care; Haloperidol; Humans; Quetiap

2022
Prevention and treatment of traumatic brain injury-related delirium: a systematic review.
    Journal of neurology, 2023, Volume: 270, Issue:12

    Topics: Adult; Aged; Brain Injuries, Traumatic; Delirium; Haloperidol; Humans; Middle Aged; Propofol

2023
Antipsychotics for Treating Delirium in Hospitalized Adults: A Systematic Review.
    Annals of internal medicine, 2019, 10-01, Volume: 171, Issue:7

    Topics: Antipsychotic Agents; Cognition; Delirium; Electrocardiography; Haloperidol; Heart; Hospital Mortali

2019
Antipsychotics for Preventing Delirium in Hospitalized Adults: A Systematic Review.
    Annals of internal medicine, 2019, 10-01, Volume: 171, Issue:7

    Topics: Antipsychotic Agents; Cognition; Delirium; Electrocardiography; Haloperidol; Heart; Hospital Mortali

2019
Haloperidol for the treatment of delirium in critically ill patients: A systematic review with meta-analysis and Trial Sequential Analysis.
    Acta anaesthesiologica Scandinavica, 2020, Volume: 64, Issue:2

    Topics: Bias; Cause of Death; Cognition; Critical Illness; Delirium; Electrocardiography; Haloperidol; Human

2020
Efficacy and safety of haloperidol for delirium prevention in adult patients: An updated meta-analysis with trial sequential analysis of randomized controlled trials.
    Journal of clinical anesthesia, 2020, Volume: 61

    Topics: Adult; Delirium; Haloperidol; Humans; Intensive Care Units; Length of Stay; Randomized Controlled Tr

2020
Drug therapy for delirium in terminally ill adults.
    The Cochrane database of systematic reviews, 2020, 01-21, Volume: 1

    Topics: Adult; Antipsychotic Agents; Chlorpromazine; Delirium; Haloperidol; Humans; Lorazepam; Randomized Co

2020
Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an intensive care unit.
    The Cochrane database of systematic reviews, 2020, 02-28, Volume: 2

    Topics: Antipsychotic Agents; Benzodiazepines; Critical Care; Delirium; Haloperidol; Humans; Lorazepam; Pall

2020
Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis.
    Journal of psychiatric research, 2020, Volume: 125

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Network Meta-Analysis; Risperidone

2020
Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.
    Critical care (London, England), 2020, 06-08, Volume: 24, Issue:1

    Topics: Analgesia; Analgesics, Non-Narcotic; Analgesics, Opioid; Benzodiazepines; Critical Illness; Deep Sed

2020
Antipsychotic Drugs in Prevention of Postoperative Delirium-What Is Known in 2020?
    International journal of environmental research and public health, 2020, 08-20, Volume: 17, Issue:17

    Topics: Aged; Antipsychotic Agents; Delirium; Haloperidol; Humans; Postoperative Period; Prospective Studies

2020
Haloperidol for preventing delirium in ICU patients: a systematic review and meta-analysis.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:3

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Intensive Care Units

2021
Comparative effectiveness of pharmacological interventions to prevent postoperative delirium: a network meta-analysis.
    Scientific reports, 2021, 06-07, Volume: 11, Issue:1

    Topics: Adult; Antipsychotic Agents; Bayes Theorem; Delirium; Haloperidol; Humans; Network Meta-Analysis; Ph

2021
Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk of delirium: a systematic review.
    JBI database of systematic reviews and implementation reports, 2017, Volume: 15, Issue:5

    Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Critical

2017
Update in perioperative medicine: practice changing evidence published in 2016.
    Hospital practice (1995), 2017, Volume: 45, Issue:4

    Topics: Amines; Analgesics; Anticoagulants; Antipsychotic Agents; Arthritis, Rheumatoid; Blood Transfusion;

2017
Delirium in hospitalized patients: Risks and benefits of antipsychotics.
    Cleveland Clinic journal of medicine, 2017, Volume: 84, Issue:8

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Haloperidol; Hospitalization; Humans;

2017
Haloperidol for delirium in critically ill patients - protocol for a systematic review.
    Acta anaesthesiologica Scandinavica, 2018, Volume: 62, Issue:5

    Topics: Data Interpretation, Statistical; Delirium; Haloperidol; Humans; Randomized Controlled Trials as Top

2018
Effects of Haloperidol on Delirium in Adult Patients: A Systematic Review and Meta-Analysis.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2018, Volume: 27, Issue:3

    Topics: Adult; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; Postoperative Complication

2018
Antipsychotics for treatment of delirium in hospitalised non-ICU patients.
    The Cochrane database of systematic reviews, 2018, 06-18, Volume: 6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Hospitalization; Humans

2018
Palliative Sedation for the Terminally Ill Patient.
    CNS drugs, 2018, Volume: 32, Issue:10

    Topics: Decision Making; Deep Sedation; Delirium; Haloperidol; Humans; Hypnotics and Sedatives; Midazolam; T

2018
Interventions for preventing intensive care unit delirium in adults.
    The Cochrane database of systematic reviews, 2018, 11-23, Volume: 11

    Topics: Aged; Antipsychotic Agents; Cognition Disorders; Cognitive Behavioral Therapy; Delirium; Female; Hal

2018
Haloperidol for the management of delirium in adult intensive care unit patients: A systematic review and meta-analysis of randomized controlled trials.
    Journal of critical care, 2019, Volume: 50

    Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans; Intensive Care Units;

2019
Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis.
    JAMA psychiatry, 2019, 05-01, Volume: 76, Issue:5

    Topics: Antipsychotic Agents; Delirium; Drug Therapy, Combination; Haloperidol; Humans; Indenes; Lorazepam;

2019
[Pharmacological treatment of delirium in palliative care patients. A systematic literature review].
    Schmerz (Berlin, Germany), 2013, Volume: 27, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Delirium; Evidence-Ba

2013
What do we really know about the treatment of delirium with antipsychotics? Ten key issues for delirium pharmacotherapy.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2013, Volume: 21, Issue:12

    Topics: Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Haloperidol; Humans; Risperidone

2013
Haloperidol cytotoxicity and its relation to oxidative stress.
    Mini reviews in medicinal chemistry, 2013, Volume: 13, Issue:14

    Topics: Antipsychotic Agents; Delirium; Gene Expression Regulation; Haloperidol; Humans; Mitogen-Activated P

2013
Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development.
    Journal of pain and symptom management, 2014, Volume: 48, Issue:2

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Randomized Controlled Trials a

2014
Management of delirium in palliative care: a review.
    Current psychiatry reports, 2015, Volume: 17, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholinesterase Inhibitors; Delirium; Disease Ma

2015
Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review.
    Journal of critical care, 2015, Volume: 30, Issue:4

    Topics: Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Dexmedetomidine; Haloperidol; Human

2015
Antipsychotic-induced akathisia in delirium: A systematic review.
    Palliative & supportive care, 2016, Volume: 14, Issue:1

    Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Delirium; Haloperidol; Humans; Prevalence; Risperidon

2016
Efficacy and safety of haloperidol for in-hospital delirium prevention and treatment: A systematic review of current evidence.
    European journal of internal medicine, 2016, Volume: 27

    Topics: Aged; Antipsychotic Agents; Delirium; Haloperidol; Hospitalization; Humans; Randomized Controlled Tr

2016
[The neurotoxicity of pyridinium metabolites of haloperidol].
    Postepy higieny i medycyny doswiadczalnej (Online), 2015, Oct-19, Volume: 69

    Topics: Antipsychotic Agents; Biotransformation; Brain; Delirium; Haloperidol; Humans; Nausea; Neurodegenera

2015
Acetylcholinesterase Inhibitors for Delirium in Older Adults.
    American journal of Alzheimer's disease and other dementias, 2016, Volume: 31, Issue:4

    Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Delirium; Haloperidol; Humans; Randomized Controlle

2016
[Delirium and delirium management in critically ill patients].
    Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2016, Volume: 111, Issue:1

    Topics: Checklist; Combined Modality Therapy; Critical Care; Delirium; Dexmedetomidine; Early Ambulation; Ev

2016
Neuroleptics in the management of delirium in patients with advanced cancer.
    Current opinion in supportive and palliative care, 2016, Volume: 10, Issue:4

    Topics: Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Drug Therapy, Combination; Haloper

2016
Treatment of delirium in supportive and palliative care.
    Current opinion in supportive and palliative care, 2008, Volume: 2, Issue:1

    Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Dopamine Antagonists; Haloperidol; Humans; Olanzapi

2008
[Delirium--management in the hospital: diagnosis and treatment].
    Zeitschrift fur Gerontologie und Geriatrie, 2008, Volume: 41, Issue:6

    Topics: Aged; Antipsychotic Agents; Confusion; Delirium; Frail Elderly; Haloperidol; Hospitalization; Humans

2008
Pharmacological management of delirium in hospitalized adults--a systematic evidence review.
    Journal of general internal medicine, 2009, Volume: 24, Issue:7

    Topics: Adult; Anesthetics, Inhalation; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Delirium; Ha

2009
[Delirium in the light of the most recent guidelines].
    Przeglad lekarski, 2009, Volume: 66, Issue:4

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Practice Guidelines as Topic; Psychiatric Statu

2009
Intensive care unit delirium.
    Critical care nursing clinics of North America, 2010, Volume: 22, Issue:2

    Topics: Algorithms; Antipsychotic Agents; Critical Care; Delirium; Dexmedetomidine; Diagnostic and Statistic

2010
Delirium at the end of life.
    BMJ clinical evidence, 2009, Jul-16, Volume: 2009

    Topics: Analgesics, Opioid; Antipsychotic Agents; Barbiturates; Delirium; Haloperidol; Humans; Incidence; Ne

2009
Role of haloperidol in palliative medicine: an update.
    The American journal of hospice & palliative care, 2012, Volume: 29, Issue:4

    Topics: Delirium; Dopamine Antagonists; Haloperidol; Humans; Nausea; Palliative Care; Vomiting

2012
Haloperidol dosing strategies in the treatment of delirium in the critically ill.
    Neurocritical care, 2012, Volume: 16, Issue:1

    Topics: Antipsychotic Agents; Critical Illness; Delirium; Dose-Response Relationship, Drug; Drug Administrat

2012
ICU delirium: an update.
    Current opinion in critical care, 2012, Volume: 18, Issue:2

    Topics: Anesthesia, General; Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Female; Halope

2012
Confusion, agitation and delirium.
    Frontiers of neurology and neuroscience, 2012, Volume: 30

    Topics: Antipsychotic Agents; Confusion; Delirium; Haloperidol; Humans; Prevalence; Psychomotor Agitation; R

2012
Brain dysfunction in patients with chronic critical illness.
    Respiratory care, 2012, Volume: 57, Issue:6

    Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Chronic Disease; Coma; Comorbid

2012
Drug therapy for delirium in terminally ill adult patients.
    The Cochrane database of systematic reviews, 2012, Nov-14, Volume: 11

    Topics: Adult; Antipsychotic Agents; Chlorpromazine; Delirium; Haloperidol; Humans; Lorazepam; Randomized Co

2012
Delirium.
    American family physician, 2003, Mar-01, Volume: 67, Issue:5

    Topics: Antipsychotic Agents; Delirium; Diagnosis, Differential; Haloperidol; Humans; Length of Stay; Risk F

2003
[Acute brain syndrome].
    Ryoikibetsu shokogun shirizu, 2003, Issue:40

    Topics: Acute Disease; Antipsychotic Agents; Delirium; Diagnostic and Statistical Manual of Mental Disorders

2003
Drug therapy for delirium in terminally ill patients.
    The Cochrane database of systematic reviews, 2004, Issue:2

    Topics: Antipsychotic Agents; Chlorpromazine; Delirium; Haloperidol; Humans; Lorazepam; Terminally Ill

2004
Haloperidol in palliative care.
    Palliative medicine, 2004, Volume: 18, Issue:3

    Topics: Antipsychotic Agents; Conscious Sedation; Delirium; Haloperidol; Humans; Long QT Syndrome; Nausea; V

2004
Delirium in severely ill young children in the pediatric intensive care unit (PICU).
    Journal of the American Academy of Child and Adolescent Psychiatry, 2005, Volume: 44, Issue:4

    Topics: Antipsychotic Agents; Child, Preschool; Delirium; Female; Haloperidol; Humans; Intensive Care Units;

2005
Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:11

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Hospital Departments; Hospitalization; Humans; Surgery

2006
Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients.
    Pharmacotherapy, 2007, Volume: 27, Issue:4

    Topics: Acute Disease; Adult; Antipsychotic Agents; Delirium; Haloperidol; Humans; Treatment Outcome

2007
Delirium dilemma.
    Orthopedics, 2007, Volume: 30, Issue:4

    Topics: Antioxidants; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Hospitalization; Humans;

2007
Antipsychotics for delirium.
    The Cochrane database of systematic reviews, 2007, Apr-18, Issue:2

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Humans; Male; Olanzapin

2007
Atypical antipsychotics for the treatment of delirious elders.
    Journal of the American Medical Directors Association, 2008, Volume: 9, Issue:1

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Delirium;

2008
Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients.
    The neurologist, 2008, Volume: 14, Issue:2

    Topics: Aged; Antipsychotic Agents; Chemotherapy, Adjuvant; Delirium; Haloperidol; Humans; Male; Postoperati

2008
Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients.
    The neurologist, 2008, Volume: 14, Issue:2

    Topics: Aged; Antipsychotic Agents; Chemotherapy, Adjuvant; Delirium; Haloperidol; Humans; Male; Postoperati

2008
Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients.
    The neurologist, 2008, Volume: 14, Issue:2

    Topics: Aged; Antipsychotic Agents; Chemotherapy, Adjuvant; Delirium; Haloperidol; Humans; Male; Postoperati

2008
Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients.
    The neurologist, 2008, Volume: 14, Issue:2

    Topics: Aged; Antipsychotic Agents; Chemotherapy, Adjuvant; Delirium; Haloperidol; Humans; Male; Postoperati

2008
Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients.
    Clinical cardiology, 1995, Volume: 18, Issue:5

    Topics: Aged; Delirium; Dose-Response Relationship, Drug; Electrocardiography; Female; Haloperidol; Heart Di

1995
[Delirium after open-heart surgery. Prevalence, risk factors and therapeutic approach].
    Arquivos brasileiros de cardiologia, 1994, Volume: 63, Issue:3

    Topics: Cardiac Surgical Procedures; Delirium; Haloperidol; Humans; Intraoperative Period; Postoperative Com

1994
Management of delirium associated with use of the intra-aortic balloon pump.
    American journal of critical care : an official publication, American Association of Critical-Care Nurses, 1993, Volume: 2, Issue:5

    Topics: Administration, Oral; Adult; Aged; Clinical Protocols; Coronary Disease; Delirium; Diagnosis, Differ

1993
[Confusional states in the elderly--an underdiagnosed syndrome with a poor prognosis].
    Nordisk medicin, 1996, Volume: 111, Issue:6

    Topics: Aged; Comorbidity; Confusion; Delirium; Dementia; Diagnosis, Differential; Haloperidol; Humans; Neur

1996
Delirium. Advances in diagnosis, pathophysiology, and treatment.
    The Psychiatric clinics of North America, 1996, Volume: 19, Issue:3

    Topics: Adult; Antipsychotic Agents; Brain; Brain Mapping; Child; Delirium; Droperidol; Haloperidol; Humans;

1996
Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients.
    Chest, 1997, Volume: 111, Issue:6

    Topics: Adult; Critical Care; Delirium; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Infusions, In

1997
Delirium in the terminally ill.
    Clinics in geriatric medicine, 2000, Volume: 16, Issue:2

    Topics: Antipsychotic Agents; Delirium; Diagnosis, Differential; Geriatric Assessment; Haloperidol; Humans;

2000
Diagnosing and managing delirium in the elderly.
    Canadian family physician Medecin de famille canadien, 2001, Volume: 47

    Topics: Aged; Antipsychotic Agents; Delirium; Diagnosis, Differential; Female; Geriatrics; Haloperidol; Huma

2001
Management of common symptoms in terminally ill patients: Part II. Constipation, delirium and dyspnea.
    American family physician, 2001, Sep-15, Volume: 64, Issue:6

    Topics: Analgesics, Opioid; Anti-Anxiety Agents; Antiemetics; Benzodiazepines; Cathartics; Constipation; Del

2001
[Diagnosis and treatment of delirium].
    Praxis, 2002, Mar-13, Volume: 91, Issue:11

    Topics: Age Factors; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Chlormethiazole; Deli

2002
Delirium in cancer patients.
    International psychogeriatrics, 1991,Winter, Volume: 3, Issue:2

    Topics: Aged; Delirium; Diagnosis, Differential; Haloperidol; Humans; Lorazepam; Neoplasms; Neuropsychologic

1991
Choreoathetosis: a sign of lithium toxicity.
    The Journal of neuropsychiatry and clinical neurosciences, 1989,Winter, Volume: 1, Issue:1

    Topics: Aged; Athetosis; Chorea; Clonazepam; Delirium; Depressive Disorder; Drug Therapy, Combination; Femal

1989
Management of delirium in terminally ill AIDS patients.
    International journal of psychiatry in medicine, 1989, Volume: 19, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Delirium; Haloperidol; Humans; Injections, Intravenous; Lorazepa

1989

Trials

62 trials available for haloperidol and Delirium

ArticleYear
The effect of the anticholinergic burden on duration and severity of delirium in older hip-surgery patients with and without haloperidol prophylaxis: A post hoc analysis.
    Brain and behavior, 2021, Volume: 11, Issue:12

    Topics: Aged; Cholinergic Antagonists; Delirium; Haloperidol; Humans

2021
An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home.
    Trials, 2022, Apr-14, Volume: 23, Issue:1

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Olanzapine; Psychomotor Agitation

2022
Haloperidol for the Treatment of Delirium in ICU Patients.
    The New England journal of medicine, 2022, 12-29, Volume: 387, Issue:26

    Topics: Administration, Intravenous; Adult; Antipsychotic Agents; Critical Care; Delirium; Double-Blind Meth

2022
Haloperidol vs. placebo for the treatment of delirium in ICU patients: a pre-planned, secondary Bayesian analysis of the AID-ICU trial.
    Intensive care medicine, 2023, Volume: 49, Issue:4

    Topics: Adult; Antipsychotic Agents; Bayes Theorem; Delirium; Haloperidol; Humans; Intensive Care Units

2023
Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial).
    BMC anesthesiology, 2023, 06-03, Volume: 23, Issue:1

    Topics: Critical Illness; Delirium; Dexmedetomidine; Drugs, Investigational; Haloperidol; Humans; Hypnotics

2023
Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial.
    Critical care (London, England), 2023, 10-30, Volume: 27, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Coma; Critical Illness; Delirium; Female; Haloperidol; Humans; In

2023
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.
    The oncologist, 2020, Volume: 25, Issue:3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Neoplasms; Olanzapine;

2020
Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial.
    The Lancet. Oncology, 2020, Volume: 21, Issue:7

    Topics: Aged; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; H

2020
The Agents Intervening against Delirium in the Intensive Care Unit Trial (AID-ICU trial): A detailed statistical analysis plan.
    Acta anaesthesiologica Scandinavica, 2020, Volume: 64, Issue:9

    Topics: Adult; Coma; Delirium; Haloperidol; Humans; Intensive Care Units; Respiration, Artificial

2020
Efficacy of halopeRIdol to decrease the burden of Delirium In adult Critically ill patiEnts (EuRIDICE): study protocol for a prospective randomised multi-centre double-blind placebo-controlled clinical trial in the Netherlands.
    BMJ open, 2020, 09-23, Volume: 10, Issue:9

    Topics: Adult; Critical Illness; Delirium; Double-Blind Method; Haloperidol; Humans; Intensive Care Units; M

2020
Ketamine vs. haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial.
    Journal of clinical anesthesia, 2021, Volume: 68

    Topics: Adult; Cognitive Dysfunction; Delirium; Double-Blind Method; Haloperidol; Humans; Ketamine

2021
Efficacy of quetiapine for delirium prevention in hospitalized older medical patients: a randomized double-blind controlled trial.
    BMC geriatrics, 2021, 03-31, Volume: 21, Issue:1

    Topics: Aged; Antipsychotic Agents; Delirium; Double-Blind Method; Haloperidol; Humans; Quetiapine Fumarate;

2021
Association among rescue neuroleptic use, agitation, and perceived comfort: secondary analysis of a randomized clinical trial on agitated delirium.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021, Volume: 29, Issue:12

    Topics: Antipsychotic Agents; Delirium; Double-Blind Method; Haloperidol; Humans; Lorazepam; Psychomotor Agi

2021
Personalized sedation goal for agitated delirium in patients with cancer: Balancing comfort and communication.
    Cancer, 2021, Dec-15, Volume: 127, Issue:24

    Topics: Communication; Delirium; Goals; Haloperidol; Humans; Hypnotics and Sedatives; Intensive Care Units;

2021
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
    JAMA, 2017, 09-19, Volume: 318, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me

2017
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
    JAMA, 2017, 09-19, Volume: 318, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me

2017
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
    JAMA, 2017, 09-19, Volume: 318, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me

2017
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
    JAMA, 2017, 09-19, Volume: 318, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me

2017
Haloperidol versus placebo for delirium prevention in acutely hospitalised older at risk patients: a multi-centre double-blind randomised controlled clinical trial.
    Age and ageing, 2018, 01-01, Volume: 47, Issue:1

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Chi-Square Distrib

2018
Prophylactic Use of Haloperidol and Changes in Glucose Levels in Hospitalized Older Patients.
    Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:1

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Blood Glucose; Delirium; Double-Blind Method; Female;

2018
Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial.
    JAMA, 2018, 02-20, Volume: 319, Issue:7

    Topics: Adult; Aged; Antipsychotic Agents; Critical Illness; Delirium; Dose-Response Relationship, Drug; Dou

2018
The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium.
    Cancer, 2018, 05-15, Volume: 124, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Delirium; Drug Therapy, Combination; Female; Haloperidol; Humans; Lo

2018
Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial (PRIDe): a phase IV multicenter, randomized, placebo-controlled, double-blind clinical trial of ketamine versus haloperidol for prevention of postoperative delirium.
    Trials, 2018, Feb-26, Volume: 19, Issue:1

    Topics: Anesthetics, Dissociative; Antipsychotic Agents; Clinical Trials, Phase IV as Topic; Delirium; Doubl

2018
Lorazepam Added to Haloperidol Effective for Agitated Delirium in End-of-Life Cancer Patients.
    American family physician, 2018, Feb-15, Volume: 97, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Drug Therapy, Combination; Female; H

2018
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F

2018
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F

2018
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F

2018
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F

2018
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F

2018
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F

2018
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F

2018
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F

2018
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F

2018
Preventing Postoperative Delirium After Major Noncardiac Thoracic Surgery-A Randomized Clinical Trial.
    Journal of the American Geriatrics Society, 2018, Volume: 66, Issue:12

    Topics: Administration, Intravenous; Antipsychotic Agents; Delirium; Double-Blind Method; Esophagectomy; Fem

2018
Pharmacological Management of Delirium in the Intensive Care Unit: A Randomized Pragmatic Clinical Trial.
    Journal of the American Geriatrics Society, 2019, Volume: 67, Issue:5

    Topics: Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Critical Illness; Delirium; Dose-Res

2019
Prophylactic Haloperidol Effects on Long-term Quality of Life in Critically Ill Patients at High Risk for Delirium: Results of the REDUCE Study.
    Anesthesiology, 2019, Volume: 131, Issue:2

    Topics: Aged; Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Double-Blind Method; Female;

2019
Agents intervening against delirium in the intensive care unit (AID-ICU) - Protocol for a randomised placebo-controlled trial of haloperidol in patients with delirium in the ICU.
    Acta anaesthesiologica Scandinavica, 2019, Volume: 63, Issue:10

    Topics: Delirium; Haloperidol; Humans; Intensive Care Units; Pragmatic Clinical Trials as Topic

2019
Morphine is a reasonable alternative to haloperidol in the treatment of postoperative hyperactive-type delirium after cardiac surgery.
    Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:5

    Topics: Aged; Antipsychotic Agents; Cardiac Surgical Procedures; Delirium; Female; Haloperidol; Humans; Male

2013
Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial.
    Drug design, development and therapy, 2013, Volume: 7

    Topics: Adult; Aged; Antipsychotic Agents; Delirium; Dibenzothiazepines; Double-Blind Method; Female; Halope

2013
Prevention of ICU delirium and delirium-related outcome with haloperidol: a study protocol for a multicenter randomized controlled trial.
    Trials, 2013, Nov-21, Volume: 14

    Topics: Data Collection; Delirium; Double-Blind Method; Ethics, Medical; Haloperidol; Humans; Intensive Care

2013
Effects of a screening and treatment protocol with haloperidol on post-cardiotomy delirium: a prospective cohort study.
    Interactive cardiovascular and thoracic surgery, 2014, Volume: 18, Issue:4

    Topics: Adult; Aged; Antipsychotic Agents; Cardiac Surgical Procedures; Checklist; Chi-Square Distribution;

2014
Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial.
    The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:7

    Topics: Aged; Coma; Critical Care; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; Fe

2013
Haloperidol prophylaxis does not prevent postoperative delirium in elderly patients: a randomized, open-label prospective trial.
    Surgery today, 2014, Volume: 44, Issue:12

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Digestive System Surgical Procedures; Elect

2014
A standardized, bundled approach to providing geriatric-focused acute care.
    Journal of the American Geriatrics Society, 2014, Volume: 62, Issue:5

    Topics: Academic Medical Centers; Administration, Oral; Aged; Aged, 80 and over; Decision Support Techniques

2014
Efficacy and safety of haloperidol prophylaxis for delirium prevention in older medical and surgical at-risk patients acutely admitted to hospital through the emergency department: study protocol of a multicenter, randomised, double-blind, placebo-control
    BMC geriatrics, 2014, Aug-28, Volume: 14

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Delirium; Double-Blind Method

2014
In-Hospital Haloperidol Use and Perioperative Changes in QTc-Duration.
    The journal of nutrition, health & aging, 2015, Volume: 19, Issue:5

    Topics: Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Delirium; Electrocardiography; Female; Halo

2015
Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study.
    Critical care medicine, 2016, Volume: 44, Issue:3

    Topics: Administration, Intravenous; Adult; Aged; Antipsychotic Agents; Coma; Critical Illness; Delirium; Do

2016
Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial.
    Critical care medicine, 2016, Volume: 44, Issue:7

    Topics: Aged; Antipsychotic Agents; Cost-Benefit Analysis; Delirium; Dexmedetomidine; Drug Costs; Drug Resis

2016
The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo-controlled trial.
    Intensive care medicine, 2016, Volume: 42, Issue:11

    Topics: Adult; Aged; Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Double-Blind Method;

2016
Haloperidol prophylaxis for preventing aggravation of postoperative delirium in elderly patients: a randomized, open-label prospective trial.
    Surgery today, 2017, Volume: 47, Issue:7

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Elective Surgical Procedures; Female; Halop

2017
Translating Delirium Prevention Strategies for Elderly Adults with Hip Fracture into Routine Clinical Care: A Pragmatic Clinical Trial.
    Journal of the American Geriatrics Society, 2017, Volume: 65, Issue:3

    Topics: Aged; Aged, 80 and over; Analgesics; Anti-Dyskinesia Agents; Dehydration; Delirium; Female; Haloperi

2017
Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial.
    JAMA internal medicine, 2017, 01-01, Volume: 177, Issue:1

    Topics: Administration, Oral; Aged; Antipsychotic Agents; Australia; Delirium; Double-Blind Method; Female;

2017
Long-term cognitive outcome of delirium in elderly hip surgery patients. A prospective matched controlled study over two and a half years.
    Dementia and geriatric cognitive disorders, 2008, Volume: 26, Issue:1

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Arthroplasty, Replacement, Hip; Case-Control Studies;

2008
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.
    Critical care (London, England), 2009, Volume: 13, Issue:3

    Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse

2009
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.
    Critical care (London, England), 2009, Volume: 13, Issue:3

    Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse

2009
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.
    Critical care (London, England), 2009, Volume: 13, Issue:3

    Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse

2009
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.
    Critical care (London, England), 2009, Volume: 13, Issue:3

    Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse

2009
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Double-Blind Method; Drug Therapy

2010
Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Adult; Aged; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; Humans; Inten

2010
Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial.
    Lancet (London, England), 2010, Nov-27, Volume: 376, Issue:9755

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cholinesterase Inhibitors; Critical Care; Critical Il

2010
Improving delirium care in the intensive care unit: the design of a pragmatic study.
    Trials, 2011, Jun-06, Volume: 12

    Topics: Aged; Aged, 80 and over; Artificial Intelligence; Benzodiazepines; Cholinergic Antagonists; Critical

2011
Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium.
    Journal of psychosomatic research, 2011, Volume: 71, Issue:4

    Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Delirium; Drug Administration Schedule; Female;

2011
Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.
    Critical care (London, England), 2011, Volume: 15, Issue:5

    Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Dibenzothiazepines; Double-Blind Method; Ha

2011
Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.
    Critical care (London, England), 2011, Volume: 15, Issue:5

    Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Dibenzothiazepines; Double-Blind Method; Ha

2011
Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.
    Critical care (London, England), 2011, Volume: 15, Issue:5

    Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Dibenzothiazepines; Double-Blind Method; Ha

2011
Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.
    Critical care (London, England), 2011, Volume: 15, Issue:5

    Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Dibenzothiazepines; Double-Blind Method; Ha

2011
Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: a randomized controlled trial*.
    Critical care medicine, 2012, Volume: 40, Issue:3

    Topics: Aged; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; Humans; Incidence; M

2012
Ondasetron versus haloperidol for the treatment of postcardiotomy delirium: a prospective, randomized, double-blinded study.
    Journal of cardiothoracic surgery, 2012, Mar-21, Volume: 7

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Cardiac Surgical Procedures; Delirium; Double-Blind M

2012
A reorientation strategy for reducing delirium in the critically ill. Results of an interventional study.
    Minerva anestesiologica, 2012, Volume: 78, Issue:9

    Topics: Acoustic Stimulation; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Critical Care;

2012
Haloperidol prophylaxis in critically ill patients with a high risk for delirium.
    Critical care (London, England), 2013, Jan-17, Volume: 17, Issue:1

    Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Double-Blind Method; Female; Haloperidol; Hu

2013
Olanzapine vs haloperidol: treating delirium in a critical care setting.
    Intensive care medicine, 2004, Volume: 30, Issue:3

    Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; De

2004
Antipsychotics and dopamine transporter gene polymorphisms in delirium patients.
    Psychiatry and clinical neurosciences, 2005, Volume: 59, Issue:2

    Topics: Adult; Antipsychotic Agents; Delirium; Dopamine Plasma Membrane Transport Proteins; Female; Haloperi

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Haloperidol; H

2005
Early symptoms in the prodromal phase of delirium: a prospective cohort study in elderly patients undergoing hip surgery.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2007, Volume: 15, Issue:2

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; APACHE; Cohort Studies; Delirium; Double-Blind Method

2007
[Effects of mianserin hydrochloride on delirium: comparison with the effects of oxypertine and haloperidol].
    Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 1994, Volume: 14, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; M

1994
A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients.
    The American journal of psychiatry, 1996, Volume: 153, Issue:2

    Topics: Adult; AIDS Dementia Complex; Basal Ganglia Diseases; Chlorpromazine; Delirium; Double-Blind Method;

1996
Usage of haloperidol for delirium in cancer patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1996, Volume: 4, Issue:5

    Topics: Aged; Delirium; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guidelines a

1996
A psychophysiological study of the development of delirium in coronary care units.
    Biological psychiatry, 1997, Jun-15, Volume: 41, Issue:12

    Topics: Anti-Anxiety Agents; Antipsychotic Agents; Coronary Care Units; Coronary Disease; Delirium; Diazepam

1997
Does plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on delirium.
    International clinical psychopharmacology, 1997, Volume: 12, Issue:3

    Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Delirium; Female; Haloperidol;

1997

Other Studies

194 other studies available for haloperidol and Delirium

ArticleYear
Comment on:"Ketamine vs haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial".
    Journal of clinical anesthesia, 2022, Volume: 77

    Topics: Cognitive Dysfunction; Delirium; Double-Blind Method; Haloperidol; Humans; Ketamine

2022
Concerns over haloperidol for treating delirium in older people.
    Drug and therapeutics bulletin, 2022, Volume: 60, Issue:2

    Topics: Aged; Antipsychotic Agents; Delirium; Haloperidol; Humans

2022
A retrospective comparison of haloperidol and hydroxyzine combination therapy with haloperidol alone in the treatment of overactive delirium.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022, Volume: 30, Issue:6

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Hydroxyzine; Hypnotics and Sedatives; Intensive

2022
Concerns With Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults.
    Critical care medicine, 2022, 03-01, Volume: 50, Issue:3

    Topics: Adult; Critical Illness; Delirium; Haloperidol; Humans; Intensive Care Units

2022
Agents intervening against delirium in the intensive care unit trial-Protocol for a secondary Bayesian analysis.
    Acta anaesthesiologica Scandinavica, 2022, Volume: 66, Issue:7

    Topics: Adult; Antipsychotic Agents; Bayes Theorem; Delirium; Haloperidol; Humans; Intensive Care Units

2022
Current practice of pharmacological treatment for hyperactive delirium in terminally ill cancer patients: results of a nationwide survey of Japanese palliative care physicians and liaison psychiatrists.
    Japanese journal of clinical oncology, 2022, 08-05, Volume: 52, Issue:8

    Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Japan; Neoplasms; Palliative C

2022
Demographic and clinical characteristics of patients with delirium: analysis of a nationwide Japanese medical database.
    BMJ open, 2022, 09-14, Volume: 12, Issue:9

    Topics: Aged; Antipsychotic Agents; Cross-Sectional Studies; Delirium; Demography; Female; Haloperidol; Huma

2022
Haloperidol for Treatment of ICU Delirium - Progress or Setback?
    The New England journal of medicine, 2022, 12-29, Volume: 387, Issue:26

    Topics: Antipsychotic Agents; Critical Care; Delirium; Haloperidol; Humans; Intensive Care Units

2022
Haloperidol-induced myoclonus in a patient with delirium.
    Geriatrics & gerontology international, 2023, Volume: 23, Issue:3

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Myoclonus

2023
Efficacy of blonanserin transdermal patch on terminal delirium in patients with respiratory diseases.
    Respiratory investigation, 2023, Volume: 61, Issue:2

    Topics: Antipsychotic Agents; Delirium; Dyspnea; Haloperidol; Humans; Retrospective Studies; Transdermal Pat

2023
Antipsychotic Medication Use Among Older Adults Following Infection-Related Hospitalization.
    JAMA network open, 2023, 02-01, Volume: 6, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Delirium; Dementia; Female; Ha

2023
In adults with delirium in the ICU, haloperidol did not increase number of days alive out of the hospital at 90 d.
    Annals of internal medicine, 2023, Volume: 176, Issue:3

    Topics: Adult; Antipsychotic Agents; Delirium; Haloperidol; Hospitals; Humans; Intensive Care Units

2023
[Haloperidol is not the first choice for every case of delirium].
    Revue medicale suisse, 2023, May-10, Volume: 19, Issue:826

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Medicine

2023
Delirium in Older Persons: Prevention, Evaluation, and Management.
    American family physician, 2023, Volume: 108, Issue:3

    Topics: Aged; Cognition; Delirium; Drug-Related Side Effects and Adverse Reactions; Haloperidol; Humans; Inp

2023
[Additive therapies : Intensive care studies from 2018-2019].
    Der Anaesthesist, 2020, Volume: 69, Issue:1

    Topics: Critical Care; Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles

2020
Critical Care Prophylaxis. Sometimes Less Is More.
    American journal of respiratory and critical care medicine, 2019, 12-15, Volume: 200, Issue:12

    Topics: Adult; Critical Care; Critical Illness; Delirium; Haloperidol; Humans

2019
Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium.
    Journal of critical care, 2020, Volume: 57

    Topics: Adult; Aged; Antipsychotic Agents; Critical Illness; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A

2020
An unwanted reaction by the use of Haloperidol in hyperkinetic delirium.
    Aging clinical and experimental research, 2021, Volume: 33, Issue:5

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans

2021
Anabolic steroids-induced delirium: A case report.
    Medicine, 2020, Aug-14, Volume: 99, Issue:33

    Topics: Adult; Aggression; Antipsychotic Agents; Delirium; Haloperidol; Humans; Male; Quetiapine Fumarate; T

2020
Pharmacologic Treatment for Hypoactive Delirium in Adult Patients: A Brief Report of the Literature.
    Journal of the American Medical Directors Association, 2021, Volume: 22, Issue:6

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cohort Studies; Delirium; Haloperidol; Humans

2021
Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study.
    Intensive care medicine, 2021, Volume: 47, Issue:3

    Topics: Clonidine; Cohort Studies; Critical Illness; Delirium; Haloperidol; Humans; Intensive Care Units; Pr

2021
Haloperidol and Quetiapine for the Treatment of ICU-Associated Delirium in a Tertiary Pediatric ICU: A Propensity Score-Matched Cohort Study.
    Paediatric drugs, 2021, Volume: 23, Issue:2

    Topics: Antipsychotic Agents; Child; Cohort Studies; Delirium; Female; Haloperidol; Humans; Intensive Care U

2021
Delirium in the NICU: Risk or Reality?
    Neonatal network : NN, 2021, Mar-01, Volume: 40, Issue:2

    Topics: Adult; Antipsychotic Agents; Child; Delirium; Haloperidol; Humans; Infant, Newborn; Intensive Care U

2021
Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults.
    Critical care medicine, 2021, 08-01, Volume: 49, Issue:8

    Topics: Adult; Aged; Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Female; Haloperidol; H

2021
Extrapyramidal Symptoms Induced by Treatment for Delirium: A Case Report.
    Critical care nurse, 2021, Jun-01, Volume: 41, Issue:3

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Intensive Care Units; Male; Middle Aged; Olanza

2021
Effect of Low Dose Haloperidol and Quetiapine on QTc Interval in Hospitalized Elderly Patients With Delirium.
    Journal of pharmacy practice, 2021, Volume: 34, Issue:5

    Topics: Aged; Antipsychotic Agents; Delirium; Electrocardiography; Haloperidol; Humans; Quetiapine Fumarate

2021
Haloperidol in the ICU: A Hammer Looking for a Nail?
    Critical care medicine, 2021, 08-01, Volume: 49, Issue:8

    Topics: Delirium; Haloperidol; Humans; Intensive Care Units

2021
Pseudodelirium: Psychiatric Conditions to Consider on the Differential for Delirium.
    The Journal of neuropsychiatry and clinical neurosciences, 2021,Fall, Volume: 33, Issue:4

    Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Catatonia; Delirium; Diagnosis, Differential;

2021
In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo.
    Annals of internal medicine, 2017, 03-21, Volume: 166, Issue:6

    Topics: Antipsychotic Agents; Delirium; Double-Blind Method; Haloperidol; Humans; Palliative Care; Risperido

2017
Delirium: Use Antipsychotics When Appropriate and Appropriately.
    Journal of palliative medicine, 2017, Volume: 20, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; M

2017
A National Multicenter Survey on Management of Pain, Agitation, and Delirium in Intensive Care Units in China.
    Chinese medical journal, 2017, May-20, Volume: 130, Issue:10

    Topics: Delirium; Dexmedetomidine; Fentanyl; Haloperidol; Humans; Hypnotics and Sedatives; Intensive Care Un

2017
Neuroleptics for Delirium: More Research Is Needed.
    JAMA internal medicine, 2017, 07-01, Volume: 177, Issue:7

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone

2017
Neuroleptics for Delirium: More Research Is Needed.
    JAMA internal medicine, 2017, 07-01, Volume: 177, Issue:7

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone

2017
Neuroleptics for Delirium: More Research Is Needed.
    JAMA internal medicine, 2017, 07-01, Volume: 177, Issue:7

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone

2017
Neuroleptics for Delirium: More Research Is Needed.
    JAMA internal medicine, 2017, 07-01, Volume: 177, Issue:7

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone

2017
Neuroleptics for Delirium: More Research is Needed-Reply.
    JAMA internal medicine, 2017, 07-01, Volume: 177, Issue:7

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone

2017
Population pharmacokinetics of haloperidol in terminally ill adult patients.
    European journal of clinical pharmacology, 2017, Volume: 73, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Computer Simulation; Delirium; Female; Haloper

2017
Pipamperone and delirium: a preliminary evaluation of its effectiveness in the management of delirium and its subtypes.
    Swiss medical weekly, 2017, Volume: 147

    Topics: Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Butyrophenones; Delirium; Female; Halope

2017
Hypertensive bipolar: chronic lithium toxicity in patients taking ACE inhibitor.
    BMJ case reports, 2017, Aug-28, Volume: 2017

    Topics: Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Bipolar Disorder; Delirium; Diagnosis

2017
Two unusual cases of protracted inter-ictal delirium following electroconvulsive therapy.
    Asian journal of psychiatry, 2017, Volume: 29

    Topics: Adult; Antipsychotic Agents; Delirium; Electroconvulsive Therapy; Haloperidol; Humans; Lorazepam; Ma

2017
Haloperidol for delirium prevention: uncertainty remains.
    Age and ageing, 2018, 01-01, Volume: 47, Issue:1

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Uncertainty

2018
Hydroxyethyl starch is associated with early postoperative delirium in patients undergoing esophagectomy.
    The Journal of thoracic and cardiovascular surgery, 2018, Volume: 155, Issue:3

    Topics: Age Factors; Aged; Antipsychotic Agents; Blood Transfusion; Cerebrovascular Disorders; Crystalloid S

2018
Monitoring Haloperidol Plasma Concentration and Associated Adverse Events in Critically Ill Children With Delirium: First Results of a Clinical Protocol Aimed to Monitor Efficacy and Safety.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2018, Volume: 19, Issue:2

    Topics: Adolescent; Antipsychotic Agents; Child; Child, Preschool; Clinical Protocols; Critical Illness; Del

2018
'Palliative sedation'? A retrospective cohort study on the use and labelling of continuously administered sedatives on a palliative care unit.
    Palliative medicine, 2018, Volume: 32, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Conscious Sedatio

2018
Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study.
    Intensive care medicine, 2018, Volume: 44, Issue:7

    Topics: Adolescent; Adult; Antipsychotic Agents; Brazil; Canada; Critical Care; Delirium; Europe; Haloperido

2018
Haloperidol and delirium in the ICU: the finger pointing to the moon.
    Intensive care medicine, 2018, Volume: 44, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Critical Care; Delirium; Female; Haloperidol;

2018
The influence of oxygen delivery during cardiopulmonary bypass on the incidence of delirium in CABG patients; a retrospective study.
    Perfusion, 2018, Volume: 33, Issue:8

    Topics: Aged; Cardiopulmonary Bypass; Coronary Artery Bypass; Delirium; Female; Haloperidol; Humans; Inciden

2018
Prophylactic Haloperidol for Critically Ill Adults.
    JAMA, 2018, 07-17, Volume: 320, Issue:3

    Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans

2018
Prophylactic Haloperidol for Critically Ill Adults.
    JAMA, 2018, 07-17, Volume: 320, Issue:3

    Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans

2018
Prophylactic Haloperidol for Critically Ill Adults-Reply.
    JAMA, 2018, 07-17, Volume: 320, Issue:3

    Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans

2018
Haloperidol serum concentrations in critically ill patients included in the REDUCE study.
    Intensive care medicine, 2018, Volume: 44, Issue:10

    Topics: Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans

2018
Dopamine Antagonists in ICU Delirium.
    The New England journal of medicine, 2018, 12-27, Volume: 379, Issue:26

    Topics: Critical Illness; Delirium; Dopamine Antagonists; Haloperidol; Humans; Intensive Care Units; Piperaz

2018
[A Multicenter Questionnaire Survey of Postoperative Delirium -National Hospital Organization, Surgery and Anesthesia Network Group-].
    Masui. The Japanese journal of anesthesiology, 2016, Volume: 65, Issue:7

    Topics: Aged; Anesthesia; Delirium; Female; Haloperidol; Humans; Incidence; Postoperative Complications; Pos

2016
Discussions about palliative sedation in hospice: Frequency, timing and factors associated with patient involvement.
    European journal of cancer care, 2019, Volume: 28, Issue:3

    Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antipsychotic Agents; Decision Making, Shared; Delirium

2019
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
    The New England journal of medicine, 2019, 05-02, Volume: 380, Issue:18

    Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles

2019
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
    The New England journal of medicine, 2019, 05-02, Volume: 380, Issue:18

    Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles

2019
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
    The New England journal of medicine, 2019, 05-02, Volume: 380, Issue:18

    Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles

2019
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. Reply.
    The New England journal of medicine, 2019, 05-02, Volume: 380, Issue:18

    Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles

2019
Acute and long-term effects of haloperidol on surgery-induced neuroinflammation and cognitive deficits in aged rats.
    Journal of anesthesia, 2019, Volume: 33, Issue:3

    Topics: Animals; Cognition; Cognitive Dysfunction; Cytokines; Delirium; Fear; Haloperidol; Hippocampus; Male

2019
Harms From Haloperidol for Symptom Management in Palliative Care-a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies.
    Journal of pain and symptom management, 2019, Volume: 58, Issue:3

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; Middle A

2019
Impact of an educational workshop upon psychiatrists' attitudes towards delirium care.
    Irish journal of psychological medicine, 2019, Volume: 36, Issue:2

    Topics: Aged; Attitude of Health Personnel; Delirium; Dementia; Diagnosis, Differential; Haloperidol; Humans

2019
Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation.
    Pharmacotherapy, 2013, Volume: 33, Issue:6

    Topics: Antipsychotic Agents; Critical Illness; Decision Making; Delirium; Haloperidol; Health Care Surveys;

2013
Haloperidol overdosing in the treatment of agitated hospitalized older people with delirium: a retrospective chart review from a community teaching hospital.
    Drugs & aging, 2013, Volume: 30, Issue:8

    Topics: Aged; Aged, 80 and over; Aging; Anti-Anxiety Agents; Delirium; Dopamine Antagonists; Dose-Response R

2013
[Delirium prevention and treatment in elderly hip fracture].
    Medicina clinica, 2014, Apr-22, Volume: 142, Issue:8

    Topics: Aged; Anesthesia, Epidural; Anesthesia, General; Benzodiazepines; Cognition Disorders; Combined Moda

2014
Neuroleptic malignant syndrome associated with haloperidol use in critical care setting: should haloperidol still be considered the drug of choice for the management of delirium in the critical care setting?
    BMJ case reports, 2013, Jul-12, Volume: 2013

    Topics: Antipsychotic Agents; Critical Care; Delirium; Haloperidol; Humans; Male; Middle Aged; Neuroleptic M

2013
What's new on the post-ICU burden for patients and relatives?
    Intensive care medicine, 2013, Volume: 39, Issue:10

    Topics: Antipsychotic Agents; Cognition Disorders; Critical Illness; Delirium; Family; Haloperidol; Humans;

2013
Patterns of opiate, benzodiazepine, and antipsychotic drug dosing in older patients in a medical intensive care unit.
    American journal of critical care : an official publication, American Association of Critical-Care Nurses, 2013, Volume: 22, Issue:5

    Topics: Aged; Analgesics, Opioid; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Cohort Studies; Conn

2013
Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.
    BMC psychiatry, 2013, Sep-30, Volume: 13

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Delirium; Dibenzothiazepines; Female; Haloperidol; Huma

2013
High-dose neuroleptics and neuroleptic rotation for agitated delirium near the end of life.
    The American journal of hospice & palliative care, 2014, Volume: 31, Issue:8

    Topics: Adult; Antipsychotic Agents; Delirium; Drug Substitution; Female; Gastrointestinal Neoplasms; Halope

2014
Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium.
    Journal of palliative medicine, 2013, Volume: 16, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Comorbidity; Delirium; Female; Haloperidol; Ho

2013
Delirium in acute promyelocytic leukemia patients: two case reports.
    BMC research notes, 2013, Nov-16, Volume: 6

    Topics: Antineoplastic Agents; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Idarubicin; Leuk

2013
Can critical-care delirium be treated pharmacologically?
    The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:7

    Topics: Coma; Delirium; Dopamine Antagonists; Female; Haloperidol; Humans; Male

2013
Hope for haloperidol in delirium.
    The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:8

    Topics: Coma; Delirium; Dopamine Antagonists; Female; Haloperidol; Humans; Male

2013
Prophylactic haloperidol: too early to lose hope.
    The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:8

    Topics: Coma; Delirium; Dopamine Antagonists; Female; Haloperidol; Humans; Male

2013
Prophylactic haloperidol: too early to lose hope - author's reply.
    The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:8

    Topics: Coma; Delirium; Dopamine Antagonists; Female; Haloperidol; Humans; Male

2013
Correlation of haloperidol concentration in blood and cerebrospinal fluid: a pharmacokinetic study.
    Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:4

    Topics: Aged; Aged, 80 and over; Biomarkers; Delirium; Elective Surgical Procedures; Female; Haloperidol; Hu

2014
Adverse events of haloperidol for the treatment of delirium in critically ill children.
    Intensive care medicine, 2014, Volume: 40, Issue:10

    Topics: Adolescent; Antipsychotic Agents; Child; Child, Preschool; Critical Illness; Delirium; Female; Halop

2014
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.
    Palliative & supportive care, 2015, Volume: 13, Issue:4

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Dementia; Female; Haloperidol;

2015
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.
    The American journal of hospice & palliative care, 2016, Volume: 33, Issue:5

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Delirium; F

2016
[Perioperative management of off-pump CABG for a 93-year-old man].
    Masui. The Japanese journal of anesthesiology, 2014, Volume: 63, Issue:10

    Topics: Aged, 80 and over; Anesthesia; Brain; Cerebrovascular Circulation; Consciousness Monitors; Coronary

2014
Association of cumulative dose of haloperidol with next-day delirium in older medical ICU patients.
    Critical care medicine, 2015, Volume: 43, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; APACHE; Cognition Disorders; Delirium; Dose-Response Relations

2015
Does haloperidol cause delirium?
    Critical care medicine, 2015, Volume: 43, Issue:5

    Topics: Delirium; Female; Haloperidol; Humans; Intensive Care Units; Male

2015
Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk for delirium: a systematic review of quantitative evidence protocol.
    JBI database of systematic reviews and implementation reports, 2015, Aug-14, Volume: 13, Issue:7

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans; Inte

2015
"Delirium" Is No Delirium: On Type Specifying and Drug Response.
    Critical care medicine, 2015, Volume: 43, Issue:12

    Topics: Delirium; Female; Haloperidol; Humans; Intensive Care Units; Male

2015
The authors reply.
    Critical care medicine, 2015, Volume: 43, Issue:12

    Topics: Delirium; Female; Haloperidol; Humans; Intensive Care Units; Male

2015
Early Identification of Subsyndromal Delirium in the Critically Ill: Don't Let the Delirium Rise!
    Critical care medicine, 2016, Volume: 44, Issue:3

    Topics: Antipsychotic Agents; Critical Illness; Delirium; Female; Haloperidol; Humans; Male

2016
What to Do When Haloperidol Fails to Treat Agitated Delirium: Is Dexmedetomidine the Next Step?
    Critical care medicine, 2016, Volume: 44, Issue:7

    Topics: Delirium; Dexmedetomidine; Haloperidol; Humans; Hypnotics and Sedatives

2016
Predictors of Mortality for Delirium in Palliative Care.
    Journal of palliative medicine, 2016, Volume: 19, Issue:11

    Topics: Comorbidity; Delirium; Haloperidol; Humans; Palliative Care; Prognosis

2016
Use of Dexmedetomidine in Liver Transplant Recipients With Postoperative Agitated Delirium.
    Transplantation proceedings, 2016, Volume: 48, Issue:4

    Topics: Adult; Aged; Antipsychotic Agents; Delirium; Dexmedetomidine; Female; Haloperidol; Humans; Hypnotics

2016
Delirium associated with olanzapine use in the elderly.
    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2017, Volume: 17, Issue:2

    Topics: Aged; Antipsychotic Agents; Aortic Aneurysm; Benzodiazepines; Delirium; Haloperidol; Humans; Male; O

2017
Look again at psychedelic drugs.
    Nursing standard (Royal College of Nursing (Great Britain) : 1987), 2016, Jun-29, Volume: 30, Issue:44

    Topics: Anxiety; Delirium; Depression; Diazepam; Hallucinogens; Haloperidol; Humans; Lorazepam; Midazolam; P

2016
Comparing Dexmedetomidine With Haloperidol for the Treatment of Hyperactive Delirium in Nonintubated ICU Patients.
    Critical care medicine, 2016, Volume: 44, Issue:12

    Topics: Antipsychotic Agents; Delirium; Dexmedetomidine; Haloperidol; Humans; Hypnotics and Sedatives; Inten

2016
Management of Multifactorial Infant Delirium with Intravenous Haloperidol in the Setting of Over Sedation and Poor Enteral Absorption.
    Journal of child and adolescent psychopharmacology, 2017, Volume: 27, Issue:3

    Topics: Administration, Intravenous; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Hypnotics

2017
Postoperative delirium.
    The American journal of psychiatry, 2008, Volume: 165, Issue:7

    Topics: Antipsychotic Agents; Delirium; Diagnosis, Differential; Electrocardiography; Electroencephalography

2008
Haloperidol and delirium: management or treatment?
    Critical care medicine, 2009, Volume: 37, Issue:1

    Topics: Delirium; Dopamine Antagonists; Haloperidol; Humans

2009
Delirium due to a drug-drug interaction of lithium and an NSAID.
    The journal of nutrition, health & aging, 2009, Volume: 13, Issue:3

    Topics: Accidental Falls; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antidepressi

2009
Tackling agitated delirium--the tip of the iceberg.
    Critical care (London, England), 2009, Volume: 13, Issue:3

    Topics: Antipsychotic Agents; Delirium; Dexmedetomidine; Haloperidol; Humans; Hypnotics and Sedatives; Psych

2009
Implementation of a delirium assessment tool in the ICU can influence haloperidol use.
    Critical care (London, England), 2009, Volume: 13, Issue:4

    Topics: Adult; Aged; Antipsychotic Agents; Delirium; Female; Guideline Adherence; Haloperidol; Humans; Inser

2009
Delirium in children and adolescents.
    International journal of psychiatry in medicine, 2009, Volume: 39, Issue:2

    Topics: Adolescent; Antipsychotic Agents; Child; Child, Preschool; Delirium; Dose-Response Relationship, Dru

2009
Why all the confusion about confusion?
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Critical Care; Delirium; Dibenzothiazepines; Drug Therapy, Combination; Halope

2010
Free your MIND and the rest will follow: decoding delirium in the intensive care unit.
    Critical care medicine, 2010, Volume: 38, Issue:2

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Intensive Care Units; Piperazines; Postoperativ

2010
A national survey of the management of delirium in UK intensive care units.
    QJM : monthly journal of the Association of Physicians, 2010, Volume: 103, Issue:4

    Topics: Antipsychotic Agents; Delirium; Delivery of Health Care; Haloperidol; Humans; Intensive Care Units;

2010
Neuroleptic dose in the management of delirium in patients with advanced cancer.
    Journal of pain and symptom management, 2010, Volume: 39, Issue:2

    Topics: Adult; Affective Symptoms; Aged; Aged, 80 and over; Algorithms; Antipsychotic Agents; Delirium; Dose

2010
Factors associated with persistent delirium after intensive care unit admission in an older medical patient population.
    Journal of critical care, 2010, Volume: 25, Issue:3

    Topics: Age Factors; Aged; Analgesics, Opioid; Analysis of Variance; Critical Care; Delirium; Dementia; Halo

2010
Study of rivastigmine for delirium in intensive care is stopped after deaths.
    BMJ (Clinical research ed.), 2010, May-28, Volume: 340

    Topics: Antipsychotic Agents; Critical Care; Death, Sudden; Delirium; Double-Blind Method; Drug Therapy, Com

2010
Relief by electroconvulsive therapy for postsurgical delirium in malignant catatonia.
    The journal of ECT, 2010, Volume: 26, Issue:4

    Topics: Antipsychotic Agents; Cardiac Surgical Procedures; Catatonia; Coronary Artery Bypass; Delirium; Elec

2010
Mortality associated with delirium after hip-surgery: a 2-year follow-up study.
    Age and ageing, 2011, Volume: 40, Issue:3

    Topics: Aged; Antipsychotic Agents; Delirium; Female; Follow-Up Studies; Haloperidol; Hip; Hospitalization;

2011
Aripiprazole and haloperidol in the treatment of delirium.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:6

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol;

2011
Aripiprazole and haloperidol in the treatment of delirium.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:6

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol;

2011
Aripiprazole and haloperidol in the treatment of delirium.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:6

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol;

2011
Aripiprazole and haloperidol in the treatment of delirium.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:6

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol;

2011
Aripiprazole and haloperidol in the treatment of delirium.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:6

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol;

2011
Aripiprazole and haloperidol in the treatment of delirium.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:6

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol;

2011
Aripiprazole and haloperidol in the treatment of delirium.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:6

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol;

2011
Aripiprazole and haloperidol in the treatment of delirium.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:6

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol;

2011
Aripiprazole and haloperidol in the treatment of delirium.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:6

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Databases, Factual; Delirium; Female; Haloperidol;

2011
Anesthesia and postoperative delirium in older adults undergoing hip surgery.
    Journal of the American Geriatrics Society, 2011, Volume: 59, Issue:7

    Topics: Aged; Anesthesia, Conduction; Anesthesia, General; Cognition Disorders; Delirium; Female; Haloperido

2011
Neuroleptic prescription pattern for delirium in patients with advanced cancer.
    Journal of palliative care, 2011,Summer, Volume: 27, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; M

2011
Delirium risk screening and haloperidol prophylaxis program in hip fracture patients is a helpful tool in identifying high-risk patients, but does not reduce the incidence of delirium.
    BMC geriatrics, 2011, Aug-11, Volume: 11

    Topics: Aged; Aged, 80 and over; Cohort Studies; Delirium; Female; Haloperidol; Hip Fractures; Humans; Incid

2011
Unusual presentation of a patient with GBL withdrawal: a case report.
    Psychiatria Danubina, 2011, Volume: 23 Suppl 1

    Topics: 4-Butyrolactone; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Chlorpromazine; Delirium; Hal

2011
Current perceptions and practices surrounding the recognition and treatment of delirium in the intensive care unit: a survey of 250 critical care pharmacists from eight states.
    The Annals of pharmacotherapy, 2011, Volume: 45, Issue:10

    Topics: Antipsychotic Agents; Attitude of Health Personnel; Critical Care; Delirium; Drug Monitoring; Halope

2011
Randomised control trials for delirium: current evidence and statistical methods.
    Journal of psychosomatic research, 2012, Volume: 72, Issue:1

    Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Humans; Male; Risperidone

2012
Delirium, sigma-1 receptors, dopamine, and glutamate: how does haloperidol keep the genie in the bottle?*.
    Critical care medicine, 2012, Volume: 40, Issue:3

    Topics: Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; Postoperative Complications

2012
The largest ever trial demonstrating effectiveness of intensive care unit delirium prophylaxis--we must know more!
    Critical care medicine, 2012, Volume: 40, Issue:8

    Topics: Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; Postoperative Complications

2012
Delayed onset and prolonged interictal delirium following electroconvulsive therapy.
    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2012, Volume: 12, Issue:3

    Topics: Cholinesterase Inhibitors; Delirium; Depressive Disorder; Donepezil; Electroconvulsive Therapy; Foll

2012
Unsafe use of intravenous haloperidol: evaluation of recommendation-concordant care in hospitalized elderly adults.
    Journal of the American Geriatrics Society, 2013, Volume: 61, Issue:1

    Topics: Age Factors; Aged; Antipsychotic Agents; Colorado; Death, Sudden, Cardiac; Delirium; Electrocardiogr

2013
Is dopamine administration possibly a risk factor for delirium?
    Critical care medicine, 2002, Volume: 30, Issue:7

    Topics: Delirium; Dopamine; Dopamine Antagonists; Female; Haloperidol; Humans; Injections, Intravenous; Logi

2002
[Management of psychiatric symptoms in cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:7

    Topics: Antidepressive Agents; Delirium; Depression; Disease Management; Dopamine Antagonists; Haloperidol;

2002
Delirium at the end of life.
    Annals of internal medicine, 2002, Aug-20, Volume: 137, Issue:4

    Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Terminal

2002
Haloperidol should be used sparingly.
    Critical care medicine, 2002, Volume: 30, Issue:11

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Practice Guidelines as Topic; United States

2002
[COGENTINE (BTMS) IN THE TREATMENT OF NEUROLEPTIC SYNDROMES].
    L'Encephale, 1964, Volume: 53

    Topics: Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Delirium; Depression; Hallucinations; Halope

1964
Efficacy of risperidone in treating the hyperactive symptoms of delirium.
    International clinical psychopharmacology, 2004, Volume: 19, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Fe

2004
Reply to the comment by Skrobik et al.
    Intensive care medicine, 2004, Volume: 30, Issue:7

    Topics: Antipsychotic Agents; Benzodiazepines; Critical Illness; Delirium; Haloperidol; Humans; Olanzapine;

2004
Pharmacological treatment of delirium in the intensive care unit.
    JAMA, 2004, Jul-14, Volume: 292, Issue:2

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Intensive Care Units

2004
Intravenous ziprasidone for treatment of delirium in the intensive care unit.
    Anesthesiology, 2004, Volume: 101, Issue:3

    Topics: Antipsychotic Agents; Bone Transplantation; Critical Care; Delirium; Haloperidol; Humans; Male; Midd

2004
[Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine].
    Nederlands tijdschrift voor geneeskunde, 2004, Jul-24, Volume: 148, Issue:30

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Delirium; Halo

2004
[Delirium in a 73-year-old man after many years of unwise use of betahistine].
    Nederlands tijdschrift voor geneeskunde, 2004, Nov-20, Volume: 148, Issue:47

    Topics: Aged; Betahistine; Blood-Brain Barrier; Cerebral Infarction; Delirium; Haloperidol; Histamine Agonis

2004
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
    Critical care medicine, 2005, Volume: 33, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne

2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
    Critical care medicine, 2005, Volume: 33, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne

2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
    Critical care medicine, 2005, Volume: 33, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne

2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
    Critical care medicine, 2005, Volume: 33, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne

2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
    Critical care medicine, 2005, Volume: 33, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne

2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
    Critical care medicine, 2005, Volume: 33, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne

2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
    Critical care medicine, 2005, Volume: 33, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne

2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
    Critical care medicine, 2005, Volume: 33, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne

2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
    Critical care medicine, 2005, Volume: 33, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne

2005
Agitation in the critically ill patient: a marker of health or a plea for treatment?
    Critical care medicine, 2005, Volume: 33, Issue:1

    Topics: Antipsychotic Agents; Conscious Sedation; Critical Care; Critical Illness; Delirium; Haloperidol; Ho

2005
Delirium in the older hospitalized patient.
    The Journal of the Oklahoma State Medical Association, 2005, Volume: 98, Issue:3

    Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Confusion; Delirium; Glasgow Coma Scale; Haloperido

2005
Case report: delirium associated with ovarian hyperstimulation syndrome.
    Reproductive biomedicine online, 2005, Volume: 10, Issue:2

    Topics: Adult; Chorionic Gonadotropin; Delirium; Female; Haloperidol; Humans; Infertility; Ovarian Hyperstim

2005
[Lithium use and perioperative management].
    Nederlands tijdschrift voor geneeskunde, 2005, Aug-20, Volume: 149, Issue:34

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Lithium; Male; Middle Aged; Oxazepam; Periopera

2005
Reading and writing: psychoanalytical treatment in a case of paranoia.
    American journal of psychoanalysis, 2005, Volume: 65, Issue:3

    Topics: Adult; Antipsychotic Agents; Art Therapy; Combined Modality Therapy; Delirium; Female; Haloperidol;

2005
[Paranoid delirium of cognition].
    L'Encephale, 2005, Volume: 31 Pt 2

    Topics: Antipsychotic Agents; Child; Cognition Disorders; Delirium; Haloperidol; Humans; Middle Aged; Parano

2005
Perioperative haloperidol usage for delirium management.
    Journal of the American Geriatrics Society, 2006, Volume: 54, Issue:5

    Topics: Aged; Antipsychotic Agents; Delirium; Haloperidol; Humans; Length of Stay; Perioperative Care; Posto

2006
Perioperative haloperidol to prevent postoperative delirium.
    Journal of the American Geriatrics Society, 2006, Volume: 54, Issue:5

    Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Drug Th

2006
[Delirium in critically ill children in a paediatric intensive care unit].
    Nederlands tijdschrift voor geneeskunde, 2006, Jul-15, Volume: 150, Issue:28

    Topics: Antipsychotic Agents; Child, Preschool; Critical Illness; Delirium; Diagnosis, Differential; Female;

2006
Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient.
    Archives of gerontology and geriatrics, 2007, Volume: 44 Suppl 1

    Topics: Acute Disease; Aged, 80 and over; Alzheimer Disease; Amitriptyline; Antipsychotic Agents; Cholinergi

2007
[Psychiatry and sleep disorders--delirium].
    Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2006, Volume: 108, Issue:11

    Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; I

2006
Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients.
    Psychiatry and clinical neurosciences, 2007, Volume: 61, Issue:3

    Topics: Administration, Oral; Aged; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Injections,

2007
Clinical inquiries. What steps can reduce morbidity and mortality caused by hip fractures?
    The Journal of family practice, 2007, Volume: 56, Issue:11

    Topics: Aged; Analgesics; Antibiotic Prophylaxis; Antipsychotic Agents; Bacterial Infections; Cephalosporins

2007
[Delirium in the old age].
    MMW Fortschritte der Medizin, 2008, Jan-24, Volume: 150, Issue:3-4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Dementia; Diagnosis,

2008
Laryngeal dystonia in a patient with bilateral anterior cerebral artery infarction during treatment of delirium with haloperidol.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Jul-01, Volume: 32, Issue:5

    Topics: Antipsychotic Agents; Delirium; Dystonia; Haloperidol; Humans; Infarction, Anterior Cerebral Artery;

2008
Intravenous haloperidol.
    General hospital psychiatry, 1980, Volume: 2, Issue:2

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Infusions, Parenteral

1980
Case report of a possible interaction between neuroleptics and carbamazepine.
    The American journal of psychiatry, 1984, Volume: 141, Issue:9

    Topics: Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Delirium; Drug Interactions; Female; Haloperi

1984
Issues in reimbursement for consultation-liaison psychiatry.
    Hospital & community psychiatry, 1984, Volume: 35, Issue:12

    Topics: Coronary Artery Bypass; Delirium; Haloperidol; Humans; Insurance, Health, Reimbursement; Male; Middl

1984
Complex management of postcardiotomy delirium.
    Southern medical journal, 1983, Volume: 76, Issue:1

    Topics: Cardiac Surgical Procedures; Delirium; Drug Therapy, Combination; Female; Haloperidol; Humans; Male;

1983
Delirium and stereotypy from anticholinergic antiparkinson drugs.
    Progress in neuro-psychopharmacology & biological psychiatry, 1982, Volume: 6, Issue:1

    Topics: Adult; Aged; Benztropine; Delirium; Diazepam; Drug Therapy, Combination; Dyskinesia, Drug-Induced; E

1982
Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill.
    Journal of clinical psychopharmacology, 1993, Volume: 13, Issue:2

    Topics: Adult; Alcoholism; Cardiomyopathy, Dilated; Delirium; Dose-Response Relationship, Drug; Electrocardi

1993
Continuous infusion of haloperidol.
    The American journal of psychiatry, 1993, Volume: 150, Issue:4

    Topics: Aged; Critical Care; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; Male; Middle Age

1993
Delirium associated with a combination of sertraline, haloperidol, and benztropine.
    The American journal of psychiatry, 1996, Volume: 153, Issue:7

    Topics: 1-Naphthylamine; Adult; Benztropine; Delirium; Depressive Disorder; Drug Interactions; Drug Therapy,

1996
A retrospective study of the psychiatric management and outcome of delirium in the cancer patient.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1996, Volume: 4, Issue:5

    Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperido

1996
Steroid psychosis after orthognathic surgery: a case report.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1997, Volume: 55, Issue:3

    Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Delirium; Delusions; Dexamethasone; Haloperid

1997
Steroid psychosis after orthognathic surgery: a case report.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1997, Volume: 55, Issue:3

    Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Delirium; Delusions; Dexamethasone; Haloperid

1997
Steroid psychosis after orthognathic surgery: a case report.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1997, Volume: 55, Issue:3

    Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Delirium; Delusions; Dexamethasone; Haloperid

1997
Steroid psychosis after orthognathic surgery: a case report.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1997, Volume: 55, Issue:3

    Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Delirium; Delusions; Dexamethasone; Haloperid

1997
Treating delirium among elderly patients.
    Psychiatric services (Washington, D.C.), 1997, Volume: 48, Issue:1

    Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Delirium; Diagnosis, Differential;

1997
Extrapyramidal symptoms from intravenous haloperidol in the treatment of delirium.
    The American journal of psychiatry, 1997, Volume: 154, Issue:10

    Topics: Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Injections, Intravenous; Middle Aged; P

1997
Anticholinergic delirium possibly associated with protriptyline and fluoxetine.
    The Annals of pharmacotherapy, 1997, Volume: 31, Issue:10

    Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cholinergic Antagonists;

1997
[Treatment with haloperidol of clozapine-triggered drug-induced delirium].
    Psychiatrische Praxis, 1997, Volume: 24, Issue:6

    Topics: Antipsychotic Agents; Clozapine; Delirium; Haloperidol; Humans; Male; Middle Aged; Schizophrenia, Pa

1997
The duration of delirium in medical and postoperative patients referred for psychiatric consultation.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1997, Volume: 9, Issue:4

    Topics: Aged; Delirium; Dementia; Female; Haloperidol; Humans; Length of Stay; Male; Middle Aged; Patient Ca

1997
Neuroleptic malignant syndrome in a burn patient.
    Burns : journal of the International Society for Burn Injuries, 1998, Volume: 24, Issue:6

    Topics: Accidents, Occupational; Adult; Antipsychotic Agents; Bromocriptine; Burns; Dantrolene; Debridement;

1998
Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction.
    Pharmacopsychiatry, 1998, Volume: 31, Issue:5

    Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Delirium; Dyskinesia, Drug-Induced; Female

1998
Clinical significance of delirium subtypes in older people.
    Age and ageing, 1999, Volume: 28, Issue:2

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Haloperidol; Humans; Prospective Studies; P

1999
Sedation in the intensive care unit.
    International anesthesiology clinics, 1999,Fall, Volume: 37, Issue:4

    Topics: Analgesics, Opioid; Anesthetics, General; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Benzod

1999
Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2000, Volume: 47, Issue:3

    Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Coronary Artery Bypass; Critical Care; Delirium; Elect

2000
Treatment of patients with delirium.
    The American journal of psychiatry, 2000, Volume: 157, Issue:10

    Topics: Delirium; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Haloperidol; Humans; Pract

2000
A survey on the drug therapy for delirium.
    Psychiatry and clinical neurosciences, 2001, Volume: 55, Issue:4

    Topics: Antipsychotic Agents; Delirium; Drug Approval; Drug Utilization Review; Haloperidol; Humans; Japan;

2001
Optimising management of delirium. Patients with delirium should be treated with care.
    BMJ (Clinical research ed.), 2001, Jun-30, Volume: 322, Issue:7302

    Topics: Age Factors; Aged; Antipsychotic Agents; Contraindications; Delirium; Drug Administration Schedule;

2001
Intravenous haloperidol.
    Critical care nurse, 2001, Volume: 21, Issue:3

    Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Infusions, Parenteral; Injections, Intravenous

2001
[Dangerous side effects of lithium therapy].
    Psychiatrie, Neurologie und medizinische Psychologie. Beihefte, 1977, Volume: 22-23

    Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Brain Stem; Delirium; Diabetes Insipidus; D

1977
A question on haloperidol treatment for delirium.
    The American journal of psychiatry, 1978, Volume: 135, Issue:7

    Topics: Delirium; Haloperidol; Humans

1978
Rapid treatment of delirium in critically ill patients.
    The American journal of psychiatry, 1977, Volume: 134, Issue:12

    Topics: Accidents, Traffic; Adult; Burns; Critical Care; Delirium; Drug Administration Schedule; Haloperidol

1977
Letter: Definition of "dementia" after haloperidol.
    The New England journal of medicine, 1976, Aug-19, Volume: 295, Issue:8

    Topics: Delirium; Haloperidol; Humans; Psychoses, Substance-Induced; Terminology as Topic

1976
Using intravenous haloperidol to control delirium.
    Hospital & community psychiatry, 1992, Volume: 43, Issue:3

    Topics: Delirium; Dose-Response Relationship, Drug; Haloperidol; Humans; Infusions, Intravenous

1992
[ICU syndrome].
    Kokyu to junkan. Respiration & circulation, 1991, Volume: 39, Issue:12

    Topics: Aged; Anxiety; Benzodiazepines; Clomipramine; Critical Care; Delirium; Depressive Disorder; Female;

1991
[A psychiatric disorder in an intensive care unit].
    Nederlands tijdschrift voor geneeskunde, 1991, Aug-10, Volume: 135, Issue:32

    Topics: Critical Care; Delirium; Haloperidol; Humans

1991
High-dose intravenous haloperidol for agitated delirium in a cardiac patient on intra-aortic balloon pump.
    Journal of clinical psychopharmacology, 1991, Volume: 11, Issue:2

    Topics: Delirium; Dose-Response Relationship, Drug; Haloperidol; Humans; Infusions, Intravenous; Intra-Aorti

1991
Emergency intravenous sedation of the delirious, medically ill patient.
    The Journal of clinical psychiatry, 1988, Volume: 49 Suppl

    Topics: Critical Care; Delirium; Drug Therapy, Combination; Haloperidol; Humans; Hydromorphone; Infusions, I

1988
Neurotoxicity resulting from a combination of lithium and loxapine.
    The Journal of clinical psychiatry, 1989, Volume: 50, Issue:5

    Topics: Adult; Delirium; Dibenzoxazepines; Drug Therapy, Combination; Haloperidol; Humans; Lithium; Loxapine

1989
Treatment of acute nonspecific delirium with i.v. haloperidol in surgical intensive care patients.
    Acta anaesthesiologica Belgica, 1989, Volume: 40, Issue:3

    Topics: Acute Disease; Aged; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; Male; Postoperat

1989
Delirium: recognition and management in the older patient.
    Geriatrics, 1986, Volume: 41, Issue:6

    Topics: Aged; Aging; Anti-Anxiety Agents; Benzodiazepines; Delirium; Diagnosis, Differential; Drug-Related S

1986
Controlled study of extrapyramidal reactions in the management of delirious, medically ill patients: intravenous haloperidol versus intravenous haloperidol plus benzodiazepines.
    Heart & lung : the journal of critical care, 1988, Volume: 17, Issue:3

    Topics: Aged; Anti-Anxiety Agents; Basal Ganglia Diseases; Benzodiazepines; Delirium; Drug Therapy, Combinat

1988
[Lasting neurologic injury in therapeutic lithium plasma levels].
    Nederlands tijdschrift voor geneeskunde, 1989, Jan-28, Volume: 133, Issue:4

    Topics: Aged; Delirium; Drug Combinations; Female; Haloperidol; Humans; Lithium

1989
[Delirium in the general hospital].
    Nederlands tijdschrift voor geneeskunde, 1988, Apr-02, Volume: 132, Issue:14

    Topics: Aged; Benzodiazepines; Cognition Disorders; Delirium; Haloperidol; Humans; Middle Aged; Prognosis; R

1988
Treatment of severe, refractory agitation with a haloperidol drip.
    The Journal of clinical psychiatry, 1988, Volume: 49, Issue:6

    Topics: Acute Disease; Cerebral Infarction; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; M

1988
Emergency pharmacotherapy of delirium in the critically ill cancer patient.
    Psychosomatics, 1986, Volume: 27, Issue:1 Suppl

    Topics: Adult; Aged; Delirium; Drug Therapy, Combination; Emergencies; Female; Haloperidol; Humans; Infusion

1986
A haloperidol-carbamazepine interaction in a patient with rapid-cycling bipolar disorder.
    The American journal of psychiatry, 1985, Volume: 142, Issue:6

    Topics: Bipolar Disorder; Carbamazepine; Delirium; Drug Therapy, Combination; Female; Haloperidol; Humans; M

1985
[Hallucinatory paraphrenic syndrome in the course of schizophrenia].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1967, Volume: 67, Issue:9

    Topics: Adult; Automatism; Azo Compounds; Delirium; Hallucinations; Haloperidol; Humans; Illusions; Paranoid

1967
The organic brain syndrome.
    American family physician, 1974, Volume: 10, Issue:5

    Topics: Alcoholic Intoxication; Attention; Chlordiazepoxide; Delirium; Haloperidol; Humans; Hydrocephalus; M

1974
[Delirious reactions in acute pancreatitis].
    Nordisk medicin, 1969, Sep-11, Volume: 82, Issue:37

    Topics: Acute Disease; Adult; Cerebral Ventriculography; Chlorprothixene; Cholecystectomy; Delirium; Diazepa

1969
[Complex persisting dyskinesia, secondary to neuroleptic therapy].
    Revue neurologique, 1969, Volume: 120, Issue:3

    Topics: Aged; Butyrophenones; Delirium; Electromyography; Extrapyramidal Tracts; Female; Haloperidol; Humans

1969
[Developmental study on night sleep during episodes of manias or acute depressions].
    Revue neurologique, 1969, Volume: 121, Issue:3

    Topics: Acute Disease; Adult; Bipolar Disorder; Chlorpromazine; Delirium; Electroencephalography; Female; Ha

1969
[The clinical picture and therapy of alcoholic psychoses in old age].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1970, Volume: 70, Issue:5

    Topics: Acute Disease; Apomorphine; Barbiturates; Cerebrovascular Disorders; Delirium; Delusions; Female; Ha

1970
[Complications caused by anonymous preclinical medication].
    Arzneimittel-Forschung, 1970, Volume: 20, Issue:7

    Topics: Amitriptyline; Antidepressive Agents; Barbiturates; Bromides; Cannabis; Chlordiazepoxide; Delirium;

1970